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Background: Early research in adults admitted to intensive care suggested that tight control of blood
glucose during acute illness can be associated with reductions in mortality, length of hospital stay and
complications such as infection and renal failure. Prior to our study, it was unclear whether or not children
could also beneﬁt from tight control of blood glucose during critical illness.
Objectives: This study aimed to determine if controlling blood glucose using insulin in paediatric intensive
care units (PICUs) reduces mortality and morbidity and is cost-effective, whether or not admission follows
cardiac surgery.
Design: Randomised open two-arm parallel group superiority design with central randomisation with
minimisation. Analysis was on an intention-to-treat basis. Following random allocation, care givers and
outcome assessors were no longer blind to allocation.
Setting: The setting was 13 English PICUs.
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Participants: Patients who met the following criteria were eligible for inclusion: ≥ 36 weeks corrected
gestational age; ≤ 16 years; in the PICU following injury, following major surgery or with critical illness;
anticipated treatment > 12 hours; arterial line; mechanical ventilation; and vasoactive drugs. Exclusion
criteria were as follows: diabetes mellitus; inborn error of metabolism; treatment withdrawal considered;
in the PICU > 5 consecutive days; and already in CHiP (Control of Hyperglycaemia in Paediatric
intensive care).
Intervention: The intervention was tight glycaemic control (TGC): insulin by intravenous infusion titrated
to maintain blood glucose between 4.0 and 7.0 mmol/l.
Conventional management (CM): This consisted of insulin by intravenous infusion only if blood glucose
exceeded 12.0 mmol/l on two samples at least 30 minutes apart; insulin was stopped when blood glucose
fell below 10.0 mmol/l.
Main outcome measures: The primary outcome was the number of days alive and free from mechanical
ventilation within 30 days of trial entry (VFD-30). The secondary outcomes comprised clinical and
economic outcomes at 30 days and 12 months and lifetime cost-effectiveness, which included costs per
quality-adjusted life-year.
Results: CHiP recruited from May 2008 to September 2011. In total, 19,924 children were screened and 1369
eligible patients were randomised (TGC, 694; CM, 675), 60% of whom were in the cardiac surgery stratum.
The randomised groups were comparable at trial entry. More children in the TGC than in the CM arm received
insulin (66% vs. 16%). The mean VFD-30 was 23 [mean difference 0.36; 95% conﬁdence interval (CI) –0.42 to
1.14]. The effect did not differ among prespeciﬁed subgroups. Hypoglycaemia occurred signiﬁcantly more often
in the TGC than in the CM arm (moderate, 12.5% vs. 3.1%; severe, 7.3% vs. 1.5%). Mean 30-day costs were
similar between arms, but mean 12-month costs were lower in the TGC than in CM arm (incremental
costs –£3620, 95% CI –£7743 to £502). For the non-cardiac surgery stratum, mean costs were lower in the
TGC than in the CM arm (incremental cost –£9865, 95% CI –£18,558 to –£1172), but, in the cardiac surgery
stratum, the costs were similar between the arms (incremental cost £133, 95% CI –£3568 to £3833). Lifetime
incremental net beneﬁts were positive overall (£3346, 95% CI –£11,203 to £17,894), but close to zero for the
cardiac surgery stratum (–£919, 95% CI –£16,661 to £14,823). For the non-cardiac surgery stratum, the
incremental net beneﬁts were high (£11,322, 95% CI –£15,791 to £38,615). The probability that TGC is
cost-effective is relatively high for the non-cardiac surgery stratum, but, for the cardiac surgery subgroup,
the probability that TGC is cost-effective is around 0.5. Sensitivity analyses showed that the results were robust
to a range of alternative assumptions.
Conclusions: CHiP found no differences in the clinical or cost-effectiveness of TGC compared with CM
overall, or for prespeciﬁed subgroups. A higher proportion of the TGC arm had hypoglycaemia. This study
did not provide any evidence to suggest that PICUs should stop providing CM for children admitted to
PICUs following cardiac surgery. For the subgroup not admitted for cardiac surgery, TGC reduced average
costs at 12 months and is likely to be cost-effective. Further research is required to reﬁne the TGC protocol
to minimise the risk of hypoglycaemic episodes and assess the long-term health beneﬁts of TGC.
Trial registration: Current Controlled Trials ISRCTN61735247.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 26. See the NIHR Journals Library website
for further project information.
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SAE serious adverse event
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Scientiﬁc summary
Background
Early research in adults admitted to intensive care suggested that tight control of blood glucose during
acute illness can be associated with reductions in mortality, length of hospital stay and complications such
as infection and renal failure. There was no clear information, however, about whether or not there
were different effects for adults in surgical compared with medical intensive care; nor was there clear
information concerning the longer-term economic implications of controlling blood glucose. In addition,
despite over 10,000 children being admitted to paediatric intensive care units (PICUs) in England and
Wales each year, the research did not include children.
Objectives
The objective of the Control of Hyperglycaemia in Paediatric intensive care (CHiP) trial was to determine
if a policy of strictly controlling blood glucose [tight glycaemic control (TGC)] using insulin reduces
mortality and morbidity and is cost-effective in children admitted to PICUs, whether or not admission
follows cardiac surgery.
The primary hypothesis was that:
l TGC will increase the numbers of days alive and free of mechanical ventilation within 30 days of trial
entry (VFD-30) for children aged ≤ 16 years on ventilatory support and receiving vasoactive drugs.
The secondary hypotheses were that:
l TGC will lead to improvement in a range of complications associated with intensive care treatment.
l TGC will be cost-effective.
l The clinical effectiveness of TGC will be similar whether children were admitted to a PICU following
cardiac surgery or for other reasons.
l The cost-effectiveness of TGC will be similar whether children were admitted to a PICU following
cardiac surgery or for other reasons.
Methods
Children were eligible for trial entry if they:
l were ≥ 36 weeks corrected gestational age and ≤ 16 years
l were admitted to the PICU following injury, following major surgery or in association with critical
illness, and it was anticipated treatment would be required to continue for at least 12 hours
l had an arterial line in situ and were receiving both mechanical ventilation and vasoactive drugs.
Children were excluded prior to trial entry if they:
l were born preterm (≤ 36 weeks corrected gestational age)
l had diabetes mellitus
l had an established or suspected diagnosis of an inborn error of metabolism
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l were children for whom treatment withdrawal or limitation of intensive care treatment was
being considered
l had been in a PICU for > 5 consecutive days
l had already participated in the CHiP study during a previous PICU admission.
After consent by parents/guardians, children were randomised to either of the following:
l TGC: insulin by intravenous infusion titrated to maintain a blood glucose between the limits of 4.0 and
7.0 mmol/l.
l Conventional management (CM): insulin by intravenous infusion only if blood glucose levels exceeded
12mmol/l on two blood samples taken at least 30 minutes apart and discontinued once blood glucose
fell to < 10.0 mmol/l.
Patients not entered into the trial received standard care.
Standard insulin solutions were used and changes in insulin infusion rates were guided by the glucose
levels from arterial blood sampling using commercially available ‘point-of-care’ blood gas analysers.
Training in the use of the glucose control protocol was provided.
To reduce the risk of selection bias at trial entry, allocation was carried out through a central computerised
24-hour, 7-day-a-week randomisation service. Minimisation with a probabilistic element was used to
ensure a balance of key prognostic factors between arms. The minimisation criteria were centre;
age ≤ 1 year compared with between 1 year and ≤ 16 years; admission following cardiac surgery or not;
for children admitted for cardiac surgery, Risk-adjusted Classiﬁcation for Congenital Heart Surgery 1
(RACHS1) categories 1–4 compared with 5–6; for children not admitted for cardiac surgery, Paediatric
Index of Mortality version 2 (PIM2) score categorised by probabilities of death of < 5%, 5% to < 15% and
≥ 15%; and accidental traumatic brain injury (TBI) or not.
Following randomisation, care-givers and outcome assessors were no longer blind to allocation.
The primary outcome measure was VFD-30. A difference of 2 days in VFD-30 was considered clinically
important. Taking a type I error of 1% (with a two-sided test), with an overall standard deviation across
both cardiac and non-cardiac strata of 7 days, a total sample size of 750 patients would have 90% power
to detect this difference. The target size was inﬂated to 1000 to take account of possible dilution of effect.
The trial was powered to be able to detect whether or not any effect of tight glucose control differed
between the cardiac surgery and non-cardiac surgery strata. To have 80% power for an interaction test to
be able to detect a difference of 2 days in the effect of intervention between the strata at the 5% level of
statistical signiﬁcance, the sample size was increased to 1500.
Secondary outcomes were assessed at PICU discharge or 30 days after randomisation (if on PICU ≥ 30 days)
and at 12 months. The short-term outcomes included mortality; duration of ventilation, length of PICU and
hospital stay; readmission rates; renal replacement therapy; infection; transfusions; seizures; paediatric
organ dysfunction score; and hypoglycaemia. The 12-month outcomes included mortality; attention and
behaviour in TBI patients; and total duration of PICU and hospital stay. Additional outcomes for the
economic evaluation included hospital costs within 30 days of trial entry; hospital and community health
service costs within 12 months of trial entry; and lifetime incremental net beneﬁts calculated by valuing
quality-adjusted life-years (QALYs) at the recommended threshold of £20,000 per QALY. All future costs
and life-years were discounted at the recommended rate of 3.5%.
Resource-use data were collected on the trial case report forms. Data on the level of care for PICU bed-days
were available through the Paediatric Critical Care Minimum Data Set, extracted via the Paediatric Intensive
Care Audit Network. Other data on hospital and community service use at 12 months were collected from
parents by postal questionnaire for patients randomised before 30 October 2010. Unit costs were taken
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from the 2011 NHS Payments by Results database. For children who survived to hospital discharge, vital
status at 12 months post randomisation was recorded using information from the participating PICUs,
the children’s general practitioners (GPs) or the NHS Information Centre and the NHS Central Register.
Primary analyses were by intention to treat. For the primary outcome, linear regression models were used
to estimate a mean difference in VFD-30 between the two arms of the trial. For the secondary outcomes,
appropriate generalised linear models were used to examine the effect of the intervention. Odds ratios and
mean differences are reported with 95% conﬁdence intervals (CIs). Non-parametric bootstrapping was
used when appropriate. Multiple imputation was used to handle missing data. Sensitivity analyses (SAs)
were undertaken to investigate whether or not results were robust to alternative approaches, including the
approaches taken to unit costing, handling missing data and extrapolating survival in the lifetime
cost-effectiveness analysis.
Prespeciﬁed subgroup analyses were planned for cardiac surgical compared with non-cardiac surgical
cases, age (< 1 year or between 1 and ≤ 16 years), TBI or not, RACHS1 (cardiac cases) (groups 1–4 vs. 5
and 6), PIM2 risk of mortality (non-cardiac cases) (categorised by probabilities of death of < 5%, between
5% and < 15% and ≥ 15%) and run-in cases (ﬁrst 100 randomised) compared with non-run-in cases.
Likelihood ratio tests for interactions were used to assess whether or not there was any difference in the
effect of the intervention in the different subgroups.
An independent Data Monitoring and Ethics Committee (DMEC) was established to review data from the
trial in strict conﬁdence, using the Peto–Haybittle stopping rule.
Results
Trial recruitment began on 4 May 2008 and was slower than expected, mainly because of delays in trial
initiation at some sites, clinical constraints and a ‘research learning curve’ in many of the participating units
that had no previous experience of recruiting critically ill children to clinical trials. The DMEC conﬁdentially
reviewed unblinded interim analyses on two occasions. In addition, they met to discuss serious adverse
events and recruitment rates on three further occasions. Recruitment closed on 31 August 2011. A total of
19,924 children were screened from 13 sites. Of these, 1384 were recruited and randomised (701 to TGC
and 683 to CM). Of the 1384, 15 were subsequently found to be ineligible, leaving 1369 eligible children
(694 to TGC and 675 to CM) randomised into the trial – 91% of the original target of 1500.
The randomised groups were broadly comparable at trial entry. Sixty-two per cent were randomised within
1 day of admission to PICU. In terms of the prespeciﬁed stratifying factors, two-thirds were aged under
1 year, and 60% of the children were in the cardiac surgery stratum. In the cardiac surgery stratum, 7% of
children were considered to be undergoing surgical procedures associated with a high risk of mortality
(RACHS1 score 5 or 6), and 19% of children in the non-cardiac group had a PIM2 score indicative of
> 15% risk of PICU mortality.
The management of blood glucose differed between the two arms of the study. In the TGC arm, 461 of the
694 children (66%) received insulin compared with 109 of 675 (16%) in the CM arm. Children in the TGC
arm received more insulin, received insulin treatment earlier and continued insulin treatment for longer.
The primary outcome, the mean VFD-30, was 23 in both trial arms (mean difference 0.36; 95% CI –0.42
to 1.14).
The secondary outcomes up to 30 days were similar between the arms, although less renal replacement
therapy was carried out in the TGC arm (odds ratio 0.63; 95% CI 0.45 to 0.89). Hypoglycaemia occurred
in a greater proportion of patients in the TGC arm than in the CM arm of the study (moderate, 12.5% vs.
3.1%, p < 0.001; severe, 7.3% vs. 1.5%, p < 0.001).
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None of the interaction tests between the intervention and prespeciﬁed subgroups for the primary
outcome were statistically signiﬁcant, suggesting that there was no difference in the effect of TGC on
VFD-30 in the different strata.
For the index hospital episode, the mean number of PICU bed-days, the length of stay on general medical
wards and the total length of stay were similar between arms. The mean total number of hospital days up
to day 30, including both the initial episode and readmissions to the initial PICU before day 30, was also
similar between arms. For the stratum admitted to PICUs following cardiac surgery, the mean total length
of stay was again comparable between arms, but, for the non-cardiac surgery stratum, the mean numbers
of PICU days and the length of stay on general medical wards and in total were lower for the TGC than
the CM arm.
Overall, the mean total costs at 30 days post randomisation were similar between arms. For the cardiac
surgery stratum, the mean total costs per patient were £16,228 (TGC) and £17,005 (CM). For the
non-cardiac surgery stratum, the TGC arm had lower mean costs than the CM arm, with an incremental
cost of –£2319 (95% CI –£4702 to £124).
Between 30 days and 12 months post randomisation, the mean numbers of days in a PICU, on general
medical wards and in total were lower for the TGC than the CM arm. For the cardiac surgery stratum, the
mean total length of stay at 12 months was similar between arms. For the non-cardiac surgery stratum,
the TGC arm reported fewer days on PICUs, on general medical wards and in total at 12 months post
randomisation (mean total hospital days at 12 months, 31.0 for the TGC arm vs. 44.5 for the CM arm).
Mortality at 12 months was similar between the randomised arms, and no differences were found
between the two arms of the trial in attention and behaviour measures for the 13 patients with TBI.
The mean total costs at 12 months were lower in the TGC than in the CM arm (incremental costs –£3620,
95% CI –£7743 to £502). For the cardiac surgery stratum, the mean total costs were similar between arms
(incremental costs £133, 95% CI –£3568 to £3833), but, for the patients not admitted for cardiac surgery,
the mean costs were lower in the TGC than in the CM arm, with an incremental cost of –£9865 (95% CI
–£18,558 to –£1172).
Sensitivity analyses showed that the results were robust to alternative approaches for calculating unit costs,
or handling missing data.
Overall, the lifetime incremental net beneﬁts were high (£3346, 95% CI –£11,203 to £17,894). For
patients admitted for cardiac surgery, the incremental net beneﬁts were close to zero (–£919, 95%
CI –£16,661 to £14,823). For patients not admitted for cardiac surgery, the incremental net beneﬁts were
positive (£11,322, 95% CI –£15,791 to £38,615). The cost-effectiveness acceptability curves consider
alternative thresholds of willingness to pay for a QALY gain, and show that overall, and for the cardiac
surgery stratum, it is highly uncertain that TGC is cost-effective. For the non-cardiac stratum, the
probability that TGC is cost-effective is relatively high. For example, at ceiling ratios of £10,000 to £30,000
per QALY, the probabilities that TGC is cost-effective range from 90% to 70%.
The SAs suggest that these ﬁndings are robust to alternative assumptions about the extrapolation of long-
term survival, quality of life for PICU survivors or long-term costs.
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Conclusions
Implications for health care
This study found no differences in the effectiveness of TGC compared with CM, according to the primary
outcome measure, both overall and for prespeciﬁed subgroups. The secondary clinical outcomes were
generally similar between the arms, but a lower proportion of the TGC arm had renal replacement
therapy, and a higher proportion had hypoglycaemia. For the cardiac surgery subgroup, average costs at
12 months post randomisation were similar between arms, and TGC was unlikely to be cost-effective. For
the subgroup not admitted for cardiac surgery, average costs at 12 months post randomisation were lower
for the TGC than the CM arm. Therefore, TGC is likely to be cost-effective for patients not admitted for
cardiac surgery.
The majority of PICUs in the NHS currently provide CM for patients who meet this study’s inclusion criteria.
For children following cardiac surgery, our study does not offer any evidence to suggest that PICUs should
stop CM for these patients. For children admitted to PICUs for other reasons, TGC can reduce NHS costs.
However, before a policy of TGC can be recommended for this subgroup, the potential for cost savings
has to be weighed against the small increased risk of hypoglycaemia, and further investigation of the
long-term clinical effectiveness and cost-effectiveness of TGC compared with CM is warranted.
Recommendations for research
The ﬁndings of the CHiP trial raise the following important questions to be addressed in follow-on studies:
1. Does the excess rate of moderate and severe hypoglycaemia during TGC for children admitted to PICUs
for reasons other than cardiac surgery have an impact on long-term neurodevelopmental outcomes?
2. Can we improve the delivery of TGC to minimise the risk of hypoglycaemia?
3. Does TGC in critically ill children protect the kidneys from injury?
4. Do the ﬁndings from CHiP apply to routine clinical practice?
5. What can be learnt from triallists, clinicians, parents and older children about their experiences of
participating in CHiP to aid the design and conduct of future PICU trials?
Trial registration
This trial is registered as ISRCTN61735247.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Hyperglycaemia is a common element of the early phase of the neuroendocrine response to stresswhich is observed following the onset of illness or injury in both adults and children, and is sometimes
referred to as the diabetes of critical illness,1–4 as a result of accelerated glucose production and acute
development of relative insulin resistance.
Stress has long been recognised as a programmed, co-ordinated and adaptive process conferring survival
advantage which may, if prolonged, lead to secondary harm.5 Stress hyperglycaemia was therefore usually
explained as being an adaptive response whose purpose could potentially be beneﬁcial by maintaining
intravascular volume or increasing energy substrate delivery to vital organs, and it was not usually treated
unless glucose levels were grossly and persistently elevated. These assumptions around the lack of harm
from or beneﬁts of stress hyperglycaemia have increasingly been questioned in the light of reports from a
wide range of illnesses and populations which have shown hyperglycaemia to be related to worse
clinical outcomes.
Myocardial infarction
In a meta-analysis,6 patients with acute myocardial infarction, and without diabetes mellitus, who had
glucose concentrations in the range 6.1–8.0 mmol/l or higher had a 3.9-fold [95% conﬁdence interval (CI)
2.9- to 5.4-fold] higher risk of death than patients who had lower glucose concentrations. Glucose
concentrations higher than values in the range of 8.0–10.0 mmol/l on admission were associated with
increased risk of congestive heart failure or cardiogenic shock.
Stroke
Capes et al.7 conducted a systematic review and meta-analysis of the literature relating glucose levels in
the interval immediately post stroke to the subsequent course. A comprehensive literature search was
carried out to identify cohort studies reporting mortality and/or functional recovery after stroke in relation
to admission glucose level. In total, 32 studies were identiﬁed, and predeﬁned outcomes could be analysed
for 26 of these. After stroke, the unadjusted relative risk (RR) of in-hospital or 30-day mortality associated
with an admission glucose level above the range of 6–8mmol/l was 3.07 (95% CI 2.50 to 3.79) in
non-diabetic patients and 1.30 (95% CI 0.49 to 3.43) in diabetic patients. Non-diabetic stroke survivors
whose admission glucose level was above the range of 6.7–8mmol/l also had a greater risk of poor
functional recovery (RR 1.41; 95% CI 1.16 to 1.73).
Head injury and multisystem trauma
Hyperglycaemia has been shown to be an independent predictor of poor outcomes in adults with head
injury8 and in cases of multiple trauma.9
Pulmonary function
Hyperglycaemia has been shown to be associated with diminished pulmonary function in adults, even in
the absence of diabetes mellitus,10 and a range of risk factors for lung injury.11
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Gastrointestinal effects
Hyperglycaemia has been shown to be associated with delayed gastric emptying,12 decreased small bowel
motility and increased sensation and cerebral-evoked potentials in response to a range of gastrointestinal
stimuli in adult volunteers.13–16
Infections
The in vitro responsiveness of leucocytes stimulated by inﬂammatory mediators is inversely correlated with
glycaemic control.17 This reduction in polymorphonuclear leucocyte responsiveness may contribute to
the compromised host defence associated with sustained hyperglycaemia,17 and, indeed, hyperglycaemia
has been shown to be associated with an increased rate of serious infections after adult cardiac18 and
vascular surgery.19
These studies, which associate poorer outcomes with patients with the highest levels of stress glycaemia,
raise the question of whether high blood glucose levels simply identify the more severely ill patients, in
whom worse outcomes are inevitable, or whether speciﬁc homeostatic or allostatic glycaemic dysfunction
inﬂuences outcomes independently. If the latter were true, then perhaps measures to prevent or limit
stress-induced hyperglycaemia would improve clinical outcomes.
Does hyperglycaemia matter for adults in the critically
ill setting?
Although the importance of good glycaemic control has long been established in minimising complications
of chronic hyperglycaemia in patients with diabetes mellitus,20,21 and a number of mechanisms for
glucotoxicity identiﬁed,22 in the era up to the year 2000, a permissive approach was typically adopted
when managing non-diabetic patients in intensive care settings. A very reasonable question, however,
is Could shorter-term hyperglycaemia in non-diabetic populations be associated with clinically important
adverse outcomes? Early reports from adult populations started to explore the possible association
between acute stress-induced hyperglycaemia and outcome in both diabetic and non-diabetic patients.
Furnary et al.18 noted that hyperglycaemia is associated with higher sternal wound infection rates following
adult cardiac surgery and questioned whether more aggressive control of glycaemia might lead to lower
infection rates. In a prospective study of 2467 consecutive diabetic patients who underwent open-heart
surgical procedures, patients were classiﬁed into two sequential groups. The control group included 968
patients treated with sliding-scale-guided intermittent subcutaneous insulin injections. The study group
included 1499 patients treated with a continuous intravenous insulin infusion in an attempt to maintain
a blood glucose level of < 11.1 mmol/l. Compared with subcutaneous insulin injections, continuous
intravenous insulin infusion induced a signiﬁcant reduction in perioperative blood glucose levels, which
was associated with a signiﬁcant reduction in the incidence of deep-sternal wound infection in the
continuous intravenous insulin infusion group [0.8% (12 of 1499) vs. 2.0% (19 of 968) in the intermittent
subcutaneous insulin injection group; p = 0.01]. The use of perioperative, continuous intravenous insulin
infusion in diabetic patients undergoing open-heart surgical procedures appeared to signiﬁcantly reduce
the incidence of major infections.
Malmberg et al.23 randomly allocated patients with diabetes mellitus and acute myocardial infarction to
intensive insulin therapy (n = 306) or standard treatment (controls, n = 314). The mean (range) follow-up
was 3.4 (1.6–5.6) years. There were 102 (33%) deaths in the treatment group compared with 138 (44%)
deaths in the control group (RR 0.72; 95% CI 0.55 to 0.92; p = 0.011). The effect was most pronounced
among a predeﬁned group that included 272 patients who had not received insulin treatment previously
and who were at a low cardiovascular risk (0.49; 0.30 to 0.80; p = 0.004). Intensive insulin therapy
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improved survival in diabetic patients with acute myocardial infarction. The effect seen at 1 year continued
for at least 3.5 years, with an absolute reduction in mortality of 11%.
In 2001, Van den Berghe and colleagues from Leuven, Belgium,24 extended this approach to non-diabetic
hyperglycaemic populations. They performed a single-centre randomised trial in adults undergoing
intensive care following surgical procedures which showed that the use of insulin to tightly control blood
glucose led to a reduction in mortality from 10.9% to 7.2%, and a signiﬁcantly lower incidence of a range
of important complications of critical illness including renal failure, infection, inﬂammation, anaemia and
polyneuropathy and need for prolonged ventilatory support.
The same group undertook a similar trial in non-surgical, adult, critically ill patients25 and again found
beneﬁts from the control of blood glucose with intensive insulin therapy. Patients were randomly assigned
to a regimen of strict normalisation of blood glucose (4.4–6.1 mmol/l) with use of insulin or conventional
therapy whereby insulin was administered only when blood glucose levels exceeded 12 mmol/l, with the
infusion tapered when the level fell below 10mmol/l. In the intention-to-treat analysis of the 1200 patients,
intensive care unit (ICU) and in-hospital mortality were not signiﬁcantly altered by intensive insulin therapy;
however, for those patients who stayed > 3 days in intensive care (an a priori subgroup), mortality was
signiﬁcantly reduced from 52.5% to 43% (p = 0.009). Morbidity was signiﬁcantly reduced by intensive
insulin therapy, with a lower incidence of renal injury and shorter length of mechanical ventilation and
duration of hospital stay noted. For patients who stayed > 5 days in intensive care after trial entry, all
morbidity end points were signiﬁcantly improved in the intensive insulin therapy group.
Although the precise mechanisms by which different glucose control strategies might inﬂuence clinical
outcomes had not been fully elucidated, the clinical effects of ‘tight glycaemic control’ (TGC) for adults in
critical care appeared promising. As a result, TGC was widely adopted in adult critical care standards in the
years following the publication of Van den Berghe et al. 2001 paper.24
Stress hyperglycaemia in the critically ill child
Over 12,000 children are admitted to ICUs in England and Wales each year.26 Hyperglycaemia occurs
frequently during critical illness or after major surgery in children, with a reported incidence of up to 86%,3
but children in critical care may not respond to interventions in the same way as adults.
References to hyperglycaemia and its management in critically ill children were identiﬁed through searches
in MEDLINE27 from 1990 to December 2006. Articles were also identiﬁed through searches of the authors’
own ﬁles. Only papers published in English were reviewed. The ﬁnal reference list was generated on the
basis of originality and relevance to the genesis of this research proposal. The search terms used were
‘glycaemia’, ‘control’, ‘insulin’, ‘critical illness’ and ‘intensive care’; the limits applied were ‘clinical trials’,
‘meta-analysis’, ‘randomised controlled trial’ and ‘humans’ and ‘age 0–18 years’. No randomised trials or
meta-analyses of glycaemic control in childhood critical illness were identiﬁed.
The non-randomised studies identiﬁed included a number of reports of critically ill children receiving care
in general,3,28,29 cardiac surgical,30,31 trauma9,32,33 and burns34 ICUs, all showing that high blood glucose
levels occur frequently and that levels are signiﬁcantly higher in children who die than in children who
survive. As in adults, the occurrence of hyperglycaemia was associated with poorer outcomes including
death, sepsis and longer length of intensive care stay for critically ill children.
Srinivasan et al.3 studied the association of timing, duration and intensity of hyperglycaemia with mortality
in critically ill children. The study had a retrospective, cohort design and included 152 critically ill children
receiving vasoactive infusions or mechanical ventilation. A peak blood glucose of > 7mmol/l occurred in
86% of patients. Non-survivors had a higher peak blood glucose [mean ± standard deviation (SD)] than
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survivors (17.3 ± 6.4 mmol/l vs. 11.4 ± 4.4 mmol/l, p < 0.001). Non-survivors had more intense
hyperglycaemia during the ﬁrst 48 hours in the paediatric intensive care unit (PICU) (7 ± 2.1 mmol/l)
than survivors (6.4 ± 1.9 mmol/l, p < 0.05). Median blood glucose levels > 8.3 mmol/l were associated with
a threefold increased risk of mortality compared with median levels of < 8.3 mmol/l. Univariate logistic
regression analysis showed that peak blood glucose and the duration and intensity of hyperglycaemia
were each associated with PICU mortality (p < 0.05). Multivariate modelling controlling for age and
paediatric risk of mortality scores showed an independent association of peak blood glucose and duration
of hyperglycaemia with PICU mortality (p < 0.05). This study demonstrated that hyperglycaemia is
common among critically ill children. Peak blood glucose and duration of hyperglycaemia appear to be
independently associated with mortality. The study was limited by its retrospective design, its single-centre
location and the absence of cardiac surgical cases, a group which make up approximately 40% of
paediatric intensive care (PIC) admissions in the UK.
Yates et al.30 conducted a retrospective review of data from 184 children < 1 year of age who underwent
major cardiac surgery over a 22-month period ending in August 2004. Factors analysed included peak
glucose levels and duration of hyperglycaemia. The duration of hyperglycaemia was signiﬁcantly longer
in children who developed renal insufﬁciency, liver insufﬁciency and infection and those who required
mechanical circulatory support or who died, and was associated with longer PICU and hospital lengths of
stay (LOS).
Hall et al.35 investigated the incidence of hyperglycaemia in infants with necrotising enterocolitis (NEC) and
the relationship between glucose levels and outcome in these infants. Glucose measurements (n = 6508)
in 95 neonates with conﬁrmed NEC admitted to the surgical ICU were reviewed. Glucose levels ranged
from 0.5 to 35.0 mmol/l; 69% of infants became hyperglycaemic (> 8mmol/l) during their admission;
and 32 infants died. The mortality rate tended to be higher in infants whose peak glucose concentration
exceeded 11.9 mmol/l than in those with peak glucose concentrations of < 11.9 mmol/l, and the late
(> 10 days after admission) mortality rate was signiﬁcantly higher in the former infants (29% vs. 2%;
p = 0.0009). Linear regression analysis indicated that peak glucose concentration was signiﬁcantly related
to LOS (p < 0.0001).
Branco et al.29 showed an association between hyperglycaemia and increased mortality in children
with septic shock. They prospectively studied children admitted to a regional PICU with septic shock
refractory to ﬂuid therapy over a period of 32 months. The peak glucose level in those with septic
shock was 11.9 ± 5.4 mmol/l (mean ± SD), and the mortality rate was 49.1% (28/57). In non-survivors,
the peak glucose level was 14.5 ± 6.1 mmol/l, which was higher (p < 0.01) than that found in
survivors (9.3 ± 3.0 mmol/l). The RR of death in patients with peak glucose levels of ≥ 9.9 mmol/l was
2.59 (p = 0.012).
Faustino and Apkon28 demonstrated that hyperglycaemia occurs frequently among critically ill non-diabetic
children and is associated with higher mortality and longer LOSs in PICUs. They performed a retrospective
cohort study of 942 non-diabetic patients admitted to a PICU over a 3-year period. The prevalence of
hyperglycaemia was based on initial PICU glucose measurement, peak value within 24 hours and peak
value measured during PICU stay up to 10 days after the ﬁrst measurement. Using three cut-off values
(6.7, 8.3 and 11.1 mmol/l), the prevalence of hyperglycaemia was 16.7–75.0%. The RR for death increased
for peak glucose within 24 hours of > 8.3 mmol/l (RR, 2.50; 95% CI 1.26 to 4.93) and peak glucose within
10 days of > 6.7 mmol/l (RR, 5.68; 95% CI 1.38 to 23.47).
Pham et al.34 reviewed the records of children with ≥ 30% total body surface area burn injury admitted
to a regional paediatric burn centre during two consecutive periods, during the ﬁrst of which patients
received ‘conventional insulin therapy’ (n = 31), and during the second of which they were managed with
TGC (n = 33). Intensive insulin therapy was positively associated with survival and a reduced incidence of
infections. The authors concluded that intensive insulin therapy to maintain normoglycaemia in severely
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burned children could be safely and effectively implemented in a paediatric burns unit and that this
therapy seemed to lower infection rates and improve survival.
There was, therefore, mounting evidence to suggest that stress hyperglycaemia occurred in both neonates
and children (as in adults). From adult studies, TGC appeared to offer the possibility of clinical beneﬁts,
particularly following surgery, but there was no convincing randomised controlled trial (RCT) evidence
for children, whether or not admitted to PICUs following surgery. This was of particular importance as
approximately one-third of admissions of children to UK PICUs are associated with surgery, in particular
cardiac surgery.
Evidence on the cost-effectiveness of tight glycaemic control
The existing evidence on the clinical effectiveness of TGC is derived from studies in both critically ill
adults and critically ill children. However, to inform whether or not the NHS should provide TGC rather
than conventional management (CM) for critically ill children, it is important to consider whether or not
the additional costs associated with implementing a TGC protocol are offset by subsequent reductions in
resource use and improved health outcomes. Limited evidence suggests that any additional costs associated
with implementing a TGC protocol may be relatively small.36 A post-hoc analysis of the Van den Berge 2001
RCT24,37 for critically ill adults admitted for surgery reported that TGC can reduce ICU LOS, and hence
hospital costs.37 However, this study had several limitations. The study was not designed to measure costs;
resource use after the initial hospital episode was not recorded; the study was undertaken in a single
centre and lacked generalisability; and it is unclear whether the results apply to other patient groups
(e.g. critically ill children, patients not admitted for surgery).
For critically ill children, any assessment of the effect of a TGC protocol compared with CM on resource
use and costs is hindered by the lack of evidence from RCTs. The costs of each PICU bed-day are
substantial (ranging from £1000 to £5000 per bed-day),38 so if TGC reduces PICU LOS then it would be
anticipated to also reduce short-term costs (i.e. those incurred within 30 days of admission to the PICU).
It is also plausible that TGC may have an effect on longer-term costs. A previous study reported that
around 10% of PICU survivors had residual long-term disability (median follow-up of 3.5 years from initial
admission).39 Therefore, the long-term costs following PICU survival may be substantial, and may be
increased if TGC increases PICU survival, or reduced if improved blood glucose control reduces morbidity.
There is little available evidence on the net effect of TGC compared with CM on longer-term morbidity
and hence costs, either in general or speciﬁcally for critically ill children.
The previous evidence, therefore, raises the hypotheses that TGC may have an impact on costs, both in
the short term (e.g. 30 days post PICU admission) and in the longer term (e.g. 12 months post PICU
admission). It would, therefore, seem important to consider the net effect of TGC on costs alongside any
change in clinical outcomes. No previous study has considered the effect of TGC on health service costs for
paediatric patients.
The Control of Hyperglycaemia in Paediatric intensive care (CHiP) trial, therefore, sought to address the
question of whether or not a policy of strictly controlling blood glucose using insulin in children admitted
to PIC reduces mortality and morbidity and is cost-effective.
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Chapter 2 Methods
Study design
The study was an individually randomised controlled open trial with two parallel arms. The allocation ratio
was 1 : 1.
The planned ﬂow of patients through the trial is summarised in Figure 1.
Primary hypothesis
The primary hypothesis was that TGC will increase the numbers of days alive and free of mechanical
ventilation at 30 days post randomisation (VFD-30) for children aged ≤ 16 years on ventilatory support
and receiving vasoactive drugs.
Secondary hypotheses
The secondary hypotheses were as follows:
l TGC will lead to improvement in a range of complications associated with intensive care treatment.
l TGC will be cost-effective.
l The clinical effectiveness of TGC will be similar whether children were admitted to PICU following
cardiac surgery or for other reasons.
l The cost-effectiveness of TGC will be similar whether children were admitted to PICU following cardiac
surgery or for other reasons.
Participants
Inclusion criteria
Included were children ≥ 36 weeks corrected gestational age and ≤ 16 years admitted to PICU who had
an arterial line in situ and who were also receiving both mechanical ventilation and vasoactive drugs
[catecholamines or similar (dopamine, dobutamine, adrenaline, noradrenaline), phosphodiesterase type III
inhibitors (milrinone, enoximone), other vasopressors (vasopressin, phenylephrine or similar)] following
injury, following major surgery or in association with critical illness, and in whom it was anticipated such
treatment would be required to continue for at least 12 hours.
Exclusion criteria prior to trial entry
l Children born preterm (< 36 weeks corrected gestational age).
l Children with diabetes mellitus.
l Children with an established or suspected diagnosis of an inborn error of metabolism.
l Children for whom treatment withdrawal or limitation of intensive care treatment was
being considered.
l Children who had been in a PICU for > 5 consecutive days.
l Children admitted to PICU who had already participated in the CHiP study during a previous
PICU admission.
Consent
All parents/guardians of children in PICUs who wished to enter their child into the trial were asked by the
principal investigator (PI) or delegated investigator to give consent. The trial team recognised that parents
were likely to be stressed and anxious, and often had limited time to consider trial entry, but it was
considered medically inappropriate to delay the start of treatment. Parents of children listed for cardiac
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surgery were given information about the trial preoperatively by the PI or delegated investigator, and this
afforded families some additional time to think about participation. Provisional consent was sought at
this time, and conﬁrmed later if the child was admitted to the PICU. In addition, when possible, older
children were given information by the PI or delegated investigator and, if they wished to enter the trial,
were asked to assent to their participation in the study. Information sheets and consent forms are shown
in Appendix 1.
Patients not entered into the trial received standard care.
Potentially eligible patients
•
•
Information given to parents of babies and children (≤ 16 years) 
likely to have cardiac surgery
Babies and children screened in PICU:
Information given to parents
Inclusion criteria
• Children from birth to ≤ 16 years who are undergoing intensive care
treatment with an arterial line in situ and receiving both mechanical
ventilation and vasoactive support drugs following injury, major surgery
or in association with critical illness in whom it is anticipated such
treatment will be required to continue for at least 12 hours
Exclusion criteria prior to trial entry
•
•
•
•
•
•
Children born preterm and who are < 36 weeks corrected gestational age
Children with diabetes mellitus
Children with an established or suspected diagnosis of an inborn
error of metabolism
Children for whom treatment withdrawal or limitation of intensive
care treatment is being considered
Children who have been in a PICU for more than 5 days in succession
Children admitted to a PICU who have already participated in the
CHiP study during a previous PICU admission
Consent given
No traumatic brain injury Traumatic brain injury
TGC CM
Follow-up for 30 days (or discharge if hospital stay > 30 days)
Follow-up
•
•
Letter to GP/health visitor
Following discharge
◊
◊
letter to parents about follow-up
registration with NHS IC and NHS CR
At 11-month check with GP/health visitor before contact with parents
(for patients recruited until November 2010)
No traumatic brain injury
Letter to parents with resource
use questionnaire between
discharge and 12 months
Traumatic brain injury
Letter to parents with resource use questionnaire
between discharge and 12 months, Conners’
rating scale, Health Utilities Index and Child
Behavioural Checklist
Allocation to: Allocation to:
CMTGC
FIGURE 1 Flow chart summarising the planned flow of patients through the trial. CR, Central Register; GP, general
practitioner; IC, Information Centre.
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Ethical approval
The trial (protocol version 1) was approved by the Brighton East Research Ethics Committee (07/Q1907/24)
in 2007. Subsequent amendments are detailed in Appendix 2. The ﬁnal substantive version (protocol
version 6, 23 August 2010) is shown in Appendix 3, and the published version is in Appendix 4.
Allocation of patients
After inclusion in the study, children were randomised to one of two arms:
l group 1 – CM
l group 2 – TGC.
To reduce the risk of selection bias at trial entry, allocation was administered through a central
computerised 24-hour, 7-day-a-week randomisation service established at the London School of Hygiene
and Tropical Medicine (LSHTM), with telephone backup if required. Minimisation was used, with the ﬁrst
child randomly allocated to a trial arm, and each subsequent child allocated randomly to a trial arm with a
weighting in favour of the trial arm that minimises the imbalance on selected key prognostic factors.
The following factors were used:
l centre
l age ≤ 1 year compared with between 1 year and ≤ 16 years
l admitted following cardiac surgery or not
l for children who were admitted for cardiac surgery, risk-adjusted classiﬁcation for congenital heart
surgery (RACHS1)40 categories 1–4 compared with 5 or 6
l for children who were not admitted for cardiac surgery, Paediatric Index of Mortality version 2 (PIM2)
score at randomisation categorised by probabilities of death of < 5%, 5% to < 15% and ≥ 15%
l accidental traumatic brain injury (TBI) or not.
Interventions
After inclusion in the study, children were randomised to one of two arms: arm 1 (CM) or arm 2 (TGC).
Arm 1: conventional management
Children in this arm were treated according to a standard approach to blood glucose management. Insulin
was given by intravenous infusion in this group only if blood glucose levels exceeded 12mmol/l on two
blood samples taken at least 30 minutes apart and was discontinued once blood glucose fell to
< 10 mmol/l.
The protocol for glucose control in this arm is shown in Appendix 3A.
Arm 2: tight glycaemic control
Children in this arm received insulin by intravenous infusion titrated to maintain a blood glucose level
between the limits of 4 and 7.0 mmol/l.
The protocol for glucose control in this arm is shown in Appendix 3B.
The protocol for glucose control in arm 2 was carefully designed to achieve tight glucose control while
minimising the risk of hypoglycaemia, the principal side effect of insulin therapy. Standard insulin solutions
were used and changes in insulin infusion rates were guided by both the current glucose level and its rate
of change from previous measurements. Blood glucose levels were routinely measured as in all ICUs using
commercially available ‘point-of-care’ blood gas analysers, usually with extended biochemical panels,
which utilise very small blood samples, producing results in approximately 1 minute. All of the hospitals in
this study have laboratories registered with Clinical Pathology Accreditation (UK) Ltd. The NHS executive
accreditation standards specify the requirement for the operation and management of chemical pathology,
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including the operation of a quality management system for all testing (see http://www.cpa-uk.co.uk).
The CHiP protocol advised blood glucose testing using arterial rather than venous blood sampling.
Training in the use of the glucose control protocol was provided before the ﬁrst patient was enrolled in
each collaborating centre and for new staff throughout the trial. The clinical co-ordinating centre
team liaised closely with local clinicians to ensure that glucose control algorithms were followed closely
and safely.
Blinding
Following random allocation, care-givers and outcome assessors were no longer blind to allocation.
Outcome measures
Primary
Following the inﬂuential Acute Respiratory Distress Syndrome NETwork (ARDSNET) study,41 VFD-30 was
chosen as the primary outcome measure. Death is obviously an important outcome. Mechanical ventilation
can be seen as a measure of disease severity, deﬁning the need for complex intensive care. The concept of
ventilator-free days (VFDs) brings together these two outcomes. Schoenfeld et al.42 deﬁne VFDs as follows:
VFD = 0 if the child dies before 30 days; VFD = 30 – x if the child is successfully weaned from ventilator
within 30 days (where x is the number of days on ventilator); or VFD = 0 if the child is ventilated for
≥ 30 days. This use of organ-failure-free days to determine patient-related morbidity surrogate end points
in paediatric trials has been supported by inﬂuential paediatric triallists in the current low-mortality
paediatric critical care environment.43
Secondary
Clinical outcomes at discharge from paediatric intensive care unit or 30 days
(if at paediatric intensive care unit ≥ 30 days)
l Death within 30 days of trial entry (or before discharge from hospital if duration of hospital stay was
≥ 30 days).
l Number of days in PICU.
l Duration of mechanical ventilation.
l Duration of vasoactive drug usage.
l Need for renal replacement therapy (RRT).
l Bloodstream infection (positive cultures associated with two or more features of systemic inﬂammation
or any positive blood culture for fungi).
l Use of antibiotics for > 10 days.
l Number of red cell transfusions.
l Number of hypoglycaemic episodes either moderate (blood glucose < 2.5 mmol/l) or severe (blood
glucose < 2.0 mmol/l).
l Occurrence of seizures (clinical seizures requiring anticonvulsant therapy).
l Paediatric organ dysfunction score.43–45
l Number of children readmitted within 30 days of trial entry.
Thirty-day economic outcomes
l Hospital LOS within 30 days of trial entry.
l Hospital costs within 30 days of trial entry.
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Twelve-month end points (resource use; survival; attention and
behaviour in traumatic brain injury patients; costs)
l Number of days in PICU, and hospital LOS.
l Death within 12 months of trial entry.
l Assessment of attention and behaviour in patients with TBI as measured by the Health Utilities Index
[HUI®, Health Utilities Inc. (HUInc), Dundas, ON, Canada; www.healthutilities.com], the King’s outcome
scale for childhood head injury (KOSCHI),46 the Child Behavioural Checklist (CBCL) (ASEBA, University
of Vermont, Burlington, VT, USA; www.ASEBA.org) and the Conners’ rating scales revised – short
version (CRS-R:S).47
l Hospital and community health service costs within 12 months of trial.
Lifetime cost-effectiveness
l Cost per life-year (based on 12-month costs and survival for all cases).
l Cost per quality-adjusted life-year (QALY).
l Incremental net beneﬁts (INB).
l Cost per disability-free survivor (based on 12-month cost and outcomes data for subgroup with TBI).
Follow-up at 12 months
Parents were informed about the follow-up study at trial entry and asked to give consent for their children
to be included. The trial manager at the data co-ordinating centre (DCC) wrote to parents following
discharge from hospital to remind them about the follow-up, ask them whether or not they wished to
receive the trial results and ask them to keep the DCC informed about any change of address. A separate
letter was sent to bereaved parents.
At hospital discharge, parents were given a sample copy of a questionnaire (see Appendix 8) about service
use post discharge, and a letter explaining that they would be sent and asked to complete the same
questionnaire at the 12-month follow-up. To help the parents record and later recall use of any NHS
services, at hospital discharge parents were also given a diary (see Appendix 5). The purpose of this diary
was to allow parents to prospectively note resource use and to help them to remember it when the time
came to complete the questionnaire. They were not asked to return the diary. After 11 months, following
checks with the patient’s general practitioner (GP) to ﬁnd out whether or not the patient was still alive,
and whether or not the GP judged it was appropriate for the parents to receive the service-use
questionnaire, the trial manager sent the questionnaire to the parents of those patients who met the
eligibility criteria. For those parents who did not respond within 4 weeks, a ﬁrst reminder was issued by
post, and, if there was still no response after a further 4 weeks, the parent was contacted by telephone.
Follow-up ended when a postal questionnaire was returned either complete or blank, when a refusal was
obtained or after both reminders had been issued.
Because of the slower than expected recruitment rates, the funder, the National Institute for Health
Research’s Health Technology Assessment (HTA) programme, agreed a funding extension, but reduced the
time period for which patients could be followed up, that is patients randomised after 30 October 2010
were ineligible for this 1-year follow-up. This also had implications for the analysis of total LOS and costs
up to 12 months (see below).
Follow-up of traumatic brain injury subgroup
This subgroup is more likely to have longer-term morbidity. Although there were unlikely to be large
numbers of such children in the trial, parents of children (aged ≥ 4 years) in this subgroup were asked to
provide additional information at 12 months (for patients recruited until 2010), regarding overall health
status, global neurological outcome, and attention and behavioural status. Further details are given
in Appendix 6.
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Survival up to 12 months
If parents gave their consent, all children who survived to hospital discharge were followed up for up to
12 months post randomisation to determine mortality using information from the participating PICUs, the
children’s GPs or the NHS Information Centre and the NHS Central Register. The NHS number was used to
ensure accurate linkage to national death registration using the ‘list cleaning’ service of the Medical
Research Information Service at the NHS Information Centre for Health and Social Care.
Adverse events and safety reporting
The Royal Brompton and Hareﬁeld NHS Trust, as sponsor of this study, had the responsibility of ensuring
arrangements were in place to record, notify, assess, report, analyse and manage adverse events in order
to comply with Medicines for Human Use (Clinical Trials) Regulations 2004.
All sites involved in the study were expected to inform the chief investigator and lead research nurse of
any serious adverse events (SAEs)/reactions within 24 hours so that appropriate safety reporting procedures
could be followed by the sponsor.
It was therefore important that all site investigators involved in the study were aware of the reporting
process and timelines. Details of the mandatory adverse event and safety reporting requirements are
detailed in Appendix 3C.
Expected side effects
All adverse events judged by either the investigator or the sponsor as having a reasonable suspected causal
relationship to insulin therapy qualiﬁed as adverse reactions. Whereas any suspected, unexpected, serious
adverse reactions (SUSARs) involving insulin therapy were reported according to the timelines for SUSARs,
expected side effects of insulin were reported in the annual safety report unless serious enough to warrant
expedited reporting.
Hypoglycaemia is the principal side effect of insulin therapy. Moderate and severe hypoglycaemia were
deﬁned as a blood glucose < 2.5 mmol/l and < 2mmol/l48 respectively. The insulin administration protocols
aimed to achieve blood glucose control with the lowest possible incidence of hypoglycaemia and the
avoidance of neuroglycopenia (hypoglycaemia associated with neurological symptoms and signs such
as seizures and cerebral oedema). By deﬁnition, children in the TGC arm were at increased risk of
hypoglycaemia because the target range in this arm of the study (i.e. blood glucose 4–7mmol/l) was much
closer to the trial’s predeﬁned hypoglycaemic thresholds than the 10–12 mmol/l therapeutic window used
as a target for the control of blood glucose in the CM arm of the study. The principal operating procedure
used to avoid hypoglycaemia was blood glucose measurement every 30 minutes when insulin was ﬁrst
administered, and then every 45 minutes until blood glucose was controlled within the required range and
stable glucose and insulin infusion rates were achieved, and then hourly once stabilised.
Insulin is reported to occasionally cause a rash which may be associated with itching.
Data collection
To minimise the data collection load for busy units, the trial collaborated with the Paediatric Intensive Care
Audit Network (PICANet)49 to make best use of the established data collection infrastructure which exists
in all PICUs in the UK. The PICANet data set included many of the items being used in the trial and these
data were transmitted from the participating centres to the DCC electronically using strong encryption.
The remaining short-term data items were collected locally by the research nurses, and those for the
longer-term follow-up were collected separately by telephone and postal questionnaires. These data were
used to report the mean number of inpatient days following readmissions after 30 days, and the mean
outpatient and community service use at 12 months for all patients randomised. The main data collection
forms, questionnaires and covering letters are shown in Appendix 7.
All case report form (CRF) data were double entered onto electronic database storage systems at the DCC.
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Sample size
The primary outcome was VFD-30. A difference of 2 days in VFD-30 was considered clinically important.
Information from PICANet from a sample of PICUs for 2003–4 provided estimates that the mean VFD-30
in cardiac patients is 26.7 days, with a SD of 4.2 days. The corresponding ﬁgures for non-cardiac patients
were a mean of 22.7 days and a SD of 6.8 days. As the SD is estimated with error, to be conservative a SD
nearer 5.5 days for the cardiac and 8 days for the non-cardiac patients was assumed. There were likely to
be more non-cardiac than cardiac patients eligible for the trial. An overall SD across both cardiac and
non-cardiac strata of 7 days was therefore assumed. Assuming this was the same in both trial arms, and
taking a type I error of 1% (with a two-sided test), a total sample size of 750 patients would have 90%
power to detect this difference. Although minimal loss to follow-up at 30 days could be assumed, there
was the possibility of some non-compliance (some patients allocated to TGC not receiving this, and some
allocated to CM being managed with TGC). The target size was therefore inﬂated to 1000 to take account
of possible dilution of effect.
As information from PICANet indicated that there were differences in outcome between cardiac and
non-cardiac patients, not merely in VFD-30 but also in 30-day mortality (3.4% vs. 20%) and mean
duration of ventilation (3.7 vs. 8.0 days, survivors and non-survivors combined), the trial was powered to
be able to detect whether or not any effect of tight glucose control differed between the cardiac and
non-cardiac strata. To have 80% power for an interaction test to be able to detect a difference of 2 days
in the effect of intervention between the strata at the 5% level of statistical signiﬁcance, the sample size
was increased to 1500. If the interaction test was positive, this size would allow assessment of the effect
of TGC separately in the two strata.
Centres
The following PICUs in the UK planned to recruit patients into the CHiP trial: Birmingham Children’s
Hospital; Bristol Royal Hospital for Children; Great Ormond Street Hospital; Leeds General Inﬁrmary;
University Hospitals of Leicester – Glenﬁeld Hospital and Leicester Royal Inﬁrmary; Royal Brompton and
Hareﬁeld NHS Trust (Royal Brompton Hospital); Royal Liverpool Children’s NHS Trust; Royal Manchester
Children’s Hospital; St George’s Hospital; St Mary’s Hospital; Shefﬁeld Children’s NHS Foundation Trust;
Southampton General Hospital; and University Hospital of North Staffordshire.
Recruitment rate
There were estimated to be approximately 1300 eligible cardiac and 1550 eligible non-cardiac patients per
year in collaborating PICUs at the start of the trial. About half of those eligible were anticipated to be
recruited into the trial, predicting that the overall total sample size of 1500 would be accrued by
September 2011.
Type of analysis for clinical outcomes at discharge from paediatric
intensive care unit or at 30 days
Primary analyses were by intention to treat. For the primary outcome, linear regression models were used
to estimate a mean difference in VFD-30 between the two arms of the trial. For the secondary outcomes,
appropriate generalised linear models were used to examine the effect of the intervention. Odds ratios
and mean differences are reported with 95% CIs. Where there was evidence of non-normality in the
continuous outcome measures, non-parametric bootstrapping, with 1000 samples, was used to estimate
the effect of the intervention50 and bias-corrected CIs are reported.
Secondary analyses included the following prespeciﬁed subgroup analyses: cardiac surgical compared with
non-cardiac cases, age (< 1 year or between 1 and ≤ 16 years), TBI or not, RACHS1 (cardiac cases) (groups
1–4 vs. 5 and 6), PIM2 risk of mortality (non-cardiac cases) (categorised by probabilities of death of < 5%,
between 5% and < 15% and ≥ 15%), run-in cases (ﬁrst 100 randomised) compared with non-run-in
cases. Likelihood ratio tests for interactions were used to assess whether or not there was any difference in
the effect of the intervention in the different subgroups. Where stratiﬁed results are presented, the effects
in the different strata are estimated directly from the regression model with the interaction term included.
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Frequency of analysis
An independent Data Monitoring and Ethics Committee (DMEC) planned to review, in strict conﬁdence,
data from the trial approximately half-way through the recruitment period. The chair of the DMEC could
also request additional meetings/analyses. In the light of these data, and other evidence from relevant
studies, the DMEC would inform the Trial Steering Committee (TSC) if in their view:
i. There was proof that the data indicated that any part of the protocol under investigation was either
clearly indicated or clearly contraindicated for either all patients or a particular subgroup of patients,
using the Peto and Haybittle rule.51,52
ii. It was evident that no clear outcome would be obtained with the current trial design.
iii. They had a major ethical or safety concern.
Except for those who supplied the conﬁdential information, everyone (including the TSC, funders,
collaborators and administrative staff) remained ignorant of the results of the interim analysis
Economic evaluation
Overview
Cost–consequence analyses were undertaken to assess whether or not any additional costs of achieving
TGC were justiﬁed by subsequent reductions in hospitalisation costs and/or by improvements in patient
outcomes. The evaluations were conducted in two phases: in the ﬁrst phase, all hospital costs at 30 days
post randomisation were compared across randomised arms alongside 30-day clinical outcomes; and, in
the second phase, cost and outcomes at 12 months post randomisation were compared between arms,
and used to project relative cost-effectiveness over the lifetime. This aspect of the costing study took the
health and personal services perspective recommended by the National Institute for Health and Care
Excellence (NICE).53
Measurement of resource use up to 30 days post randomisation
The trial CRFs recorded the number of inpatient days for the index hospital episode following
randomisation, up to day 30. Within this index hospital episode, the CRFs recorded the number of PICU
days spent on the unit where the patient was randomised, and any subsequent PICU bed-days following
transfers to other hospitals. The CRFs also recorded the LOS on general medical (GM) wards, both within
the acute hospital where the patient was randomised and following transfer to other hospitals. The
number of day-case admissions was also noted. The total LOS for the initial hospital episode was
calculated as the sum of the LOS at PICUs and GM wards up to a maximum of 30 days following
randomisation. Any readmissions within 30 days to the PICU where the child was randomised were also
recorded. The LOS following these readmissions was added to the total number of days for the initial
episode, to give the total hospital LOS up to 30 days post randomisation.
Data on the level of care for PICU bed-days were available through routine collection of the Paediatric
Critical Care Minimum Data Set (PCCMDS)54 in 11 of the participating centres via the PICANet database.
The PCCMDS consists of 32 items recorded for each PICU bed-day that can be used to deﬁne the level of
care, that is the paediatric critical care health-care resource group (HRG).55 The PCCMDS data items were
extracted for each PICU bed-day after randomisation. Each PICU bed-day was then assigned to the
appropriate HRG (HRG, version 4), using the HRG grouper.55 [The HRG classiﬁcation includes items for
primary and secondary diagnosis, OPCS (Ofﬁce of Population, Censuses and Surveys’ Classification of
Surgical Operations and Procedures) codes for high-cost drugs, and ﬁelds for critical care activity.] Table 1
lists the HRG classiﬁcations for PIC with examples of procedures for each category. Figure 2 reports the
distribution of PICU bed-days across HRG categories for the 8954 PICU bed-days that were grouped
during the ﬁrst 30 days, both overall and for each site. The most common HRG category was ‘intensive
care basic enhanced’ [HRG level 4 (HRG4)]. For 1862 bed-days in the 11 sites that provided information,
PCCMDS data were missing or incomplete, and, for three centres (254 bed-days), no PCCMDS information
METHODS
14
NIHR Journals Library www.journalslibrary.nihr.ac.uk
was available. All these bed-days were assigned to the modal HRG category (HRG4) (see Sensitivity
analysis). For a total of 326 bed-days, the activity reported was categorised by the HRG grouper as ‘not
critical care activity’, and designated as bed-days on GM wards.
Unit costs
Unit costs were taken from the 2011 NHS Payments by Results (PbR) database, which includes reference
costs returns from each NHS trust.38 For all critical care admissions, each bed-day was costed with the
corresponding unit cost per bed-day from the PbR database.38 The unit cost of bed-days classiﬁed as
‘intensive care basic’ was taken as the average across all CHiP centres that returned reference costs for
that HRG category (HRG3, Table 2) (see Sensitivity analysis). Few NHS trusts returned reference cost
information for all seven paediatric critical care HRGs, so the relative unit costs for all HRGs apart from
TABLE 1 Health-care resource groups for paediatric critical care: deﬁnitions and examples
HRG Level Critical care unit Examples of procedures
HRG1 HDU basic ECG or CVP monitoring, oxygen therapy plus pulse oximetry
HRG2 HDU advanced Non-invasive ventilation, acute haemodialysis, vasoactive infusion
(inotrope, vasodilator)
HRG3 ICU basic Invasive mechanical ventilation, or non-invasive ventilation + vasoactive
infusion + haemoﬁltration
HRG4 ICU basic enhanced Invasive mechanical ventilation + vasoactive infusion, or advanced respiratory support
HRG5 ICU advanced Invasive mechanical ventilation or advanced respiratory support + haemoﬁltration
HRG6 ICU advanced
enhanced
Invasive mechanical ventilation or advanced respiratory support + burns > 79% BSA
HRG7 ICU ECMO/ECLS ECMO or ECLS, including VAD or aortic balloon pump
BSA, burns surface area; CVP, central venous pressure; ECG, electrocardiogram; ECLS, extracorporeal life support;
ECMO, extracorporeal membrane oxygenation; HDU, high-dependency unit; VAD, ventricular assist device.
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FIGURE 2 Distribution of paediatric critical care bed-days within 30 days post randomisation across HRG categorises
for CHiP patients. Proportion of paediatric critical care bed-days within each HRG category, overall and by centre.
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‘intensive care basic’ (HRG3) were calculated by multiplying the unit costs for HRG 3 by the relative cost
ratio from a previous detailed multicentre PICU costing study (see Sensitivity analysis).56 This previous study
assessed the relative staff input according to HRG category and reported the cost ratios listed (see Table 2).
Table 2 reports the PICU costs taken for the base case and subsequent sensitivity analyses (SAs). The unit
costs for GM bed-days and day-case admissions were taken from previous studies (Table 3).58,59
TABLE 2 Unit costs (£) of paediatric critical care for each HRG
HRG
Cost ratios (NHS
information centre)
PCC reference costs
(n = 11 CHiP centres)
PCC reference cost for ICU basic
weighted by cost ratios
HDU basic 0.75 1112 1324
HDU advanced 0.91 1315 1607
ICU basic 1 1765 1765
ICU basic
enhanced
1.22 2065 2154
ICU advanced 1.4 1998 2472
ICU advanced
enhanced
2.12 3061 3743
ICU ECMO/
ECLS
3.06 4026 5402
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; HDU, high-dependency unit;
PCC, paediatric critical care.
TABLE 3 Unit costs (£) of hospital and personal social services
Personal or social service Unit costa
Hospital inpatient bed-day 252
Hospital outpatient visit 147
Day cases 202
GP contact 47
GP practice nurse contact 11
Health visitor contact 11
District nurse contact 11
Social worker contact 9
Speech and language therapist contact 8
Occupational therapist contact 10
Physiotherapist contact 8
Children’s disability team contact 7
Hospital discharge co-ordinator contact 6
Child psychologist contact 15
Dietitian contact 8
Mental health service contact 27
Specialist paediatric nurse contact 14
School nurse contact 3
a Source of unit costs and assumed duration of contacts was taken
from Curtis 2011.57
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The base-case analysis assumed that all resource use required implementation of the TGC protocol or
management of side effects and was recognised by the HRG categorisation, as including any additional
resources could represent double-counting. A SA was also undertaken to investigate whether or not the
results were robust to an alternative approach whereby the resources and unit costs of implementing
the TGC protocol and managing hypoglycaemic events were considered as additional unit costs (see
Sensitivity analysis). To inform these SAs, information was collected on the nurse time, clinical time, number
of blood gas analyses and insulin required in managing a subsample of patients in either group during the
ﬁrst 48 hours in critical care after randomisation. Soluble insulin (Actrapid®, Novo Nordisk Limited) was
assumed to be used over a 24-hour period, the unit costs of which were taken from the British National
Formulary.60 The additional resources required in managing patients who in the CRFs were recorded as
having moderate or severe hypoglycaemic episodes were also considered. All unit costs were reported in
2010–11 prices.
Statistical analysis for the 30-day economic end points
All the economic analyses were based on the treatment arms as randomly allocated (‘intention to treat’).
Mean differences between treatment arms in resource use (e.g. total LOS summed across the index
hospital episode and readmissions to PICU within 30 days) were reported for the overall cohort, and
separately for subgroups admitted following either cardiac surgery (cardiac surgery) or no cardiac surgery
(non-cardiac). Incremental costs were estimated as the mean difference (95% CI) in total costs at 30 days
using ordinary least squares (OLS) regression analysis, with randomised arm as the only independent
variable. To test the hypothesis that incremental costs differed according to cardiac surgery status, the OLS
regression was repeated, including independent effects for randomised arm, cardiac surgery status and an
interaction term for randomised arm by cardiac status. A likelihood ratio test was then employed to
compare the model ﬁt to that from an OLS model that included randomised arm and cardiac surgery
status as independent effects. Finally, the above OLS regression models that included the interaction terms
for randomised arm by cardiac status were used to report the incremental costs for each subgroup (cardiac
surgery, non-cardiac).
Resource-use measurement between 30 days and 12 months
post randomisation
Index hospital episode and readmissions to the paediatric intensive care unit
within 30 days post randomisation
Information on PICU days and hospital LOS for up to 12 months was collected from the CHiP trial CRFs.
For CHiP patients whose index hospital episode exceeded 30 days, the CRFs collected information on their
continuing hospital stay up to a maximum of 12 months. The CRFs also noted any readmissions that were
within 30 days to the PICU where the patient was randomised. For both initial hospital episodes and
readmissions, the CRFs recorded subsequent transfers to other hospitals. For initial hospital admissions and
readmissions, the CRFs distinguished between the total LOS in PIC and those on GM wards, and day cases.
These data were used to report the total days in PIC and on GM wards up to 12 months. The last time
point at which 12-month follow-up data were available from the CRFs was 31 March 2012, so, for
patients randomised after 1 April 2011, it was possible that an index admission or a readmission was
censored before 12 months post randomisation.
Other hospital and community service use
The postal questionnaires were used to collect information on hospital and community service use, from
discharge from the index hospital episode up to 12 months post randomisation. This questionnaire was
based on one previously developed for neonatal intensive care,61 and modiﬁed to include those items of
service use most relevant to patients discharged from PIC. The items for the questionnaires were further
amended following comments from a panel of parents from the Medicines for Children Research Network
(MCRN). The ﬁnal questionnaire is appended61 (see Appendix 8). The items considered covered readmissions
to PIC other than those collected on the CRFs, readmissions to GM wards, outpatient visits, and contacts with
the GP, practice nurse, health visitor, social worker, speech and language therapist and child psychologist.
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Unit costs and calculation of total 12-month costs per patient
For PICU bed-days from 30 days to 12 months post randomisation, PCCMDS information was not available
for categorising each bed-day into the appropriate HRG4 category. Each PICU bed-day was, therefore,
assumed to be in the modal HRG4 category (intensive care basic enhanced) and assigned the
corresponding unit cost. GM bed-days and outpatient and community service use were valued with
national unit costs (see Table 3). Total costs for each patient were then calculated by summing the costs of
all hospital and community health services used.
Statistical analysis for the 12-month end points (resource use,
survival, costs)
Mean differences in resource use (e.g. days in PICU, on GM wards and combined) between the
randomised arms were reported. The proportion of patients still in hospital (index admission) was plotted
for up to 12 months post randomisation. Each of these items was reported for the overall cohort and
separately for those admitted for cardiac surgery or not.
The effect of TGC compared with CM on 12-month mortality and cost was then reported, overall and for
the cardiac and non-cardiac stratum. For a subsample of patients, 12-month health and community cost
data were censored. Other patients were judged ineligible or did not respond to the 12-month service-use
questionnaire. The cost data that were either censored or missing at 12 months were addressed with
multiple imputation (MI).62–64 The imputation models included baseline covariates, the number of ventilated
days, total LOS and costs at 30 days, and information on 12-month costs for those individuals for whom
this end point was observed. Each imputation model assumed that the data were ‘missing at random’,
that is conditional on the variables included in each imputation model.62 MI was employed based on
predictive mean matching,65 which offers relative advantages when dealing with data, such as costs that
have irregular distributions.66
Incremental costs were estimated as the mean difference (95% CI) in total costs at 12 months post
randomisation with OLS regression analysis. Incremental costs were reported both overall and for the
cardiac and non-cardiac strata.
As the missingness pattern may differ across treatment groups, separate imputation models were speciﬁed
for each comparator. Five imputed data sets were generated for the imputation models (see Sensitivity
analysis). After imputation, the analytical models were applied to estimate incremental costs overall, and
by subgroup to each imputed data set. Each of the resultant estimates was combined with Rubin’s
formulae,62 which recognise uncertainty both within and between imputations. All MI models were
implemented in R with multivariate imputation by chained equations.67
Sensitivity analysis
The base-case cost analysis made the following assumptions that a priori were judged potentially
important: (1) all relevant resource use relating to implementing the TGC protocol and managing side
effects was recognised by the paediatric critical care HRG categorisation; (2) PICU bed-days for which
PCCMDS data were missing or incomplete were in the HRG category for ‘basic enhanced intensive care’
(HRG4); (3) the cost ratios from a previous PICU costing study reﬂected the relative costs; (4) the average
unit costs for HRG4 were taken just from CHiP sites; (5) the regression models had residuals that were
normally distributed.
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The following separate, univariate, SAs tested whether or not the results were robust to the following
alternative assumptions.
1. Inclusion of the costs of implementing the TGC protocol and managing hypoglycaemic episodes as
specific additional items. The HRG categorisation could be insensitive to the resource use required to
implement the TGC protocol, and for managing hypoglycaemic episodes. SAs were therefore
conducted that considered any additional staff times, blood gas analyses and insulin required for:
i. implementing the TGC protocol compared with CM
ii. as for i. but also including any further costs for managing the moderate or severe hypoglycaemic
episodes recorded.
2. Reassignment of PICU bed-days without HRG classification to either:
i. ‘ICU basic’ (HRG3); or
ii. ‘ICU advanced’ (HRG5).
(a) The unit costs for each level of care in PICU were taken directly from PbR. Rather than using the
cost ratios, unit costs from PbR were used for each HRG level.
(b) PICU costs were taken as national averages: the unit costs of PIC were taken as averages from all
centres that returned the relevant costs in PbR including non-CHiP sites.
(c) Assume gamma rather than normal distributions for costs at 30 days and 12 months. The
assumption that costs are normally distributed may not be plausible,68 so here costs were allowed to
follow a gamma distribution.69
3. The MI was rerun with 10 imputations. In some circumstances, ﬁve imputations may be insufﬁcient to
test the impact of increasing the number of imputations; the imputation models were rerun but with
10 imputations.
For each SA, the effect of TGC compared with CM on 12-month costs was reported, overall and for the
cardiac and non-cardiac subgroups.
Lifetime cost-effectiveness analysis
The cost and outcome data collected at 1 year were used to project the impact of the intervention on
longer-term costs and outcomes. Kaplan–Meier survival curves were plotted out to the maximum time
of follow-up, overall and then separately for cardiac and non-cardiac cases. Alternative parametric
functions were considered for extrapolating mortality up to 5 years, by ﬁtting commonly recommended
alternative distributions to the CHiP survival data, excluding the ﬁrst 365 days post randomisation, as the
event rate during this early period was anticipated to be atypical and not to provide an appropriate basis
for extrapolation. The base-case analysis used the ‘most appropriate’ parametric survival curves judged
according to which gave the best ﬁt to the observed data and the most plausible extrapolation relative to
the age- and gender-matched general population.70 Survival extrapolations were considered for the ﬁrst
5 years from randomisation, as this was anticipated to be the period over which the risk of death
would be higher than that for the age- and gender-matched general population. After 5 years post
randomisation, all-cause death rates were assumed to be that of the age- and gender-matched general
population. The parametric extrapolations for years 1–5 were combined, applying all-cause death rates
for years 6 onwards to report life expectancy for each CHiP patient observed to survive at 1 year.
The projected life expectancy was used to report life-years following TGC compared with CM both
overall and for the cardiac and non-cardiac strata.
Previous evidence suggests that a minority of PICU survivors may suffer from long-term disability and
reductions in quality of life (QoL), and therefore QALYs were reported. QoL data were not collected for the
patients who did not have TBI in the CHiP trial. Instead, information was used from a previous study that
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included a large sample of PICU patients with similar baseline characteristics to those of the
patients of the CHiP study71 and reported QoL with the HUI questionnaire at 6 months after the index
admission. The mean QoL from this previous study (0.73, on a scale anchored at 0, death, and 1,
perfect health) was applied to weight each life-year of those CHiP patients predicted to be alive 12 months
after randomisation.
To project costs attributable to the initial critical care admission for years 1–5, the inpatient, outpatient and
community service costs reported from the service-use survey at 1 year were assumed to be maintained
until the end of year 2. Previous studies have suggested that, between 3 and 4 years after the initial PICU
admission, around 10% of survivors have relatively severe disability. Those predicted to survive in years 3–5
were, therefore, assumed to have incurred 10% of the mean costs reported at 12 months. Those patients
who were observed or predicted to die before 12 months were assigned zero QALYs.
Lifetime incremental costs per life-year, and per QALY gained, were reported. INBs were calculated by
valuing each QALY at the £20,000 per QALY threshold recommended by NICE.53 All future costs and
life-years were discounted at the recommended rate of 3.5%.53 All incremental cost-effectiveness results
are reported overall, and then for the cardiac and non-cardiac strata.
Sensitivity analysis on lifetime cost-effectiveness analysis
The following further SAs were run to test the assumptions made in the lifetime analyses:
1. An alternative parametric extrapolation was used to project survival from year 1 to 5.
2. Excess mortality compared with the age- and gender-matched general population was assumed to
remain for 10 rather than 5 years post randomisation, that is the parametric extrapolation was applied
for years 1–10, and then applied for all-cause death rates.
3. It was assumed that trial patients were not subject to any excess mortality other than that of the
age- and gender-matched general population.
4. Rather than assuming the mean QoL (0.73) from a previous study, the values given by the lower and
upper 95% CIs around that mean (0.71 to 0.75) were assumed.
5. Alternative assumptions were made about the duration and magnitude of the costs:
i. For all patients who survived beyond 1 year, it was assumed that costs were maintained until the
end of year 3 (rather than 2).
ii. 10% of costs were assumed to be maintained over years 3–10 rather than years 3–5.
iii. The costs for years 2–5 were assumed to be 50% not 10% of those at 12 months.
iv. i. to iii. above were combined.
For each of these SAs, the lifetime INBs of TGC compared with CM overall and for the cardiac and
non-cardiac strata were reported.
Ancillary studies
In addition to the main study, the grant holders welcomed more detailed or complementary studies,
provided that proposals were discussed in advance with the TSC and appropriate additional research ethics
approval was sought. These will not be discussed further in this monograph.
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Publication policy
To safeguard the integrity of the trial, data from this study were not presented in public or submitted for
publication without requesting comments and receiving agreement from the TSC. The primary results of
the trial will be published by the group as a whole in collaboration with local investigators and local
investigators will be acknowledged. The success of the trial was dependent on the collaboration of many
people. The results were, therefore, presented ﬁrst to the trial local investigators. A summary of the results
of the trial will be sent to parents of participating children on request and also made available on the
trial website.
Organisation
A TSC (see Appendix 9) and a DMEC were established (see Appendix 10). Day-to-day management of the
trial was overseen by a Trial Management Group (TMG) (see Appendix 11). Each participating centre
identiﬁed a paediatric intensivist as a PI (see Appendix 12). Each participating centre was allocated funding
(from the core trial grant, from the MCRN and/or from local Comprehensive Local Research Networks) for
research nursing time, and employed or reallocated a research nurse to support all aspects of the trial at
the local centre.
Conﬁdentiality
Patients were identiﬁed by their trial number to ensure conﬁdentiality. However, as the patients in the trial
were contacted about the study results (and patients recruited until November 2010 were followed up for
12 months following randomisation), it was essential that the team at the DCC had the names and
addresses of the trial participants recorded on the data collection forms in addition to the allocated trial
number. Stringent precautions were taken to ensure conﬁdentiality of names and addresses at the DCC.
The chief investigator and local investigators ensured conservation of records in areas to which access
is restricted.
Audit
To ensure that the trial was conducted according to the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and Good Clinical
Practice (GCP) guidelines, site audits were carried out on a random basis. The local investigator was
required to demonstrate knowledge of the trial protocol and procedures and ICH and GCP. The
accessibility of the site ﬁle to trial staff and its contents were checked to ensure all trial records were
being properly maintained. Adherence to local requirements for consent was examined.
If the site had full compliance, the site visit form was signed by the lead research nurse. In the event of
non-compliance, the DCC and/or the lead research nurse addressed the speciﬁc issues to ensure that
relevant training and instruction were given.
The CHiP trial also passed an inspection by the Medicines and Healthcare products Regulatory Agency
(MHRA) (August 2009).
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Termination of the study
At the termination of planned recruitment, the DCC contacted all sites by telephone, email or fax in order
to terminate all patient recruitment as quickly as possible. After all recruited patients had been followed
until 30 days post randomisation (or hospital discharge if stay > 30 days), a declaration of the end of trial
form was sent to EudraCT and the Multicentre Research Ethics Committee (MREC). The following
documents will be archived in each site ﬁle and kept for at least 5 years: original consent forms, data
forms, trial-related documents and correspondence. At the end of the analysis and reporting phase, the
trial master ﬁles at the clinical co-ordinating centre and DCC will be archived for 15 years.
Funding
The costs for the study itself were covered by a grant from the HTA programme. Clinical costs were met by
the NHS under existing contracts.
Indemnity
If there is negligent harm during the clinical trial, when the NHS body owes a duty of care to the person
harmed, NHS indemnity covers NHS staff, medical academic staff with honorary contracts and those
conducting the trial. NHS indemnity does not offer no-fault compensation.
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Chapter 3 Results
Recruitment
Trial recruitment began on 4 May 2008. As indicated in Chapter 2, recruitment was slower than expected.
This was mainly a result of delays in trial initiation at some sites, clinical constraints and a ‘research
learning curve’ in many of the participating units which had no previous experience of recruiting critically ill
children to clinical trials. These delays necessitated an application to the HTA programme for an extension
to the trial. The HTA programme granted funding to allow recruitment to be extended to allow the trial to
achieve sufﬁcient power (1500 children) to identify whether or not there was a differential effect for the
primary end point (VFD-30) in the two strata (cardiac and non-cardiac).
The DMEC conﬁdentially reviewed unblinded interim analyses on two occasions. In addition, they met to
discuss SAEs and recruitment rates on three further occasions.
Recruitment closed on 31 August 2011, as agreed in the HTA funding. A total of 19,924 children were screened
from 13 sites. Of these, 1384 were recruited and randomised (701 to TGC and 683 to CM). The reasons for
non-recruitment are shown in Table 4. Of the 1384, 15 were subsequently found to be ineligible (Table 5),
leaving 1369 eligible children (694 to TGC and 675 to CM) randomised into the trial – 91% of the original target
of 1500. The ﬂow of patients is shown in Figure 3 and cumulative recruitment in Figure 4. Recruitment by site is
shown in Table 6.
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TABLE 4 Numbers screened with reasons for non-recruitment
Reason not recruited
All screened, non-recruited
patients N = 18,540
n n/N (%)
Inclusion criteria > 16 years 211 1.14
Mechanical ventilator and vasoactive drugs not likely
to be continued for > 12 hours
2285 12.32
Arterial line not in situ 1576 8.50
Not ventilated 2637 14.22
No inotropes 9601 51.79
Exclusion criteria < 36 weeks corrected gestational age 565 3.05
Diabetes mellitus 56 0.30
Error of metabolism 268 1.45
Treatment withdrawal/limitation 312 1.68
> 5 days on PICU 135 0.73
Already participated in CHiP 262 1.41
Other Refused consent 1116 6.02
Patient died 143 0.77
Not asked within time frame 531 2.86
Other (further details in box below) 1573 8.48
Text responses for category ‘other’
Research nurse on leave/ill/unavailable (weekend) 322
ECMO/transplant 134
Language difﬁculties 127
In another trial/approached for another trial 116
Legal/social issues 109
No decision within time frame 97
PI – clinical decision 95
Parents not available/too upset 89
Transferred to another hospital 48
Non-TBI site 33
Other 403
ECMO, extracorporeal membrane oxygenation.
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TABLE 5 Ineligible patients
TGC arm CM arm
During a monitoring visit it was found that this patient had
not fully consented
During the ﬁnal data analysis the trial statistician found
that this patient actually met one of the exclusion criteria,
i.e. he or she was in PICU for > 5 days before he or she
was randomised
In response to a query it was found that this patient was
recruited in error. He or she did not meet one of the
eligibility criteria (taking vasoactive drugs)
During the ﬁnal data analysis the trial statistician found
that this patient actually met one of the exclusion criteria,
i.e. he or she was in PICU for > 5 days before he or she
was randomised
Patient randomised incorrectly, possibly met one of the
exclusion criteria,as when randomised had suspected
metabolic illness; therefore treatment was stopped early
During the ﬁnal data analysis the trial statistician found
that this patient actually met one of the exclusion criteria,
i.e. he or she was in PICU for > 5 days before he or she
was randomised
Parents had forgotten that their child had previously been
in the trial; therefore he or she was not eligible for the trial
During the ﬁnal data analysis the trial statistician found
that this patient actually met one of the exclusion criteria,
i.e. he or she was in PICU for > 5 days before he or she
was randomised
Patient randomised in error: met the exclusion criterion of
having an inborn error of metabolism (Refsum’s disease,
which is a rare disorder of lipid metabolism)
Patient randomised in error: met the exclusion criterion of
being in PICU for > 5 days but site did not realise until after
randomised
During the ﬁnal data analysis the trial statistician found
that this patient actually met one of the exclusion criteria,
i.e. he or she was in PICU for > 5 days before he or she
was randomised
Patient randomised in error: met the exclusion criterion of
being in PICU for > 5 days but site did not realise until after
randomised
Patient randomised in error: did not meet the inclusion
criterion of being on inotropes at randomisation
Patient randomised in error: met the exclusion criterion of
having an inborn error of metabolism (Barth syndrome)
Patient randomised in error: did not meet the inclusion
criterion of being on inotropes at randomisation
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Patients considered potentially
eligible for trial (n = 4441)
Randomised (n = 1384)
Refused consent (n = 1093)
Not asked within time frame (n = 513)
Other (n = 1469)
Not randomised  (n = 3057)
Protocol violations (n = 7) Protocol violations (n = 8)
< 36 weeks’ gestation (n = 565)
> 16 years (n = 211)
Diabetes mellitus (n = 56)
Established or suspected diagnosis of inborn error of metabolism (n = 268)
Treatment withdrawal or limitation (n = 312)
Inpatient on PICU/CICU for > 5 consecutive days (n = 135)
Already participated in CHiP trial during previous admission (n = 262)
Mechanical ventilation and vasoactive support drugs not likely to
 continue beyond 12 hours (n = 2285)
Arterial line not in situ (n = 1576)
Refused consent (n = 23)
Patient died (n = 143)
Not asked within time frame (n = 18)
Other (n = 104)
Not ventilated (n = 2637)
No inotropes (n = 9601)
Ineligible (n = 15,483)
Screened (n = 19,924)
Did not receive insulin
(n = 233)
Received insulin
(n = 461)
n = 694 Information available for primary
outcome
n = 675
CM (n = 675)TGC (n = 694)
Did not receive insulin
(n = 566)
Received insulin
(n = 109)
Deaths within 30
days (n = 35)
Deaths within 30
days (n = 34)
n = 329
n = 607
n = 194
n = 84
n = 128
n = 34
Potentially eligible for 12-month follow-up
Administratively censored before 12 months
Ineligible for 12-month follow-up
Questionnaire sent
Did not respond to questionnaire
Responded to questionnaire
Died within 30 days and before 12 months
Refused to participate
n = 622
n = 202
n = 89
n = 330
n = 207 (62.7%) n = 201 (61.1%)
n = 123
n = 37
n = 1 n = 0
FIGURE 3 A flow chart showing the flow of patients. Note that the information on vital status up to 12 months was
available from the Office for National Statistics, aside from for 17 non-UK nationals.
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Comparability at baseline
The characteristics of the children at baseline are shown in Table 7. The randomised groups were broadly
comparable at trial entry. Sixty-two per cent were randomised within 1 day of admission to PICU. In terms
of the prespeciﬁed stratifying factors, two-thirds were aged < 1 year, and 60% of the children were in the
cardiac surgery stratum. Seven per cent of children in the cardiac surgery stratum were considered to be
undergoing surgical procedures associated with a high risk of mortality (RACHS1 score 5 or 6), and 19%
of children in the non-cardiac group had a PIM2 score indicative of a ≥ 15% risk of PICU mortality.
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FIGURE 4 Cumulative recruitment – actual accrual vs. revised expected.
TABLE 6 Recruitment per site
Site Screened (N) Randomised [n (%)]
1. Birmingham Children's Hospital 3490 241 (6.9)
2. Bristol Royal Hospital for Children 1525 148 (9.7)
3. Great Ormond Street Hospital 3878 210 (5.4)
4. Leeds General Inﬁrmary 278 3 (1.1)
5. Royal Brompton Hospital 1695 158 (9.3)
6. Royal Liverpool Children's NHS Trust 2145 164 (7.6)
7. Royal Manchester Children's Hospital 1806 75 (4.2)
8. St Mary’s Hospital 935 60 (6.4)
9. Shefﬁeld Children's NHS Foundation Trust 320 22 (6.9)
10. Southampton General Hospital 2416 219 (9.1)
11. University Hospital of North Staffordshire 419 15 (3.6)
12. University Hospitals of Leicester 946 63 (6.7)
14. St George's Hospital 71 6 (8.5)
Total 19,924 1384
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TABLE 7 Characteristics at baseline
Characteristic TGC (N = 694) CM (N = 675)
Centrea
1 122 119
2 71 75
3 101 106
4 1 2
5 78 76
6 82 80
7 41 34
8 31 28
9 10 12
10 111 106
11 9 6
12 34 29
14 3 2
Sex
Male [n (%)] 389 (56.05) 363 (53.78)
Age (years)a
0 to < 1 [n (%)] 432 (62.24) 421 (62.36)
1 to < 16 [n (%)] 262 (37.75) 254 (37.63)
Median (IQR) 0.49 (0.07–2.72) 0.53 (0.08–2.73)
Weight (kg) [mean (SD)] 12.13 (15.11) 11.31 (12.88)
Height (cm) [mean (SD)] 76.24 (32.67) 76.09 (31.75)
Not measured 65 63
Waist circumference (cm) [mean (SD)] 44.88 (14.30) 44.13 (12.82)
Not measured 140 150
Trial entry following cardiac surgery [n (%)]a 421 (60.66) 416 (61.63)
Other trial entry [n (%)]a 273 (39.34) 259 (38.37)
Undergoing cardiopulmonary bypass N = 421b N = 416b
n (%) 396 (94.06) 392 (94.23)
RACHS1 scorea,c N = 421b N = 416b
1–4 [n (%)] 388 (92.16) 393 (94.47)
5–6 [n (%)] 33 (7.84) 23 (5.53)
Predicted risk of mortality (PIM2)a,c N = 273b N = 259b
< 5% [n (%)] 74 (27.11) 67 (25.87)
5–15% [n (%)] 144 (52.75) 144 (55.60)
≥ 15% [n (%)] 55 (20.15) 48 (18.53)
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Actual management
Table 8 describes the observed management of blood glucose after randomisation, and shows a clear
difference between the two arms of the study. In the TGC arm, 461 of the children (66%) received insulin
compared with 109 of 675 (16%) in the CM arm. Children in the TGC arm received more insulin, and
continued on insulin for longer. Figure 5 shows the mean daily blood glucose level by arm. There was a
clear separation between the two randomised arms, with children in the TGC arm having a signiﬁcantly
lower blood glucose proﬁle than those in the CM arm.
TABLE 7 Characteristics at baseline (continued )
Characteristic TGC (N = 694) CM (N = 675)
Time from admission to trial entry (days) [median (IQR)] 1 (0–2) 1 (0–1)
Inotrope score [mean (SD)] 15.00 (21.58) 16.22 (21.07)
Blood glucose (mmol/l) [mean (SD)] 7.10 (2.76) 7.02 (2.86)
Not measured 1
Plasma creatinine (µmol/l) [mean (SD)] 50.69 (44.33) 54.54 (40.58)
Not measured 69 52
PELOD scorec [mean (SD)] 7.46 (7.04) 7.70 (6.58)
IQR, interquartile range; PELOD, paediatric organ dysfunction.
a Minimisation factor.
b Number who entered the trial following cardiac surgery.
c Higher score indicates poorer performance.
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FIGURE 5 Mean glucose level.
TABLE 8 Actual management after randomisation
Actual management TGC (N = 694) CM (N = 675)
Insulin administered (yes) [n (%)] 461 (66.43) 109 (16.15)
Total insulin given (IU/kg body weight) [mean (SD)] 2.56 (6.18) (N = 461) 1.29 (2.85) (N = 109)
Number of days on insulin [mean (SD)] 3.24 (3.32) 1.71 (1.19)
Time from randomisation to starting insulin (hours) [median (IQR)] 3.37 (0.78–17.93) 3.1 (0.09–42.18)
IU, international unit.
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Thirty-day clinical outcomes
Primary outcome
Results for the primary outcome are shown in Table 9. The mean number of VFD-30 from randomisation
was 23 in both trial arms (mean difference 0.36; 95% CI –0.42 to 1.14).
Secondary outcomes
The secondary outcomes up to 30 days are shown in Table 10, and the duration of ventilation in Figure 6
and of vasoactive drug use in Figure 7. In general, the secondary outcomes are similar between the arms
over the 30-day period, although less RRT was undertaken in the TGC arm (odds ratio 0.63; 95% CI 0.45
to 0.89). Additionally, mean caloric intake (Figure 8) was similar between the two groups.
TABLE 10 Secondary outcomes 30 days post randomisation
Outcome
TGC
(N = 694)
CM
(N = 675)
Mean difference/odds
ratio (95% CI)
Death within 30 days of trial entry [n (%)] 35 (5.04)a 34 (5.04)a 1.00 (0.62 to 1.63)
Number of days in PICU [mean (SE)] 6.50 (0.21) 6.96 (0.24) –0.47 (–1.12 to 0.15)
Number of days in hospital [mean (SE)] 16.40 (0.34) 16.73 (0.36) –0.33 (–1.24 to 0.62)
Duration of mechanical ventilation (days) [mean (SE)] 5.30 (0.19) 5.61 (0.21) –0.31 (–0.87 to 0.25)
PELOD score [mean (SE)] 9.79 (0.19) 9.79 (0.21) –0.31 (–0.87 to 0.25)
Duration of vasoactive drug use (days) [median (IQR)] 3 (2 to 6) 4 (2 to 6) –0.20 (–0.64 to 0.25)
RRT [n (%)] 62 (8.93) 91 (13.48) 0.63 (0.45 to 0.89)
Bloodstream infection [n (%)] 38 (5.48) 43 (6.37) 0.85 (0.54 to 1.34)
Use of antibiotics > 10 days [n (%)] 62 (8.93) 74 (10.96) 0.80 (0.56 to 1.14)
Number of red blood cell transfusions [mean (SE)] 1.00 (0.11) 1.12 (0.11) –0.11 (–0.43 to 0.18)
Number of patients who experienced at least one hypoglycaemic
episode (moderate or severe) [n (%)]
110 (15.85) 25 (3.70) 4.90 (3.13 to 7.67)
Number of moderate hypoglycaemic episodes (< 2.0–2.5mmol/l)
Number of episodes 127 30
Number of patients who experienced at least one episodeb [n (%)] 87 (12.54) 21 (3.11) 4.46 (2.73 to 7.28)
Mean number of episodes per patient (SE) 0.18 (0.03) 0.04 (0.01)
Number of severe hypoglycaemic episodes (< 2.0mmol/l)
Number of episodes 70 11
Number of patients who experienced at least one episodeb [n (%)] 51 (7.35) 10 (1.48) 5.27 (2.65 to 10.48)
Mean number of episodes per patient (SE) 0.1 (0.02) 0.02 (0.005)
Seizures given pharmacological treatment [n (%)] 23 (3.31) 15 (2.22) 1.15 (0.77 to 2.98)
PELOD, paediatric organ dysfunction; SE, standard error.
a Outcome missing for two patients (one in TGC arm and one in CM arm).
b Patients who experienced moderate episodes may also have experienced a severe episode and vice versa.
TABLE 9 Primary outcome 30 days post randomisation
Outcome
TGC (n = 694)
[mean (standard error)]
CM (n = 675)
[mean (standard error)]
Mean difference/odds
ratio (95% CI)
VFD-30 23.61 (0.27) 23.24 (0.29) 0.36 (–0.42 to 1.14)
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In terms of adverse effects, there were 135 patients whose blood glucose level was below the threshold
that deﬁned moderate hypoglycaemia; 61 of these had one or more episodes that were considered severe.
Hypoglycaemia occurred in 33 (4.1%) patients not given insulin, but was more commonly observed in
patients who received insulin [102 (17.9%)].
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FIGURE 6 Proportion of patients on mechanical ventilation.
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Hypoglycaemia occurred in a greater proportion of patients in the TGC arm than in the CM arm of the
study (moderate, 12.5% vs. 3.1%, p < 0.001; severe, 7.3% vs. 1.5%, p < 0.001). Of the patients who
experienced any hypoglycaemic episode, 11.1% died as opposed to 4.4% of those who did not
experience any hypoglycaemic episode (p = 0.001).
Stratified analyses
Table 11a–e shows the primary outcome for the main prespeciﬁed stratiﬁcation factors. None of the
interaction tests between the intervention and prespeciﬁed subgroups was statistically signiﬁcant,
suggesting that there is no difference in the effect of TGC on VFD-30 in the different strata [p = 0.63
(cardiac vs. non-cardiac); p = 0.28 (age < 1 vs. ≥ 1 year); p = 0.09 (RACHS1 1–4 vs. 5–6); p = 0.88 (PIM2
< 5% vs. 5–15% vs. ≥ 15%) and p = 0.66 (run-in cases vs. non-run-in cases)]. One of the prespeciﬁed
stratiﬁed analyses (TBI or not) was not included, as only 13 TBI patients were followed up at 1 year.
TABLE 11a Ventilator-free days at 30 days post randomisation stratiﬁed by cardiac and non-cardiac patients
TGC (N = 694) CM (N = 675) Mean difference (95% CI)
Cardiac
n 421 416
Mean (SE) 25.05 (0.27) 24.80 (0.31) 0.25 (–0.71 to 1.22)
Non-cardiac
n 273 259
Mean (SE) 21.37 (0.52) 20.74 (0.54) 0.63 (–0.58 to 1.84)
SE, standard error.
TABLE 11b Ventilator-free days at 30 days post randomisation stratiﬁed by age < 1 year and age ≥ 1 year
TGC (N = 694) CM (N = 675) Mean difference (95% CI)
Age < 1 year
n 432 421
Mean (SE) 23.59 (0.35) 23.56 (0.36) 0.03 (–0.96 to 1.02)
Age ≥ 1 year
n 262 254
Mean (SE) 23.63 (0.44) 22.72 (0.49) 0.91 (–0.36 to 2.18)
SE, standard error.
TABLE 11c Ventilator-free days at 30 days post randomisation stratiﬁed by operative complexity (cardiac)
Operative complexity TGC (N = 421) CM (N = 416) Mean difference (95% CI)
RACHS 1–4
n 388 393
Mean (SE) 25.29 (0.27) 25.13 (0.29) 0.17 (–0.66 to 0.99)
RACHS 5 or 6
n 33 23
Mean (SE) 22.21 (1.32) 19.26 (2.27) 2.95 (–0.15 to 6.06)
SE, standard error.
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In both cardiac and non-cardiac strata, hypoglycaemia occurred in a greater proportion of patients in the
TGC arm than in the CM arm of the trial (moderate: cardiac 10.9% vs. 1.4%, p < 0.001; non-cardiac
15.4% vs. 5.8% p < 0.001; severe: cardiac 5.5% vs. 0.5%, p < 0.001; non-cardiac 10.3% vs. 3.1%,
p = 0.001). Cardiac cases receiving insulin were not at a greater risk of hypoglycaemia than non-cardiac
cases (16.4% vs. 20.3%).
Thirty-day economic outcomes
For the index hospital episode, the mean PICU bed-days, LOS on GM wards and total LOS for the index
hospital episode were similar between arms (Table 12). The mean total number of hospital days up to
day 30, including both the initial episode and readmissions to the initial PICU before day 30, were similar
between arms (see Table 12). For the stratum admitted for cardiac surgery, the mean total LOS was again
comparable between arms (Table 13). As regards the non-cardiac stratum, for the initial hospital episode,
the mean numbers of PICU days, LOS on GM wards and total LOS were lower for the TGC than the
CM arm (Table 14).
TABLE 11d Ventilator-free days at 30 days post randomisation stratiﬁed by predicted risk of mortality (non-cardiac)
Predicted risk of mortality TGC (N = 272) CM (N = 261) Mean difference (95% CI)
PIM2 < 5%
n 74 67
Mean (SE) 24.22 (0.70) 22.82 (0.87) 1.40 (–1.42 to 4.42)
PIM2 5–15%
n 144 144
Mean (SE) 21.22 (0.72) 20.59 (0.70) 0.63 (–1.33 to 2.58)
PIM2 ≥ 15%
n 55 48
Mean (SE) 17.95 (1.39) 18.29 (1.50) –0.35 (–3.63 to 2.94)
SE, standard error.
TABLE 11e Ventilator-free days at 30 days post randomisation stratiﬁed by run-in (ﬁrst 100 cases) and non-run-in
TGC (N = 694) CM (N = 675) Mean difference (95% CI)
Run-in – ﬁrst 100 cases
n 47 53
Mean (SE) 23.62 (1.04) 22.64 (1.05) 0.98 (–1.91 to 3.86)
Non-run-in
n 647 254
Mean (SE) 23.61 (0.28) 23.30 (0.30) 0.31 (–0.50 to 1.12)
SE, standard error.
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TABLE 12 Lengths of stay (days) within 30 days post randomisation: whole study cohort
TGC (N = 694) CM (N = 675)
Index hospital episode
Mean (SD) PICU days 6.50 (5.50) 6.96 (6.12)
Mean (SD) days on general wards 9.91 (7.43) 9.77 (7.52)
Mean (SD) total days 16.40 (8.84) 16.73 (9.26)
Readmission
n (%) 39 (5.62) 37 (5.48)
Mean (SD) total days 0.21 (1.02) 0.25 (1.27)
Mean (SD) total hospital daysa 16.62 (8.81) 16.98 (9.25)
a Total days for the index episode and readmissions, from randomisation up to day 30.
TABLE 13 Lengths of stay (days) within 30 days post randomisation: cardiac surgery subgroup
TGC (N = 421) CM (N = 416)
Index hospital episode
Mean (SD) PICU days 5.69 (4.79) 5.89 (5.37)
Mean (SD) days on general wards 9.26 (6.83) 8.32 (6.34)
Mean (SD) total days 14.96 (8.29) 14.22 (8.19)
Readmission
n (%) 35 (8.31) 26 (6.25)
Mean (SD) total days 0.31 (1.20) 0.32 (1.49)
Mean (SD) total hospital daysa 15.27 (8.29) 14.54 (8.25)
a Total days for the index episode and readmissions, from randomisation up to day 30.
TABLE 14 Lengths of stay (days) within 30 days post randomisation: non-cardiac surgery subgroup
TGC (N = 273) CM (N = 259)
Index hospital episode
Mean (SD) PICU days 7.74 (6.25) 8.68 (6.83)
Mean (SD) days on general wards 10.90 (8.18) 12.10 (8.62)
Mean (SD) total days 18.63 (9.22) 20.78 (9.46)
Readmission
n (%) 4 (1.47) 11 (4.25)
Mean (SD) total days 0.07 (0.64) 0.13 (0.80)
Mean (SD) total hospital daysa 18.70 (9.20) 20.91 (9.43)
a Total days for the index episode and readmissions, from randomisation up to day 30.
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Tables 15–17 report that the mean numbers of PICU bed-days, by HRG level, were similar between arms.
Overall, the mean total costs at 30 days post randomisation were similar between arms (Table 18). For the
cardiac subgroup, the mean total costs per patient were £16,228 (TGC) and £17,005 (CM) (Table 19). For
the non-cardiac subgroup, the TGC arm had lower mean costs than the CM group, with an incremental
cost of –£2319 (95% CI –£4702 to £124) (Table 20). Including the treatment by cardiac interaction term
led to a statistically signiﬁcant improvement in model ﬁt (p < 0.001).
TABLE 17 Mean (SD) PICU bed-days by HRG level within 30 days post randomisation: non-cardiac surgery subgroup
HRG level TGC (n = 273) CM (n = 259)
1 0.53 (1.07) 0.37 (0.73)
2 0.63 (1.40) 0.80 (1.90)
3 1.48 (2.69) 1.91 (3.26)
4 2.80 (3.33) 2.61 (3.65)
5 0.68 (2.88) 0.65 (1.74)
6 0.25 (0.59) 0.40 (1.10)
7 0.14 (1.62) 0.08 (0.66)
TABLE 16 Mean (SD) PICU bed-days by HRG level within 30 days post randomisation: cardiac surgery subgroup
HRG level TGC (n = 421) CM (n = 416)
1 0.17 (0.48) 0.19 (0.55)
2 0.81 (1.26) 0.96 (1.77)
3 0.57 (1.46) 0.60 (1.57)
4 2.44 (2.99) 2.42 (2.79)
5 0.42 (1.62) 0.37 (1.21)
6 0.14 (0.65) 0.11 (0.39)
7 0.09 (1.40) 0.03 (0.35)
TABLE 15 Mean (SD) PICU bed-days by HRG level within 30 days post randomisation: whole study cohort
HRG level TGC (n = 694) CM (n = 675)
1 0.31 (0.80) 0.26 (0.63)
2 0.74 (1.32) 0.90 (1.83)
3 0.93 (2.08) 1.10 (2.44)
4 2.59 (3.13) 2.48 (3.14)
5 0.52 (2.20) 0.48 (1.44)
6 0.18 (0.63) 0.22 (0.74)
7 0.11 (1.49) 0.05 (0.50)
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TABLE 18 Total and incremental costs (£) within 30 days post randomisation: whole study cohort
TGC (n = 694)
[mean (SD)]
CM (n = 675)
[mean (SD)]
Incremental
[mean (95% CI)]
Index hospital episode
PICU costs 13,607 (13,579) 14,446 (12,938)
GM costs 2497 (1872) 2463 (1895)
Total costs 16,104 (13,499) 16,908 (12,923)
Readmission
PICU costs 58 (658) 26 (499)
GM costs 54 (240) 64 (316)
Total costs 112 (750) 90 (612)
Total costs (index admission and readmissions) 16,228 (13,504) 17,005 (12,913) –776 (–2183 to 632)
TABLE 19 Total and incremental costs (£) within 30 days post randomisation: cardiac surgery subgroup
TGC (n = 421)
[mean (SD)]
CM (n = 416)
[mean (SD)]
Incremental
[mean (95% CI)]
Index hospital admission
PICU costs 11,956 (12,379) 12,119 (11,200)
GM costs 2336 (1722) 2098 (1597)
Total costs 14,291 (12,413) 14,216 (11,272)
Readmissions
PICU costs 80 (771) 42 (635)
Other ward costs 76 (288) 82 (367)
Total costs 156 (873) 124 (761)
Total costs (index admission and readmissions) 14,465 (12,437) 14,350 (11,285) 114 (–1496 to 1725)
TABLE 20 Total and incremental costs (£) within 30 days post randomisation: non-cardiac surgery subgroup
TGC (n = 273)
[mean (SD)]
CM (n = 259)
[mean (SD)]
Incremental
[mean (95% CI)]
Index hospital admission
PICU costs 16,153 (14,915) 18,184 (14,587)
GM costs 2746 (2060) 3048 (2172)
Total costs 18,899 (14,609) 21,232 (14,195)
Readmission
PICU costs 26 (427) 0 (0)
GM costs 19 (129) 36 (207)
Total costs 45 (501) 36 (207)
Total costs (index admission and readmissions) 18,949 (14,614) 21,268 (14,183) –2319 (–4762 to 124)
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Twelve-month results
Index hospital episode and readmissions to paediatric intensive care unit
within 30 days post randomisation
Table 21 reports the mean total number of hospital days up to 12 months post randomisation, including
the initial hospital episode and any readmissions to PICU within 30 days. A lower proportion of patients in
the TGC than in CM arm had an index hospital admission or relevant readmission that continued beyond
day 30. Between 30 days and 12 months post randomisation, the mean number of days in PICU, on GM
wards and in total, was lower for the TGC than the CM arm (see Table 21).
Four patients were still in hospital at the date of administrative censoring, with LOS ranging from 119 to
359 days. Each of these patients was assumed to have the mean total LOS taken across the whole sample
still in hospital at the respective time point. (For example, for the patient censored at a LOS of 119 days,
the assumed LOS was 228 days, according to the mean across the 46 patients still in hospital 118 days
post randomisation.) One patient withdrew consent for participation in the study, after 8 days in hospital,
and was assumed to have a total hospital LOS of 60 days, the mean across the whole sample of patients
who were still in hospital after day 8.
For the cardiac stratum, the mean total LOS at 12 months was similar between arms (Table 22). For the
non-cardiac subgroup, the TGC arm had a lower proportion of patients who had a hospital admission that
continued beyond 30 days post randomisation, and on average reported fewer days on PICUs, and on GM
wards (Table 23), than the CM arm. For the non-cardiac stratum, the mean total LOS for the initial episode
TABLE 22 Lengths of stay (days) within 12 months post randomisation: cardiac surgery subgroup
TGC (N = 421) CM (N = 416)
Mean (SD) days at 30 days post randomisation 15.27 (8.29) 14.54 (8.25)
30 days to 1 year
n (%) continuing admission 59 (14.01) 52 (12.50)
Mean (SD) PICU days 1.39 (8.81) 1.26 (6.70)
Mean (SD) days on general wards 3.25 (18.54) 4.40 (26.48)
Mean (SD) total days 4.64 (22.17) 5.65 (29.30)
Mean (SD) total hospital daysa 19.90 (26.40) 20.19 (33.19)
a Includes hospital days between randomisation and 12 months for initial hospital episode and readmissions to initial PICU
that were within 30 days.
Source: CRFs.
TABLE 21 Lengths of stay (days) within 12 months post randomisation: whole study cohort
TGC (N = 694) CM (N = 675)
Mean (SD) total days up to 30 days post randomisation 16.62 (8.81) 16.98 (9.25)
30 days to 1 year
n (%) continuing admission 130 (18.73) 152 (22.52)
Mean (SD) PICU days 1.98 (11.86) 2.79 (15.19)
Mean (SD) days on general wards 5.67 (25.89) 9.75 (36.22)
Mean (SD) total days 7.64 (31.18) 12.54 (41.47)
Mean (SD) total hospital daysa 24.26 (35.40) 29.52 (46.18)
a Includes hospital days between randomisation and 12 months for initial hospital episode and readmissions to initial PICU
that were within 30 days.
Source: CRFs.
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and readmissions to PICU within 30 days was 31.0 days for the TGC arm compared with 44.5 days for the
CM arm (see Table 23).
Figure 9 plots the proportion of patients over time who were still in hospital following the index
admission. For the overall sample, and the cardiac patients, the proportion still in hospital was similar
between arms at each time point. For the non-cardiac patients, a higher proportion of the CM than the
TGC arm were still in hospital 60 and 90 days post randomisation.
Mortality
Mortality at 12 months was similar between the randomised groups (Table 24). The CIs around each of the
odds ratios all encompassed 1.
Assessment of attention and behaviour in patients with traumatic
brain injury
No differences were found between the two arms of the trial in attention and behaviour measures for
those patients with TBI (Table 25).
Other hospital and community service use (after discharge from
index hospital episode but excluding any readmissions to the initial
paediatric intensive care unit within 30 days)
Figure 10 shows the ﬂow of patients from randomisation to response to the service-use questionnaire. In
the overall sample, a total of 397 patients (203 in the TGC arm, 194 in the CM arm) were randomised
after 30 October 2010 and could not be followed up for 1 year; that is, for the purposes of collecting
information on service use, these patients were administratively censored. Patients were also ineligible for
the service-use questionnaire if their GP did not conﬁrm that it was appropriate to contact them to
administer the questionnaire. Of the eligible patients, the response rate to the service-use questionnaire
was 63% in the TGC arm and 61% in the CM arm. For those who responded to the questionnaire,
the mean LOS following hospital readmissions after 30 days post randomisation, and the mean number
of contacts with hospital and personal social services, was similar between the randomised arms
(Tables 26–28). The mean total costs of hospital and community health services were also similar between
the randomised arms (Tables 29–31).
TABLE 23 Lengths of stay (days) within 12 months post randomisation: non-cardiac surgery subgroup
TGC (N = 273) CM (N = 259)
Mean (SD) days at 30 days post randomisation 18.70 (9.20) 20.91 (9.43)
30 days to 1 year
n (%) continuing admission 71 (26.01) 100 (38.61)
Mean (SD) PICU days 2.88 (15.40) 5.25 (22.82)
Mean (SD) days on general wards 9.40 (33.97) 18.35 (46.66)
Mean (SD) total days 12.27 (41.03) 23.60 (53.98)
Mean (SD) total hospital daysa 30.98 (45.18) 44.51 (58.59)
a Includes hospital days between randomisation and 12 months for initial hospital episode and readmissions to initial PICU
that were within 30 days.
Source: CRFs.
RESULTS
38
NIHR Journals Library www.journalslibrary.nihr.ac.uk
0.00
0.25
0.50
0.75
1.00
675
694
162
139
76
46
40
22
29
17
21
12
12
8
CM
TGC
0 30 60 90 120 150 180
Time from randomisation (days)
CM
TGC
(a)
Pr
o
p
o
rt
io
n
 o
f 
p
at
ie
n
ts
Number at risk
0.00
0.25
0.50
0.75
1.00
416
421
55
65
19
19
9
9
7
6
5
2
5
1
CM
TGC
0 30 60 90 120 150 180
Time from randomisation (days)
CM
TGC
(b)
Pr
o
p
o
rt
io
n
 o
f 
p
at
ie
n
ts
Number at risk
0.00
0.25
0.50
0.75
1.00
259
273
107
74
57
27
31
13
22
11
16
10
7
7
CM
TGC
0 30 60 90 120 150 180
Time from randomisation (days)
CM
TGC
(c)
Pr
o
p
o
rt
io
n
 o
f 
p
at
ie
n
ts
Number at risk
FIGURE 9 Proportion of patients remaining in hospital (index admission) up to 180 days post randomisation.
Proportion of patients remaining in hospital: (a) whole study cohort; (b) cardiac surgery subgroup; and
(c) non-cardiac surgery group.
TABLE 24 Vital status within 12 months post randomisation: overall, cardiac and non-cardiac
Deaths within 12 months
by group [n (%)]
Odds ratio (95% CI)TGC CM
Overall (TGC, N = 694; CM, N = 675) 73 (10.52) 71 (10.52) 1.00 (0.71 to 1.41)
Cardiac (TGC, N = 421; CM, N = 416) 31 (7.36) 30 (7.21) 1.02 (0.61 to 1.72)
Non-cardiac (TGC, N = 273; CM, N = 259) 42 (15.38) 41 (15.83) 0.97 (0.61 to 1.54)
Information on vital status at 12 months was not available for 17 patients who were non-UK nationals.
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TABLE 25 Attention and behaviour measures at 12 months (subgroup comprising children diagnosed with brain
injury at trial entry)
Measure TGC (N = 6) CM (N = 7)
KOSCHIa
1–4A [n (%)] 2 (33.3) 2 (28.7)
4B–5B [n (%)] 4 (66.7) 5 (71.4)
HUIa [mean (SE)] 0.74 (0.15) 0.97 (0.03)
Behaviour – CBCL total scoreb [mean (SD)] 62.8 (5.66) 55.6 (4.22)
CRS-R:S total scoreb [mean (SE)] 51.2 (5.53) 54.4 (5.40)
SE, standard error.
a Lower score indicates lower health status.
b Higher score indicates lower health status.
12-month follow-up
Potentially eligible for 12-month follow-up
Administratively censored
before 12 months
n = 329
Ineligible for 12-month follow-up
Questionnaire sent
n = 622
n = 202
n = 607
n = 194
n = 84n = 89
n = 128
Did not respond to questionnaire
Responded to questionnaire
n = 330
n = 207 (62.7%)
n = 123
n = 201 (61.1%)
Died before 12 months
n = 694
n = 72
n = 675
n = 68
TGC CM
n = 1 Refused to participate n = 0
FIGURE 10 Flow chart for 12-month follow-up for service-use questionnaire.
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TABLE 26 Levels of service use for questionnaire responders within 12 months post randomisation: whole
study cohort
Service
TGC (n = 207)
[mean (SD)]
CM (n = 201)
[mean (SD)]
Inpatient hospital days following readmissiona 6.12 (1.01) 6.63 (1.29)
Hospital outpatient visits 6.81 (0.46) 6.93 (0.45)
GP contacts 1.23 (0.12) 1.08 (0.99)
Practice nurse contacts 1.76 (0.21) 2.14 (0.29)
Health visitor contacts 5.85 (0.74) 6.87 (0.69)
Social worker contacts 0.10 (0.02) 0.08 (0.02)
Speech and language therapist contacts 2.18 (0.38) 1.88 (0.32)
Occupational therapist contacts 7.83 (1.80) 11.94 (2.30)
Other health service contacts 9.52 (1.13) 10.04 (1.11)
a Readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or readmissions to the
same PICU that were after day 30.
Source: service-use questionnaire.
TABLE 27 Levels of service use for questionnaire responders within 12 months post randomisation: cardiac
surgery subgroup
Service
TGC (n = 127)
[mean (SD)]
CM (n = 121)
[mean (SD)]
Inpatient hospital days following readmissiona 7.10 (1.50) 8.25 (2.03)
Hospital outpatient visits 6.81 (0.59) 6.64 (0.55)
GP contacts 1.37 (0.17) 1.19 (0.13)
Practice nurse contacts 1.88 (0.25) 2.11 (0.05)
Health visitor contacts 6.24 (0.78) 8.24 (0.98)
Social worker contacts 0.05 (0.02) 0.03 (0.01)
Speech and language therapist contacts 2.32 (0.71) 1.77 (0.50)
Occupational therapist contacts 5.84 (1.99) 7.20 (2.26)
Other health service contacts 8.86 (1.31) 9.06 (1.44)
a Readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or readmissions to the
same PICU that were after day 30.
Source: service-use questionnaire.
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TABLE 28 Levels of service use for questionnaire responders within 12 months post randomisation:
non-cardiac surgery subgroup
Service
TGC (n = 79)
[mean (SD)]
CM (n = 80)
[mean (SD)]
Inpatient hospital daysa 4.54 (1.00) 4.15 (1.00)
Hospital outpatient visits 6.82 (0.75) 7.36 (0.75)
GP contacts 1.02 (0.19) 0.91 (0.13)
Practice nurse contacts 1.58 (0.39) 2.18 (0.53)
Health visitor contacts 5.22 (1.47) 4.78 (0.86)
Social worker contacts 0.17 (0.04) 0.17 (0.04)
Speech and language therapist contacts 2.32 (0.71) 1.77 (0.50)
Occupational therapist contacts 11.04 (3.45) 11.17 (4.58)
Other health service contacts 10.60 (2.08) 10.63 (1.97)
a Readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or readmissions to the
same PICU that were after day 30.
Source: service-use questionnaire.
TABLE 29 Costs (£) of health and personal social services for questionnaire responders, between discharge from the
index admission and 12 months post randomisation: whole study cohort
Service
TGC (n = 207)
[mean (SD)]
CM (n = 201)
[mean (SD)]
Inpatient hospital daysa 1367 (243) 1402 (264)
Hospital outpatient visits 1019 (66) 1002 (68)
GP contacts 51 (5) 58 (6)
Practice nurse contacts 13 (3) 10 (4)
Health visitor contacts 67 (8) 78 (8)
Social worker contacts 3 (1) 3 (1)
Speech and language therapist contacts 18 (3) 15 (3)
Other health service contacts 115 (15) 119 (15)
a Refers to readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or
readmissions to the same PICU that were after day 30.
Source: service-use questionnaire.
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Twelve-month total costs
Tables 32–34 report the total costs at 12 months across all the resource-use items recorded. The values
presented are the results after using MI to handle missing values for health and community service costs at
12 months. Table 32 reports that, overall, the mean total costs were lower in the TGC than in the CM
group, but with 95% CIs that encompass zero. For the cardiac surgery stratum, the mean total costs were
similar between the groups (see Table 33), but, for non-cardiac patients, the mean costs were lower in
the TGC than in the CM group, with an incremental cost of –£9865 (95% CI –£18,558 to –£1172)
(see Table 34).
TABLE 30 Costs (£) of health and personal social services for questionnaire responders, between discharge from the
index admission and 12 months post randomisation: cardiac surgery subgroup
Service
TGC (n = 127)
[mean (SD)]
CM (n = 121)
[mean (SD)]
Inpatient hospital daysa 1576 (358) 1732 (414)
Hospital outpatient visits 976 (82) 1001 (87)
GP contacts 56 (6) 65 (8)
Practice nurse contacts 12 (5) 5 (3)
Health visitor contacts 71 (9) 94 (11)
Social worker contacts 2 (1) 1 (1)
Speech and language therapist contacts 17 (16) 16 (3)
Other health service contacts 107 (19) 104 (19)
a Readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or readmissions to the
same PICU that were after day 30.
Source: service-use questionnaire.
TABLE 31 Costs (£) of health and personal social services for questionnaire responders, between discharge from the
index admission and 12 months post randomisation: non-cardiac subgroup
Service
TGC (n = 79)
[mean (SD)]
CM (n = 80)
[mean (SD)]
Hospital inpatient daysa 1029 (256) 900 (211)
Hospital outpatient visits 1082 (111) 1004 (111)
GP contacts 48 (7) 48 (9)
Practice nurse contacts 16 (7) 17 (8)
Health visitor contacts 59 (17) 54 (10)
Social worker contacts 4 (11) 5 (11)
Speech and language therapist contacts 19 (6) 14 (4)
Other health service contacts 127 (25) 141 (26)
a Readmissions to GM wards, to PICUs other than the one the patient was originally randomised to or readmissions to the
same PICU that were after day 30.
Source: service-use questionnaire.
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TABLE 32 Total costs (£) at 12 months post randomisation: whole study cohort
TGC (n = 694)
[mean (SD)]
CM (n = 675)
[mean (SD)]
Incremental
[mean (95% CI)]
Hospital costs at 30 days 16,228 (13,504) 17,005 (12,913)
Hospital costs between 30 days and
12 monthsa
5683 (27,978) 8463 (35,366)
Other hospital and community health
service costs
at 12 monthsb
2388 (3659) 2452 (4010)
Grand total costs up to 1 year 24,300 (34,503) 27,920 (42,775) –3620 (–7743 to 502)
a Includes index hospital admissions and readmissions to initial PICU that were within 30 days but that continued beyond
day 30. Source: CRF.
b Includes other hospital readmissions, and other hospital and community service use. Source: service-use questionnaire.
TABLE 33 Total costs (£) at 12 months post randomisation: cardiac surgery subgroup
TGC (n = 421)
[mean (SD)]
CM (n = 416)
[mean (SD)]
Incremental
[mean (95% CI)]
Hospital costs at 30 days 14,465 (12,437) 14,350 (11,285)
Hospital costs between 30 days and
12 monthsa
3811 (20,497) 3815 (17,720)
Other hospital and community health
service costs at 12 monthsb
2652 (3890) 2630 (4319)
Grand total costs up to 1 year 20,929 (27,385) 20,796 (26,520) 133 (–3568 to 3833)
a Includes index hospital admissions and readmissions to initial PICU that were within 30 days but that continued beyond
day 30. Source: CRF.
b Includes other hospital readmissions, and other hospital and community service use. Source: service-use questionnaire.
TABLE 34 Total costs (£) at 12 months post randomisation: non-cardiac surgery subgroup
TGC (n = 273)
[mean (SD)]
CM (n = 259)
[mean (SD)]
Incremental
[mean (95% CI)]
Hospital costs at 30 days 18,949 (14,614) 21,268 (14,183)
Hospital costs between 30 days and
12 monthsa
8569 (36,495) 15,927 (51,688)
Other hospital and community health
service costs at 12 monthsb
1979 (3056) 2167 (3437)
Grand total costs up to 1 year 29,498 (4267) 39,363 (58,551) –9865 (–18,558 to –1172)
a Includes index hospital admissions and readmissions to initial PICU that were within 30 days but that continued beyond
day 30. Source: CRF.
b Includes other hospital readmissions, and other hospital and community service use. Source: service-use questionnaire.
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Figures 11–13 report SAs that investigate whether or not the base-case results are robust to alternative
assumptions. The results show that the incremental costs under these alternative scenarios are similar to
the base case. For example, in the SAs that include additional costs of staff time and tests associated with
monitoring TGC, and further costs for managing hypoglycaemic episodes, the mean incremental costs of
TGC overall and for the non-cardiac subgroup are similar to the base case (see Figures 11–13). Moreover,
when alternative approaches were taken to unit costing, this had little impact on the results.
Base case
Extra costs for implementing
protocol
Extra costs for implementing protocol
and managing hypoglycaemic episodes
Reassignment of critical care
bed-days (ICU basic)
Reassignment of critical care
bed-days (ICU advanced)
Unit cost from payment
by results
National average critical care
unit costs
Gamma distribution of costs
10 multiple imputation data sets
– 12,000 – 10,000 – 8000 – 6000 – 4000 – 2000 20000
Incremental cost (TGC vs. CM)
Vertical dashed line indicates incremental costs in the base-case analysis.
Solid vertical line indicates no difference in costs between TGC and CM.
FIGURE 11 Sensitivity analysis reporting mean total costs at 12 months post randomisation according to alternative
assumptions: whole study cohort.
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Extra costs for implementing
protocol
Extra costs for implementing protocol
and managing hypoglycaemic episodes
Reassignment of critical care
bed-days (ICU basic)
Reassignment of critical care
bed-days (ICU advanced)
Unit cost from payment
by results
National average critical care
unit costs
Gamma distribution of costs
10 multiple imputation data sets
– 10,000 – 6000– 8000 – 4000 – 2000 0 2000 60004000
Incremental cost (TGC vs. CM)
Vertical dashed line indicates incremental costs in the base-case analysis.
Solid vertical line indicates no difference in costs between TGC and CM.
FIGURE 12 Sensitivity analysis reporting mean total costs at 12 months post randomisation according to alternative
assumptions: cardiac surgery subgroup.
Base case
Extra costs for implementing
protocol
Extra costs for implementing protocol
and managing hypoglycaemic episodes
Reassignment of critical care
bed-days (ICU basic)
Reassignment of critical care
bed-days (ICU advanced)
Unit cost from payment
by results
National average critical care
unit costs
Gamma distribution of costs
10 multiple imputation data sets
– 20,000 – 12,000– 16,000 – 8000 – 4000 0
Incremental cost (TGC vs. CM)
Vertical dashed line indicates incremental costs in the base-case analysis.
Solid vertical line indicates no difference in costs between TGC and CM.
FIGURE 13 Sensitivity analysis reporting mean total costs at 12 months post randomisation according to alternative
assumptions: non-cardiac surgery subgroup.
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Lifetime cost-effectiveness results
The Kaplan–Meier survival curves show that when the time horizon was extended beyond 1 year,
for those for whom survival data were available, the probability of survival remained similar between
arms (Figure 14).
Figure 15 considers alternative parametric extrapolations for both treatment arms combined, using the
observed survival data after day 30. Of the alternative survival functions, the Gompertz function appears to
ﬁt the observed data best in that it reports the lowest Akaike and Bayesian information criterion (Table 35).
The Gompertz function also offers the most plausible projections of future survival (Table 36), in that the
levels of excess death compared with those for the age- and gender-matched general population remain
constant over time from 2 years post randomisation onwards.
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FIGURE 14 Kaplan–Meier survival curves. Overall cohort, TGC vs. CM.
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FIGURE 15 Comparison of alternative parametric extrapolations for survival from 12 months to 5 years post
randomisation, across both randomised arms.
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Tables 37–39 present the resultant life-years, QALYs, lifetime costs and INBs according to the base-case
assumptions. Overall, at a threshold of £20,000 per QALY, the INBs are positive, but with wide 95% CIs
that include zero. For cardiac patients, the INBs are close to zero with wide CIs. For non-cardiac patients,
the INBs are positive but with 95% CIs that include zero.
The cost-effectiveness acceptability curves consider alternative thresholds of willingness to pay for a QALY
gain, and show that, overall and for the cardiac surgery stratum, it is highly uncertain whether or not TGC
is cost-effective (Figures 16 and 17). For the non-cardiac stratum, the probability that TGC is cost-effective
is relatively high. For example, at ceiling ratios of £10,000 to £30,000 per QALY, the probability that
TGC is cost-effective ranges from 90% to 70% (Figure 18).
The SA on the lifetime results suggests that these ﬁndings are robust to alternative assumptions about the
extrapolation of long-term survival, QoL for PICU survivors or long-term costs (Figures 19–21).
TABLE 36 Ratios of the death rates from applying alternative parametric extrapolations for all patients from the
CHiP Study compared with the age- and gender-matched general population
Year Gompertz Logistic Weibull Log-normal Exponential Gamma
1 6.51 5.60 5.57 5.65 3.55 6.05
2 4.86 4.49 4.46 4.58 4.25 4.72
3 5.28 5.85 5.82 5.90 6.67 5.67
4 5.31 6.96 6.95 6.91 8.97 6.28
5 5.23 7.89 7.89 7.73 11.12 6.70
TABLE 35 Fit of alternative parametric survival functions applied to the CHiP study data after day 365
Distribution AIC BIC
Gompertz 305.9559 326.3428
Gamma 302.0634 327.547
Log-normal 306.6391 327.026
Logistic 310.0006 330.3875
Weibull 310.2893 330.6762
Exponential 315.8474 331.1376
AIC, Akaike information criterion; BIC, Bayesian information criterion.
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TABLE 39 Lifetime cost-effectiveness analysis: mean (SD) costs (£), life-years and INBs (£): non-cardiac surgery
subgroup
TGC (n = 273)
[mean (SD)]
CM (n = 259)
[mean (SD)]
Incremental
[mean (95% CI)]
Lifetime costs 32,364 (42,515) 42,214 (58,432) –9850 (–18,521 to –1180)
Life-years 23.48 (10.03) 23.38 (10.15) 0.10 (–1.62 to 1.82)
QALY 17.14 (7.32) 17.07 (7.41) 0.07 (–1.18 to 1.33)
INBs 11,322 (–15,791 to 38,615)
Costs, QALYs and life-years all discounted at 3.5%; INBs calculated by valuing a QALY gain at a threshold of £20,000
per QALY.
TABLE 37 Lifetime cost-effectiveness analysis: mean (SD) costs (£), life-years and INBs (£): whole study cohort
TGC (n = 694)
[mean (SD)]
CM (n = 675)
[mean (SD)]
Incremental
[mean (95% CI)]
Lifetime costs 27,330 (34,262) 30,951 (42,600) –3620 (–7723 to 482)
Life-years 24.99 (8.58) 25.01 (8.58) –0.02 (–0.93 to 0.89)
QALY 18.25 (6.26) 18.26 (6.27) –0.01 (–0.68 to 0.65)
INBs 3346 (–11,203 to 17,894)
Costs, QALYs and life-years all discounted at 3.5%; INBs calculated by valuing a QALY gain at a threshold of £20,000
per QALY.
TABLE 38 Lifetime cost-effectiveness analysis: mean (SD) costs (£), life-years and INBs (£): cardiac surgery subgroup
TGC (n = 421)
[mean (SD)]
CM (n = 416)
[mean (SD)]
Incremental
[mean (95% CI)]
Lifetime costs 24,066 (27,139) 23,939 (26,304) 128 (–3542 to 3797)
Life-years 25.97 (7.33) 26.03 (7.26) –0.05 (–1.04 to 0.94)
QALY 18.96 (5.35) 19.00 (5.30) –0.04 (–0.76 to 0.68)
INBs –919 (–16,661 to 14,823)
Costs, QALYs and life-years all discounted at 3.5%; INBs calculated by valuing a QALY gain at a threshold of £20,000
per QALY.
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FIGURE 18 Probability that TGC vs. CM is cost-effective at alternative levels of willingness to pay for a life-year
gained: non-cardiac surgery subgroup.
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FIGURE 16 Probability that TGC vs. CM is cost-effective at alternative levels of willingness to pay for a life-year
gained: whole study cohort.
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FIGURE 17 Probability that TGC vs. CM is cost-effective at alternative levels of willingness to pay for a life-year
gained: cardiac surgery subgroup.
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Excess deaths applied for 10 years
No excess deaths
Excess deaths from gamma
distribution
QoL upper
QoL lower
Inpatient costs maintained up to 3 years
and 50% cases incurred costs 4 – 10 years
Inpatient costs maintained up to 2 years
and 10% cases incurred costs 3 – 10 years
Inpatient costs maintained up to 2 years
and 50% cases incurred costs 3 – 5 years
Inpatient costs maintained up to 3 years
and 10% cases incurred costs 4 – 5 years
Base case
– 30,000– 20,000– 10,000 10,000 20,000 30,000 40,000 50,0000
Incremental net benefits (TGC vs. CM)
Vertical dashed line indicates incremental net benefits in the base-case analysis. Solid vertical line
indicates difference in incremental net benefits between TGC and CM.
FIGURE 19 Sensitivity analysis reporting lifetime INBs (£) according to alternative assumptions: whole study cohort.
Excess deaths applied for 10 years
No excess deaths
Excess deaths from gamma
distribution
QoL upper
QoL lower
Inpatient costs maintained up to 3 years
and 50% cases incurred costs 4 – 10 years
Inpatient costs maintained up to 2 years
and 10% cases incurred costs 3 – 10 years
Inpatient costs maintained up to 2 years
and 50% cases incurred costs 3 – 5 years
Inpatient costs maintained up to 3 years
and 10% cases incurred costs 4 – 5 years
Base case
– 30,000– 20,000– 10,000 10,000 20,000 30,000 40,000 50,0000
Incremental net benefits (TGC vs. CM)
Vertical dashed line indicates incremental net benefits in the base-case analysis. Solid vertical line
indicates difference in incremental net benefits between TGC and CM.
FIGURE 20 Sensitivity analysis reporting lifetime INBs (£) according to alternative assumptions: cardiac
surgery subgroup.
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and 10% cases incurred costs 4 – 5 years
Base case
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Incremental net benefits (TGC vs. CM)
Vertical dashed line indicates incremental net benefits in the base-case analysis. Solid vertical line
indicates difference in incremental net benefits between TGC and CM.
FIGURE 21 Sensitivity analysis reporting lifetime INBs (£) according to alternative assumptions:
non-cardiac surgery subgroup.
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Chapter 4 Discussion
The aims of the CHiP trial were to evaluate the clinical effectiveness, safety and cost-effectiveness of apolicy of TGC compared with CM for an overall population of children in PICUs and for subgroups
admitted to PICU following cardiac surgery or for other reasons. The results suggest that, overall, TGC
has no effects on major clinical outcomes such as death and/or ventilator days, whether at 30 days or at
1 year. However, the secondary outcomes reveal a complex relationship of gains and potential harm
from the intervention. TGC results in a slight reduction in the proportion of patients receiving RRT, but
hypoglycaemia occurs in a greater proportion of patients in the TGC arm than in the CM arm of the study
(severe hypoglycaemia 7.3% vs. 1.5%). TGC reduces mean hospital LOS and total costs at 12 months
after PICU admission. The lower costs reﬂect the reductions in PICU days and total hospital LOS for the
subgroup not admitted for cardiac surgery. For children admitted for cardiac surgery, the LOS and costs are
similar between the randomised arms.
It is interesting to speculate why there might be a differential effect of TGC on non-cardiac surgery cases
as opposed to cardiac surgery cases. Hyperglycaemia is known to be associated with the activation of
alternative metabolic pathways for glucose, some of which have the potential to generate reactive
metabolites or trigger inﬂammatory pathways. Insulin, in contrast, can promote an anti-inﬂammatory
milieu. Cardiopulmonary bypass has often been proposed as a proxy model for inﬂammation, in that it is
known to be associated with the activation of major inﬂammatory pathways. Recent developments in
clinical strategies are thought to have improved outcomes in children undergoing cardiopulmonary bypass.
For instance, corticosteroids, modiﬁed ultraﬁltration, low-prime-volume circuits and newer circuit
components have been shown to, or are assumed to, favourably modify these inﬂammatory processes.
It may be, therefore, that cardiac surgery in children is no longer associated with ‘sufﬁcient’ inﬂammatory
pathway activation for TGC to result in signiﬁcant clinical beneﬁt. In contrast, in the non-cardiac surgery
cases, stress hyperglycaemia from sepsis and a variety of other medical conditions may, in fact, be truly
detrimental,29 and hence control of the derangement is important for survival and limiting renal injury.
Given that these problems may take days to manifest, it is entirely possible that the effects may be more
identiﬁable at later time points, for example at 60 or even 90 days.
The ﬁnding that TGC leads to an average reduction in 12-month costs of approximately £10,000 for the
non-cardiac surgery subgroup is robust to alternative stand points (such as the inclusion of any additional
costs from monitoring the increased number of hypoglycaemic episodes in the TGC arm). The lifetime
cost-effectiveness analysis suggests that it is highly uncertain that TGC is cost-effective in the cardiac
surgery subgroup, whereas, for children admitted for other reasons, TGC appears relatively cost-effective.
Therefore, for the patients not admitted for cardiac surgery, the ﬁndings from this study suggest that a
TGC protocol would lead to earlier discharge from PICUs and hospital, leading to possible cost savings.
The potential NHS cost savings from a TGC policy can be estimated by combining the CHiP ﬁndings with
projections of the annual incidence of eligible cases using the trial screening logs, or the PICANet49 database.
The trial screening logs suggest that approximately 1300 admissions per year from the 13 CHiP centres
would be eligible for TGC in routine practice, approximately 500 of which (around 40%) would be admitted
for reasons other than cardiac surgery. If implementing TGC rather than CM for this subgroup does reduce
average costs per patient by £10,000, then TGC could yield annual cost savings of around 5 million pounds
in the CHiP centres alone. This approach underestimates total cost reductions, as not all potentially eligible
cases were screened in CHiP centres, and some PICUs in England and Wales did not participate in the study.
PICANet provides an alternative source for calculating the annual incidence of eligible cases; it includes all
PICUs in England and Wales and avoids undercounting the incidence of eligible cases from incomplete
screening. We applied the main CHiP eligibility criteria to PICANet data from 2004–11. This includes all
children who stayed for > 2 days in PIC in England and Wales, who received inotropes and mechanical
ventilation and who were not admitted following cardiac surgery. The result was approximately
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1500 admissions per year. To allow for the other CHiP eligibility criteria, which could not be applied to
PICANet data, we reduced the anticipated number of admissions by 20% to 1200 per year, which gives
annual cost savings to the NHS in England and Wales of approximately £12M. This approximation
recognises that most, but not all, of the inclusion criteria required for children to be eligible for TGC could
be applied to the PICANet data. More fundamentally, it should be recognised that introducing a policy of
TGC would not realise full ﬁnancial cost savings. Instead, PICU and hospital beds would be ‘released’ if
patients were discharged earlier and other patients were allowed to use these resources.
Limitations
The primary end point in the study was selected based on the best evidence at the time and took into
account usual practice in reporting short-term outcomes in studies conducted on critically ill patients. Our
results, however, indicate that for non-cardiac surgical cases, it may be better to assess VFDs or QoL at a
later time point, for example day 60, in future studies.
The cost-effectiveness analysis has some limitations. First, the level of activity was measured only within
PICUs and only for up to day 30, after which general PICU costs were assumed. But analysis using different
assumptions made little difference to the results. Second, there were some missing data on follow-up
costs and at 12 months from administrative censoring owing to study funding, but also non-response to
questionnaire. This was handled using MI, which assumes that data are missing conditional on baseline
factors and other end point and process measures that are observed; therefore, if missingness is driven
by unobserved prognostic factors, this could have led to biased estimates. However, for questionnaire
responders, the follow-up costs were similar between the groups. Third, like previous RCTs in PIC, this study
did not measure QoL. Instead, the cost-effectiveness analysis used QoL data from a previous study that
included children admitted to UK PICUs who were at least 6-months-old.71 It is unclear whether or
not the QoL values from this sample of older children (median age of approximately 5-years-old) apply
directly to the population represented by CHiP patients. However, the results of the SA suggest that
the lifetime cost-effectiveness results were robust to the QoL value assumed for PICU survivors. Four, the
cost-effectiveness analysis required that survival data from the CHiP trial were extrapolated over the
lifetime. The analysis took a standard approach and applied the parametric survival function that was judged
most plausible. There was no evidence from the survival data available from CHiP of any differences in
survival up to 24 months, and the SA again shows results were robust to alternative assumptions.
Strengths
The CHiP trial addressed both clinical and economic questions, with follow-up at 12 months. The trial was
the largest RCT in PIC, and was rigorously designed and conducted. Randomisation reduced the potential
for selection bias at trial entry, and there was no loss to follow-up for the primary outcome. Although
the local clinicians could not be blinded to allocation post randomisation, the use of a hard outcome
(mortality) as an integral component of the 30-day primary outcome ensured the risk of biased outcome
assessment was low, and it is not plausible that LOS would be inﬂuenced by allocation across the range of
PICUs involved. The reasonably small number of secondary outcomes reduced the risks of problems
associated with multiple testing.
There was careful preparation and training for the introduction of the clinical management protocol with a
run-in period and minor adjustments to address any concerns about risks of hypoglycaemia. The delivery of
TGC may be further improved by the use of continuous glucose monitoring systems,72 including those with
paediatric decision support.
The biggest drivers of cost differences between the arms were PICU and total hospital LOS. For the vast
majority of patients (99%), these resource-use data were measured until they were discharge from their
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index hospital admission or following readmission to the PICU within 30 days, and up to a maximum of
12 months from randomisation. The study employed careful resource-use and cost measurement,
estimated from large sample patient-level data drawing on the PCCMDS, which provided reasonable
inference on costs. State-of-the-art approaches to handling missing 12-month cost data were used. The
study also recorded use of other hospital and community health services and found that reductions in
hospital LOS for the TGC arm were not offset by increased use of other services.
The CHiP trial was conducted in a large proportion of the PICUs in England, increasing the generalisability
of the clinical and cost-effectiveness results to other UK PICUs, and other settings with similar populations
and systems of care.
As the largest PICU trial to date, CHiP had sufﬁcient power to reliably assess whether the balance of costs
and beneﬁts differed depending on if the admission was following cardiac surgery or not and to provide
reasonable inference on costs.
The results of the economic evaluation were subject to extensive SAs and were robust to alternative
assumptions, including, for example, the approaches taken to unit costing or the projection of life
expectancy from the trial data.
The CHiP trial results in context
In considering how the CHiP trial results compare with other research, we have drawn on the trials of TGC
with adults in critical care, with preterm neonates in neonatal ICUs (NICU) and with children in PICUs,
using studies published prior to CHiP’s initiation and reviewed in Chapter 1, and later relevant studies in
different populations of critically ill patients. The particular emphases here are the size and type of effect of
the intervention, the rate of hypoglycaemia and the differential effect in medical and surgical populations.
There are some distinctions in these classiﬁcations between the CHiP trial and the adult studies. About a
third of the patients in the Leuven surgical trial24 underwent surgery that was not cardiovascular, and,
in the CHiP trial, general surgery was incorporated in the non-cardiac surgery group. The CHiP trial
stratiﬁcation of cardiac surgical and non-cardiac surgical does, however, allow direct comparison with
the Leuven paediatric study73 and the ongoing US paediatric cardiac surgical study.74
Adults
The CHiP trial ﬁndings differ from those of the initial adult study from the Leuven group.24 In patients
randomised to receive TGC in an adult surgical intensive care setting, Van den Berghe et al.24 reported
substantial reductions in mortality, other important complications of intensive care, and length of PICU
and hospital stay. By contrast, the CHiP trial found no difference in mortality or VFD-30, and only minimal
differences in secondary outcomes in the cardiac surgical subgroup. For the non-cardiac surgical subgroup
from the CHiP trial, however, ﬁndings follow those from the Leuven25 study in critically ill, adult patients
not admitted for surgery. Neither study found beneﬁts for TGC on major clinical end points, but both
studies found that TGC reduced hospital LOS, and reduced hospital costs.
Since these studies, several more trials and two meta-analyses have been published. The largest trial,
the Normoglycaemia in Intensive Care Evaluation – Survival Using Glucose Algorithm Regulation (NICE
SUGAR),75 was an international RCT that enrolled 6104 adults undergoing intensive care to undergo TGC
(target blood glucose range 4.5–6.0 mmol/l) or conventional blood glucose control (target ≤ 10.0 mmol/l).
Contrary to the Leuven studies, the NICE SUGAR investigators found that TGC increased mortality. A total
of 829 patients in the TGC group (27.5%) died compared with 751 (24.9%) in the conventional-control
group (odds ratio for intensive control 1.14, 95% CI 1.02 to 1.28, p = 0.02). Treatment effects did not
differ signiﬁcantly between surgical and non-surgical groups. There was no signiﬁcant difference between
the treatment groups in the median number of days in ICU, but severe hypoglycaemia (blood glucose level
≤ 2.2 mmol/l) was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014
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(0.5%) in the conventional-control group (odds ratio 14.7, 95% CI 9.0 to 25.9, p < 0.001). No long-term
sequelae of severe hypoglycaemia were reported.
In 2008, Wiener et al.76 reported a meta-analysis of TGC in critically ill adults. In total, the authors
identiﬁed 8432 patients in 34 randomised trials (23 full publications, 9 abstracts, 2 unpublished studies)
and did not ﬁnd a survival beneﬁt of TGC, but showed that TGC was associated with an increased risk of
hypoglycaemia (glucose ≤ 2.2 mmol/l; 13.7% vs. 2.5%; RR, 5.13; 95% CI 4.09 to 6.43). This increased risk
was fairly consistent across different ICU settings (surgical, medical and mixed). Most trials reported that
very few of the hypoglycaemic events were associated with overt symptoms, but some studies found
that patients who experienced hypoglycaemia had a higher risk of death.
A later meta-analysis,77 which contained 26 adult studies including the NICE SUGAR trial, also concluded
that TGC conferred no overall beneﬁt among critically ill patients. A subanalysis of ﬁve trials that
included only surgical patients suggested possible beneﬁts from TGC, although the predominant inﬂuence
on this subgroup was the original Leuven study,24 which contributed 765 of the 1037 patients in the TGC
group and 783 of 935 patients in the control group. The differences between the two meta-analyses were
likely to be a result of their inclusion criteria, with the positive results for surgical patients in the Griesdale
meta-analysis reﬂecting publication bias from excluding unpublished trials with negative results.
A major impetus for the CHiP trial was the concern that the results of trials in adult ICUs may not be easily
transferable to children. In 2008 and 2009, two trials did report results for children.
Preterm neonates
The NIRTURE (neonatal insulin therapy in Europe) study78 enrolled 389 very low-birthweight neonates from
eight NICUs in the UK and mainland Europe. The trial sought to determine whether or not early insulin
replacement (continuous infusion of insulin at a dose of 0.05 IU/kg/hour with 20% dextrose support) on
days 1–7 reduced hyperglycaemia and affected outcomes in preterm newborns compared with standard
neonatal care, the primary outcome being death at the expected date of delivery (EDD).
The early insulin group had signiﬁcantly more carbohydrate infused and less weight loss in the ﬁrst week
than infants in the control group. However, more infants in the early insulin group had episodes of
hypoglycaemia (< 2.6 mmol/l) than in the control group (29% vs. 17%; odds ratio 2.21; 95% CI 1.34 to
3.65; p < 0.005). In prespeciﬁed subgroup analyses, the increase in hypoglycaemia was signiﬁcant only in
the infants with a birth weight of > 1 kg (34% vs. 12% in the control group; odds ratio 3.96; 95% CI 1.85
to 8.47; p < 0.001). There was no increase in hypoglycaemia in infants with a birth weight of < 1 kg (26%
in the early insulin group vs. 23% in the control group; odds ratio 1.17; 95% CI 0.60 to 2.28; p = 0.7).
Clinicians reported episodes of hypoglycaemia in 17 infants in the early insulin group (8.8%) (including
two who had protocol violations and four who were withdrawn from the study) and in three in the control
group (1.6%). Episodes of hypoglycaemia were not associated with clinical alterations in physiology.
The trial was stopped early by the TSC on the advice of the independent Data Monitoring Committee for
a combination of futility in terms of the primary mortality outcome, and concerns about potential harm in
terms of an excess of ventricular haemorrhage and parenchymal lesions on cerebral ultrasound scans.
There was no statistically signiﬁcant difference in the primary outcome of mortality at EDD (14% vs. 9%;
odds ratio 1.64; 95% CI 0.87 to 3.03; p = 0.2), or duration of neonatal intensive care, but mortality at
28 days was increased in the TGC group (12% vs. 6%; odds ratio 2.22; 95% CI 1.04 to 4.76; p = 0.04).
The authors speculated that the results might be due to a smaller difference in the levels of glucose control
than seen in their pilot study, or too short a period (7 days) of insulin replacement. The design of this study
was fundamentally different from other TGC studies in that a constant dose of insulin was infused, and
blood glucose levels normalised by increasing the amount of glucose infused. This different methodology
and the obvious developmental differences between the preterm infants included in this study and term or
older infants and children in the CHiP trial make direct comparisons difﬁcult to interpret.
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Children
We are aware of only one published RCT that has investigated the effects of TGC in critically ill infants and
children. This single-centre trial73 evaluated whether or not targeting age-adjusted normoglycaemia (TGC)
would improve outcomes. This trial enrolled 700 children, 317 of whom were < 1 year of age, with 75%
admitted for cardiac surgery. Patients were randomly assigned to normoglycaemia/TGC, deﬁned as
2.8–4.4 mmol/l in infants and 3.9–5.6 mmol/l in children, with insulin infusion throughout their PICU stay.
Primary end points were duration of PICU stay and inﬂammation, C-reactive protein.
Hypoglycaemia (blood glucose ≤ 2.2 mmol/l) occurred in 87 (25%) patients in the intensively targeted
blood glucose group (p < 0.0001) compared with ﬁve (1%) patients in the conventional group;
hypoglycaemia, deﬁned as blood glucose < 1.7 mmol/l, arose in 17 (5%) patients in the intensive insulin
group (15 infants and 2 children) and in 3 (1%) in the conventional group (two infants and one child)
(p = 0.001). Hypoglycaemia (≤ 2.2 mmol/l) occurred at a median of day 2 (interquartile range 1–5) in the
intensive insulin group compared with day 1 (1–3) in the conventional group (p = 0.29). Hypoglycaemia
(≤ 2.2 mmol/l) on more than two occasions occurred in 18 patients (5%) treated with intensive insulin
compared with none in the conventional group.
The study found that TGC reduced the duration of PICU stay from a mean of 6.15 days (95% CI 5.25 days
to 7.05 days) in the control group to 5.51 days (95% CI 4.65 days to 6.37 days; p = 0.017). The number
of patients whose stay in the ICU was extended (> median) was 132 (38%) in the intensively targeted
blood glucose group compared with 165 (47%) in the conventional group (p = 0.013). TGC resulted
in a greater reduction in C-reactive protein at day 5 compared with baseline [–9.75mg/l (95% CI
–19.93mg/l to 0.43 mg/l) vs. 8.97 mg/l (95% CI –0.9 mg/l to 18.84 mg/l), p = 0.007], indicating an
attenuated inﬂammatory response.
As in the CHiP trial, Vlasselaers et al.73 noted a lower requirement for RRT in those children managed by
TGC (0.6% vs. 1.7%) than in their control group. This difference did not reach statistical signiﬁcance,
perhaps owing to small numbers requiring dialysis, but a reduction in RRT was shown in the meta-analysis
by Wiener et al.76 (RR 0.64, 95% CI 0.45 to 0.92) when analysing their data using a ﬁxed-effects model.
There were 20 deaths in the conventional group (5.7%), compared with nine deaths in the TGC group
(2.6%, p = 0.38), but, given the substantially lower mortality rates in PIC than usually experienced in adult
populations, the study was not powered for a mortality end point.
During the course of the CHiP trial, the results of these trials and meta-analyses were noted by the CHiP TSC
and DMEC. The continuing uncertainty with regards to the clinical effectiveness and safety of TGC were
noted, together with the absence of evidence on its long-term clinical effectiveness and cost-effectiveness.
Although the Leuven paediatric trial is the most similar to the CHiP trial, the two trials differ in a number
of important respects. First, the CHiP trial is twice as large, giving more power to determine whether
or not TGC led to different outcomes in the cardiac surgical and non-cardiac surgical subpopulations.
Three-quarters of the Leuven trial population underwent cardiac surgery, but the two strata are not
reported separately. Second, the CHiP trial is also a test of the potential diffusibility of TGC across a range
of PICUs, contrasting with the Leuven paediatric study, which was a single-centre trial from an ‘early
adopting’ setting. Third, the hypoglycaemia rates were lower in the CHiP trial, possibly as a result of the
choice of lower glucose control ranges for TGC in the Leuven paediatric study. Finally, the CHiP trial
measured the impact of TGC over a longer follow-up period and included a rigorous economic evaluation.73
Vlasselaers and colleagues are conducting a longer-term follow-up of the children enrolled in their study
(D Vlasselaers, Catholic University of Leuven, 2011, personal communication). In addition, other groups are
planning or are recruiting to74 similar clinical trials, the ﬁndings of which will add to those of the Leuven
and CHiP trials, and further inform clinicians about the risks and beneﬁts of TGC.
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Chapter 5 Conclusions
Implications for health care
For the cardiac surgery subgroup, average costs at 12 months post randomisation were similar between
arms and TGC was unlikely to be cost-effective. For children admitted to PICUs following cardiac surgery,
our study suggests that PICUs should not adopt TGC and should continue with CM.
For children admitted to PICUs for other reasons, although TGC did not improve short-term clinical
outcomes compared with CM, children in this subgroup were discharged earlier from hospital. This clinical
beneﬁt (earlier discharge) was associated with substantially reduced NHS costs. These average reductions
in NHS costs were not offset by increased use of community health services in the TGC versus CM arm.
This is the ﬁrst study to ﬁnd that TGC may be cost-effective in children in PIC who were not admitted for
cardiac surgery. Before a policy of TGC can be recommended for this important subgroup of NHS patients
(around 1200 patients per year), careful consideration should be given to the balance of risk and beneﬁt of
this intervention: between the small increased risk of hypoglycaemia and the potential reduction in length
of hospital stay and associated cost savings.
Recommendations for further research
The ﬁndings of the CHiP trial raise the following important questions:
l Does the excess rate of moderate and severe hypoglycaemia during TGC for children
admitted to PICUs for reasons other than cardiac surgery have an impact on long-term
neurodevelopmental outcomes?
Before a policy of TGC can be recommended for children admitted to PICUs for reasons other than
cardiac surgery, further information is needed about the long-term implications of the small increased
risk of hypoglycaemia. Over 100 children in the CHiP trial experienced at least one episode of moderate
or severe hypoglycaemia. In the ﬁrst instance, we will undertake a post-hoc analysis of the data along
the lines of the recent analysis of hypoglycaemia complicating TGC in adults that was published in the
New England Journal of Medicine. One of the CHiP investigators has been in contact with the lead
investigator of NICE SUGAR and plans are being made for the post-hoc data evaluation. Subsequently,
a neurodevelopmental follow-up study of these children would inform clinicians of the long-term risk of
hypoglycaemia in this population.
l Can we improve the delivery of TGC to minimise the risk of hypoglycaemia?
If a policy of TGC is to be recommended for children admitted to PICUs for reasons other than cardiac
surgery, research is needed to further reﬁne clinical algorithms for the delivery of TGC, and to assess
whether or not delivery of TGC may be further improved by the use of continuous glucose monitoring
systems,72 including those with paediatric decision support.
l Does TGC in critically ill children protect the kidneys from injury?
One hypothesis raised by the CHiP trial is that TGC can reduce acute kidney injury (AKI). AKI is a
common complication of critical illness, which in its most severe form requires RRT. Children requiring
RRT have a prolonged stay in PICU and increased mortality (≈ 40%). Children in the TGC arm in CHiP
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had a lower incidence of RRT than those in the CM arm. However, RRT represents the most severe end
of the spectrum of AKI and is a rare outcome compared with lesser degrees of AKI. An add-on study in
CHiP patients could provide more precise measures of AKI, through estimation of daily glomerular
ﬁltration rate from sequential plasma creatinine values obtained as part of routine clinical care.
Creatinine values would be retrieved from laboratory databases and statistical analysis would be
undertaken to investigate this research question.
l Do the findings from CHiP apply to routine clinical practice?
The CHiP RCT had a pragmatic design, included the majority of English PICUs and had broad patient
eligibility criteria. However, as with any RCT, the ﬁndings might not apply directly to routine clinical
practice. Inevitably, the CHiP centres did not screen all potential patients, and eligible patients were
excluded for various reasons, for example because of refused consent. Further, the CM delivered in the
CHiP study may differ from that provided routinely. These potential concerns illustrate the general
challenge that RCT ﬁndings might not apply directly to routine clinical practice. To address these issues,
further research is required that develops an approach for maximising external validity. One possible
approach to extending the CHiP ﬁndings would be to carefully assess the external validity of the study
ﬁndings using PICANet data. This further research could examine whether or not the patients’ baseline
characteristics, resource use, costs and outcomes following CM in CHiP differed from those observed
in routine clinical practice. This setting, with a large RCT nested within an observational data set,
would provide an opportunity for considering whether or not results from pragmatic trials such as CHiP
have external validity.
l What can be learnt from triallists, clinicians, parents and older children about their experiences of
participating in CHiP, to aid the design and conduct of future PICU trials?
As more PICU RCTs assessing treatments in the NHS are funded, it is important for their success to
learn from the experiences of participants in existing trials. A substantial body of research on
participants’ experiences of NICU trials aided development of CHiP trial procedures, but there is
currently no equivalent literature from PICUs. As the largest UK PICU trial to date, CHiP offers a timely
opportunity for such work. Qualitative research exploring clinician and family experiences of
implementing the CHiP protocol would inform the conduct of future PICU trials.
CONCLUSIONS
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Appendix 1 Consent/assent forms and patient
information leaflets
Appendix 1a
Please initial box
I confirm that I have read and understand the information sheet CHiP: The Control of
Hyperglycaemia In Paediatric Intensive Care Information version 5, August 2010 for the above
study. I have had the opportunity to consider the information, ask questions and have had these
answered satisfactorily.
I understand that my participation is voluntary and that I am free to withdraw my child at any
time, without giving any reason, without his/her medical care or legal rights being affected.
I understand that relevant sections of my child’s medical notes and data collected during the
study may be looked at by individuals from The Royal Brompton Hospital, from regulatory
authorities, from the NHS Trust or from the Data Coordinating Centre at the London School
of Hygiene and Tropical Medicine where it is relevant to my child taking part in this research. I
give permission for these individuals to have access to this information. 
I agree to my child’s GP and Health Visitor (if relevant) being informed of his/her participation
in the study. 
I agree that information held by the NHS and records maintained by the NHS Information
Centre and the NHS Central Register may be used to help contact me and provide information
about my child’s health status.
I agree for researchers to contact me about the study after my child has been
discharged from the hospital.
I agree for my child to take part in the above study.
Name of parent/
authorised legal representative
date signature
signaturedate
Relationship 
to child 
Name of person 
taking consent
  
CARDIAC   Version 5 August 2010
PROTOCOL Version 6, August 2010
Site 
Number
Principal
Investigator
Patient
Name
CHiP Patient 
Study Number
CONSENT FORM
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Copies: Original to be kept in research site file 1 for hospital notes     
1 for parent/authorised legal representative 1 for CRF                               
ISRCTN61735247
EudraCT No: 2006/-005715/-10
Please initial box
I re-confirm consent given pre-operatively.
Name of parent/
authorised legal representative
date signature
signaturedate
Relationship 
to child 
Name of person 
taking consent
  
Centre 
number
Patient
name
CHiP Patient 
Study Number
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Appendix 1b
Please initial box
I confirm that I have read and understand the information sheet CHiP: The Control of
Hyperglycaemia In Paediatric Intensive Care Information version 5, August 2010 for the above
study. I have had the opportunity to consider the information, ask questions and have had these
answered satisfactorily.
I understand that my participation is voluntary and that I am free to withdraw my child at any
time, without giving any reason, without his/her medical care or legal rights being affected.
I understand that relevant sections of my child’s medical notes and data collected during the
study may be looked at by individuals from The Royal Brompton Hospital, from regulatory
authorities, from the NHS Trust or from the Data Coordinating Centre at the London School
of Hygiene and Tropical Medicine where it is relevant to my child taking part in this research. I
give permission for these individuals to have access to this information. 
I agree to my child’s GP and Health Visitor (if relevant) being informed of his/her participation
in the study. 
I agree that information held by the NHS and records maintained by the NHS Information
Centre and the NHS Central Register may be used to help contact me and provide information
about my child’s health status.
I agree for researchers to contact me about the study after my child has been
discharged from the hospital.
I agree for researchers to ask me if I would like to be sent a summary of the results of
the study when available.
I agree for my child to take part in the above study.
CONSENT FORM
Copies: Original to be kept in research site file 1 for hospital notes     
1 for parent/authorised legal representative 1 for CRF                               
Site
Number
ISRCTN61735247
EudraCT No: 2006/-005715/-10
Principal
Investigator
Name of parent/
authorised legal representative
date signature
signaturedate
Relationship 
to child 
Name of person 
taking consent
Patient
Name
CHiP Patient 
Study Number
PICU  Version 5 August 2010
PROTOCOL Version 6, August 2010
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Appendix 1c
Young person to circle all they agree with
YES NO Have you read about this project? 
YES NO Has somebody else explained about this project to you?
YES NO Do you understand what this project is about?
YES NO Have you asked all the questions you want? 
YES NO Have you had your questions answered in a way you understand?
YES NO Do you understand it is OK to stop taking part at any time?
YES NO Are you happy to take part?
If any answers are ‘No’ or you do not want to take part, don’t sign your name!
If you do want to take part, you can write your name below
ASSENT FORM
Copies: Original to be kept in research site file 1 for hospital notes     
1 for parent/authorised legal representative 1 for CRF                                
Site 
Number
ISRCTN61735247
EudraCT No: 2006/-005715/-10
Principal
Investigator
Patient
Name
CHiP Patient 
Study Number
Your name
Name of doctor
Date
Date
The doctor who explained this project needs to sign too:
YP   Version 5 August 2010
PROTOCOL Version 6, August 2010
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Appendix 1d
PATIENT INFORMATION LEAFLET 
For parents/guardians of children likely to have cardiac surgery 
C
H
iP
Control of
Hyperglycaemia in 
Paediatric intensive care
CARDIAC
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1. Introduction
Your child is being invited to take part in a nationwide medical research study called
CHiP. This information sheet gives you details about the study. We explain why we
are asking you to think about taking part, and what you can expect if you agree. Please
remember, you do not have to take part and the quality of your child’s care will not be
affected in any way, whatever you decide. 
This information sheet is in two parts: 
Part I tells you about why we are doing this study and what will happen if you agree
for your child to take part. 
Part 2 gives you some more information about how research studies like CHiP are run.
2. Why is a study needed?
When babies, children and adults are in intensive care, the levels of sugar in their blood
can go up. This is called hyperglycaemia. It can happen because they have had a
serious illness, an injury, or surgery. In Paediatric Intensive Care we take small samples
of blood regularly. We use these to check sugar levels. Babies and children with high
blood sugar are usually treated with a drug called insulin, but only if the blood sugar
reaches quite a high level. We measure the level of sugar with a scale called millimoles
per litre, shortened to mmol/L. When the level reaches 12 (mmol/L), we would say
that this is too high and should be treated. 
In adults, some research has suggested that controlling the blood sugar levels tightly
may speed recovery time. Tight control means checking the blood more often. If the
sugar level is going up, we give insulin at around level 7, rather than waiting until it
goes up to level 12 (we will tell you more about insulin later in this leaflet). This tight
control may also be a promising treatment for children, but we do not know whether
children will respond in the same way as adults. 
3. Why has my child been chosen for this study? 
Your child has been chosen for this study because s/he is likely to have a heart
operation. After the operation s/he may need to spend a few days in the Paediatric
Intensive Care Unit being helped to breathe by a machine called a ventilator and
medicines to support his/her blood pressure. We are hoping that 1500 children on a
ventilator will take part in the CHiP study. Doctors and nurses from Paediatric
Intensive Care Units in ten hospitals are helping with the study. You have been given
this information leaflet and asked if you would like to join the CHiP Study because
your child is in one of these ten hospitals.
4. What is the study testing? 
We are comparing two different ways of controlling blood sugar levels using insulin.
Insulin is a drug that is used by lots of people who have diabetes. It is also used for
If blood sugar levels are raised above normal this is called hyperglycaemia
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patients like your child who are in intensive care. It helps to control the level of sugar
in their blood. Although we would use insulin, this does not mean that your child has
diabetes. 
We are doing the study to help us find out whether it is better to tightly control the
sugar levels by giving insulin when the blood sugar rises above level 7 or to treat only
when the sugar level reaches level 12. For each approach there might be advantages
and disadvantages. The best way of finding out is to carry out a randomised study
such as the CHiP Study. A randomised study is a way of comparing the effects of the
two approaches. This is a good and a fair test of the two approaches. 
5. What will happen to my child if we agree to take part?
For the CHiP Study, half of the children will be treated using one approach, tight
control using insulin to keep the blood sugar between level 4 and 7. The other half will
be treated using the usual approach, to treat with insulin if the sugar goes up to level
12 on two checks, tested 30 minutes apart. A computer is used to put each child into
one of these two groups. It does this in a random way. This means that it uses chance,
a bit like flipping a coin, to organise the two treatment groups. 
A small blood sample will be taken without any pain from one of the drip lines which
has already been inserted as part of the care of your child. It will be used to measure the
level of blood sugar. Whichever treatment group your child is in, the insulin (if used) is
given through a tube into a vein. Treatment if necessary will take place during the time
your child is in Intensive Care. If your child is in the tight control group s/he is likely
to receive more insulin than children in the usual treatment group. If his/her blood
sugar levels do not go up then insulin will not be given, whichever group s/he is in. 
Information about all of the children in the study will be collected while they are in
hospital. The study team do not want to lose contact with you afterwards. Once you
have taken your child home, the Study Manager from the CHiP Data Co-ordinating
Centre in the London School of Hygiene and Tropical Medicine will write to you. She
will ask if you will help with some more information later, as the CHiP Study team
need to try to follow-up everyone who has been in the study. It would also be very
helpful if you would agree that your child’s name could be registered with the NHS
Information Centre and the NHS Central Register. This would make it easier for the
study team to contact you in the future and provide the study team with information
about your child’s health status even if you move house. 
If you are happy for your child to take part in the CHiP Study, and are comfortable
with the explanations from the doctors and nurses at this hospital, you will be asked to
sign a consent form. We will check with you again if your child is admitted to
We want to test whether tight control of blood sugar
levels will help children and not do any harm.
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paediatric intensive care and becomed eligible for the study, to make sure that you are
still happy to go ahead. A member of staff from the Unit will then make a telephone
call to the study centre. The staff member will give the centre some details about your
child and find out which study group your child will be in. This will tell the intensive
care staff which of the two treatment approaches they will follow if sugar levels go up. 
6. Does my child have to take part? 
No, it is up to you to decide whether or not your child takes part. You are free to
withdraw at any time without giving a reason. This would not affect the quality of care
your child receives. 
7. What treatment will my child get if s/he does not take part? 
We will give your child the same treatment that all patients in paediatric intensive care
would receive. This means that we would give insulin if the blood sugar levels go up to
level 12 on two tests. The tests would be taken 30 minutes apart. If the blood sugar
levels do not go up, then we would not need to use any insulin.
8. What are the possible benefits to my child from taking part?
We are doing this study because we do not know whether tight control of blood sugar
produces better results. Some studies carried out in adults in intensive care have shown
that patients treated with tight control of blood sugar do better but others have not
shown any benefit of tight control. If children benefit in the same way as adults did in
some of these studies, then tight control of blood sugar levels may be helpful in
speeding up recovery time. We cannot promise the study will help your child but the
information that we get might help other children in the future. 
9. What are the possible side effects of the treatment and possible risks of taking part?
There is a possibility that for children in the tight control group, giving insulin at an
earlier stage might mean that the level of sugar in the blood will drop BELOW
normal. This is called hypoglycaemia (the opposite of hyperglycaemia where sugar
levels are high). Mild hypoglycaemia can cause confusion and/or dizziness. Severe
hypoglycaemia could cause brain damage but only if left untreated for a long time. Be
reassured that the doctors and nurses in the CHiP Study will be carefully watching
your child. If your child shows signs of hypoglycaemia, this will be picked up very
quickly while still very mild and prompt action will be taken to treat it. The staff will
stop the insulin treatment straightaway and will give extra sugar either by mouth or as
a sugar solution through a drip. 
For the children who are in the usual care group, who will receive insulin if the blood
sugar level goes up to 12, the possible risks are different. For them there is the
possibility that their sugar levels might get too high. This can affect how the organs of
the body work, but as we have said, all the children in the study will be very carefully
monitored. There are not thought to be any other risks to your child from taking part
in the study.
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10. Are there any other possible disadvantages?
If your child is in the tight control group he/she is likely to have more blood samples
taken than if in the usual care group 
Also we do appreciate that we are asking you to consider a research study when you
are naturally feeling worried about your child and that this might be adding to your
stress now. 
11. What if there is a problem?
If you have any complaint about the way you or your child is dealt with during the
study or feel that you had suffered any sort of harm, this will be addressed. The
detailed information about this is given in Part 2. 
12. Will taking part in the study be kept confidential?
Yes, all information about your child’s participation in the study will be kept
confidential. The details are included in Part 2. 
13. Involvement of the Family Doctor (GP) and Health Visitor
With your permission, we will let your GP and health visitor know that your child is
taking part in the study. 
14. Your contact people for the study in this hospital are: 
If the information in Part 1 has interested you and you are considering taking part in
the CHiP Study, please continue to read the additional information in Part 2 before
making a decision.
Principal Investigator name
Hospital address 
tel: 
CHiP Research Nurse name
CHiP Research Nurse
Hospital address 
tel: 
Complaints Manager name
Complaints Manager Title
tel: 
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Part 2 gives you some more information about the conduct of research studies. Please
read it before you agree to take part in the study.
What will happen if I don’t want my child to carry on with the study?
If you decide to take part in the study but then change your mind, just tell the research
nurse or doctor. We will stop collecting information about your child and if you wish,
any information we have already collected can be destroyed. If your child is in the
tight control, s/he will instead be given usual care which is to give insulin at level 12.
If your child is in the usual care group nothing will change.    
Will my child’s taking part in the study be kept confidential?
All information about your child (including your contact details) which is collected
for the study will be kept securely and strictly confidentially within the study team
(the hospital and the Data Co-ordinating Centre at the London School of Hygiene
and Tropical Medicine), and your child’s doctor (GP) and health visitor. We will not
use your child’s name in any analysis or in any reports that we write. The study team
are responsible for analysing, storing and eventually destroying the data according to
guidelines set by the National Health Service Research & Development Unit.
Information will be kept for up to 15 years at the study centre.  
What will happen to the results of the research study?
The results will be available when all the children have been followed up and the
results analysed. This is likely to be in 2012. The research will be published in a
scientific journal and the results publicised widely.  A summary of the research and
details of how to find the scientific publication will be posted on the study website
(website www.chip-trial.org.uk). A summary of the results will be sent to parents if
you let the Study Manager know that you would like to have this. 
PART 2
What if there is a problem? 
If you have a concern about any aspect of the study you should ask to speak to 
Helen Betts (Lead Research nurse tel: 07854 980 072  or to the Chief Investigator, 
Dr. Duncan Macrae 020-7351 8546) who will do their best to answer your questions.  
If you remain unhappy and wish to make a formal complaint, you can do this through
the NHS Complaints Procedure at this hospital (name and tel number to inserted for
each collaborating hospital). The Royal Brompton and Harefield Trust is the sponsor
of this research project. In the very unlikely event that your child is harmed due to
someone’s negligence, then you may have grounds for legal action against the sponsor
of the research or NHS Trust but you may have to pay for it.  This is the normal
procedure, whether or not there is a research study. If you wish to complain about any
aspect of the way your child has been approached or treated during the course of this
study, all the normal health service complaints mechanisms are available to you. 
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Who is organising and funding the research? 
The study is funded by the Health Technology Assessment Programme of the NHS.
This study is co-ordinated by the Royal Brompton and Harefield NHS Trust and the
London School of Hygiene and Tropical Medicine (LSHTM). The Royal Brompton
Hospital is responsible for the conduct of the study. The research grant from the
Health Technology Assessment Programme pays for the employment of research
nurses and the study team at the LSHTM.  
ChiP Study Team
Dr Duncan Macrae, Chief Investigator CHiP Study
Royal Brompton Hospital 
Tel: 020-7351 8546
Email: d.macrae@rbht.nhs.uk 
Laura Van Dyck/Lucy Brooks, Study Manager 
CHiP Data Co-ordinating Centre
London School of Hygiene and Tropical Medicine
Tel: 020-7927 2075
Email: Laura.VanDyck@lshtm.ac.uk/Lucy.Brooks@lshtm.ac.uk
This study was given a favourable ethical opinion for conduct in the NHS by the
Brighton East Research Ethics Committee. 
Thank you for taking the time to read this information
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Appendix 1e
PATIENT INFORMATION LEAFLET
For parents/guardians of children in paediatric intensive care
C
H
iP
Control of
Hyperglycaemia in 
Paediatric intensive care
PICU
DOI: 10.3310/hta18260 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 26
85
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Macrae et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
If blood sugar levels are raised above normal this is called hyperglycaemia
PART 1
1. Introduction
Your child is being invited to take part in a nationwide medical research study called
CHiP. This information sheet gives you details about the study. We explain why we
are asking you to think about taking part, and what you can expect if you agree. Please
remember, you do not have to take part and the quality of your child’s care will not be
affected in any way, whatever you decide. 
This information sheet is in two parts: 
Part I tells you about why we are doing this study and what will happen if you agree
for your child to take part. 
Part 2 gives you some more information about how research studies like CHiP are
run.
2. Why is a study needed?
When babies, children and adults are in intensive care, the levels of sugar in their blood
can go up. This is called hyperglycaemia. It can happen because they have had a
serious illness, an injury, or surgery. In Paediatric Intensive Care we take small samples
of blood regularly. We use these to check sugar levels. Babies and children with high
blood sugar are usually treated with a drug called insulin, but only if the blood sugar
reaches quite a high level. We measure the level of sugar with a scale called millimoles
per litre, shortened to mmol/L. When the level reaches 12 (mmol/L), we would say
that this is too high and should be treated. 
In adults, some research has suggested that controlling the blood sugar levels tightly
may speed recovery time. Tight control means checking the blood more often. If the
sugar level is going up, we give insulin at around level 7, rather than waiting until it
goes up to level 12 (we will tell you more about insulin later in this leaflet). This tight
control may also be a promising treatment for children, but we do not know whether
children will respond in the same way as adults. 
3. Why has my child been chosen for this study? 
Your child has been chosen for this study because s/he has developed a serious illness
that needs the support of a ventilator and medicines to support his/her blood pressure.
We are hoping that 1500 children on a ventilator will take part in the CHiP Study.
Doctors and nurses from Paediatric Intensive Care Units in ten hospitals are helping
with the study. You have been given this information leaflet and asked if you would
like to join the CHiP Study because your child is in one of these ten hospitals. 
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4. What is the study testing? 
We are comparing two different ways of controlling blood sugar levels using insulin.
Insulin is a drug that is used by lots of people who have diabetes. It is also used for
patients like your child who are in intensive care. It helps to control the level of sugar
in their blood. Although we would use insulin, this does not mean that your child has
diabetes. 
We are doing the study to help us find out whether it is better to tightly control the
sugar levels by giving insulin when the blood sugar rises above level 7 or to treat only
when the sugar level reaches level 12. For each approach there might be advantages
and disadvantages. The best way of finding out is to carry out a randomised study
such as the CHiP Study. A randomised study is a way of comparing the effects of the
two approaches. This is a good and a fair test of the two approaches. 
5. What will happen to my child if we agree to take part?
For the CHiP Study, half of the children will be treated using one approach, tight
control using insulin to keep the blood sugar between level 4 and 7. The other half will
be treated using the usual approach, to treat with insulin if the sugar goes up to level
12 on two checks, tested 30 minutes apart. A computer is used to put each child into
one of these two groups. It does this in a random way. This means that it uses chance,
a bit like flipping a coin, to organise the two treatment groups. 
A small blood sample will be taken without any pain from one of the drip lines which
has already been inserted as part of the care of your child. It will be used to measure the
level of blood sugar. Whichever treatment group your child is in, the insulin (if used) is
given through a tube into a vein. Treatment if necessary will take place during the time
your child is in Intensive Care. If your child is in the tight control group s/he is likely
to receive more insulin than children in the usual treatment group. If his/her blood
sugar levels do not go up then insulin will not be given, whichever group s/he is in. 
Information about all of the children in the study will be collected while they are in
hospital. The study team do not want to lose contact with you afterwards. Once you
have taken your child home, the Study Manager from the CHiP Data Co-ordinating
Centre in the London School of Hygiene and Tropical Medicine will write to you. She
will ask if you will help with some more information later, as the CHiP Study team
need to try to follow-up everyone who has been in the study. It would also be very
helpful if you would agree that your child’s name could be registered with the NHS
Information Centre and the NHS Central Register. This would make it easier for the
study team to contact you in the future and provide the study team with information
about your child’s health status even if you move house.
We want to test whether tight control of blood sugar levels will help children
and not do any harm.
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If you are happy for your child to take part in the CHiP Study, and are comfortable
with the explanations from the doctors and nurses at this hospital, you will be asked to
sign a consent form. A member of staff from the Unit will then make a telephone call
to the study centre. The staff member will give the centre some details about your
child and find out which study group your child will be in. This will tell the intensive
care staff which of the two treatment approaches they will follow if sugar levels go up. 
6. Does my child have to take part? 
No, it is up to you to decide whether or not your child takes part. You are free to
withdraw at any time without giving a reason. This would not affect the quality of care
your child receives. 
7. What treatment will my child get if s/he does not take part? 
We will give your child the same treatment that all patients in paediatric intensive care
would receive. This means that we would give insulin if the blood sugar levels go up to
level 12 on two tests. The tests would be taken 30 minutes apart. If the blood sugar
levels do not go up, then we would not need to use any insulin.
8. What are the possible benefits to my child from taking part?
We are doing this study because we do not know whether tight control of blood sugar
produces better results. Some studies carried out in adults in intensive care have shown
that patients treated with tight control of blood sugar do better but others have not
shown any benefit of tight control. If children benefit in the same way as adults did in
some of these studies, then tight control of blood sugar levels may be helpful in
speeding up recovery time. We cannot promise the study will help your child but the
information that we get might help other children in the future. 
9. What are the possible side effects of the treatment and possible risks of taking part?
There is a possibility that for children in the tight control group, giving insulin at an
earlier stage might mean that the level of sugar in the blood will drop BELOW
normal. This is called hypoglycaemia (the opposite of hyperglycaemia where sugar
levels are high). Mild hypoglycaemia can cause confusion and/or dizziness. Severe
hypoglycaemia could cause brain damage but only if left untreated for a long time. Be
reassured that the doctors and nurses in the CHiP Study will be carefully watching
your child. If your child shows signs of hypoglycaemia, this will be picked up very
quickly while still very mild and prompt action will be taken to treat it. The staff will
stop the insulin treatment straightaway and will give extra sugar either by mouth or as
a sugar solution through a drip. 
For the children who are in the usual care group, who will receive insulin if the blood
sugar level goes up to 12, the possible risks are different. For them there is the
possibility that their sugar levels might get too high. This can affect how the organs of
the body work, but as we have said, all the children in the study will be very carefully
monitored. There are not thought to be any other risks to your child from taking part
in the study.
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10. Are there any other possible disadvantages?
If your child is in the tight control group he/she is likely to have more blood samples
taken than if in the usual care group 
Also we do appreciate that we are asking you to consider a research study when you
are naturally feeling worried about your child and that this might be adding to your
stress now. 
11. What if there is a problem?
If you have any complaint about the way you or your child is dealt with during the
study or feel that you had suffered any sort of harm, this will be addressed. The
detailed information about this is given in Part 2. 
12. Will taking part in the study be kept confidential?
Yes, all information about your child’s participation in the study will be kept
confidential. The details are included in Part 2. 
13. Involvement of the Family Doctor (GP) and Health Visitor
With your permission, we will let your GP and health visitor know that your child is
taking part in the study. 
14. Your contact people for the study in this hospital are: 
If the information in Part 1 has interested you and you are considering taking part in
the CHiP Study, please continue to read the additional information in Part 2 before
making a decision.
Principal Investigator name
Hospital address 
tel: 
CHiP Research Nurse name
CHiP Research Nurse
Hospital address 
tel: 
Complaints Manager name
Complaints Manager Title
tel: 
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Step by Step Guide to the CHiP Study
Usual treatment
Child is treated
with insulin if
blood sugar
reading reaches
level 12
Patient
selection and
consultation
with parents
Parents
decision
Parents do not wish
to take part
Children admitted to paediatric intensive care unit and on ventilators
Staff explain study and give written information to parents before surgery.
Parents given the chance to ask questions of doctors and nurses
1
2
OR
Research
in hospital
3
Half children in study receive
tight control
Child treated with insulin if blood
sugar reading reaches level 7
Child treated with insulin if blood
sugar reading reaches level 12
Randomisation
Half children in study receive
usual treatment
Research
follow-up Study manager tells GP
and health visitor that
child is in study
Study manager registers
child with NHS 
Information Centre and
NHS Central Register
On discharge from
hospital study manager
sends letter to parents
+ +
4
Parents agree for their child to be included in the study and
sign consent form
Data collected in hospital and transferred to Coordinating
Centre in the London School of Hygiene and Tropical Medicine
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Part 2 gives you some more information about the conduct of research studies. Please
read it before you agree to take part in the study.
What will happen if I don’t want my child to carry on with the study?
If you decide to take part in the study but then change your mind, just tell the research
nurse or doctor. We will stop collecting information about your child and if you wish,
any information we have already collected can be destroyed. If your child is in the
tight control, s/he will instead be given usual care which is to give insulin at level 12. If
your child is in the usual care group nothing will change. 
Will my child’s taking part in the study be kept confidential?
All information about your child (including your contact details) which is collected
for the study will be kept securely and strictly confidentially within the study team
(the hospital and the Data Co-ordinating Centre at the London School of Hygiene
and Tropical Medicine), and your child’s doctor (GP) and health visitor. We will not
use your child’s name in any analysis or in any reports that we write. The study team
are responsible for analysing, storing and eventually destroying the data according to
guidelines set by the National Health Service Research & Development Unit.
Information will be kept for up to 15 years at the study centre. 
What will happen to the results of the research study?
The results will be available when all the children have been followed up and the
results analysed. This is likely to be in 2012. The research will be published in a
scientific journal and the results publicised widely. A summary of the research and
details of how to find the scientific publication will be posted on the study website
(website www.chip-trial.org.uk). A summary of the results will be sent to parents if
you let the Study Manager know that you would like to have this. 
PART 2
What if there is a problem? 
If you have a concern about any aspect of the study you should ask to speak to 
Helen Betts (Lead Research nurse tel: 07854 980 072 or to the Chief Investigator, 
Dr Duncan Macrae 020-7351 8546) who will do their best to answer your questions. 
If you remain unhappy and wish to make a formal complaint, you can do this through
the NHS Complaints Procedure at this hospital (name and tel number to inserted for
each collaborating hospital). The Royal Brompton and Harefield Trust is the sponsor
of this research project. In the very unlikely event that your child is harmed due to
someone’s negligence, then you may have grounds for legal action against the sponsor
of the research or NHS Trust but you may have to pay for it. This is the normal
procedure, whether or not there is a research study. If you wish to complain about any
aspect of the way your child has been approached or treated during the course of this
study, all the normal health service complaints mechanisms are available to you. 
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Who is organising and funding the research? 
The study is funded by the Health Technology Assessment Programme of the NHS.
This study is co-ordinated by the Royal Brompton and Harefield NHS Trust and the
London School of Hygiene and Tropical Medicine (LSHTM). The Royal Brompton
Hospital is responsible for the conduct of the study. The research grant from the
Health Technology Assessment Programme pays for the employment of research
nurses and the study team at the LSHTM. 
ChiP Study Team
Dr Duncan Macrae, Chief Investigator CHiP Study
Royal Brompton Hospital 
Tel: 020-7351 8546
Email: d.macrae@rbht.nhs.uk 
Laura Van Dyck/Lucy Brooks, Study Manager 
CHiP Data Co-ordinating Centre
London School of Hygiene and Tropical Medicine
Tel: 020-7927 2075 
Email: Laura.VanDyck@lshtm.ac.uk/Lucy.Brooks@lshtm.ac.uk
This study was given a favourable ethical opinion for conduct in the NHS by the
Brighton East Research Ethics Committee. 
Thank you for taking the time to read this information
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Appendix 1f
PATIENT INFORMATION LEAFLET
For young people likely to have heart surgery
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1. Introduction
We are asking if you would take part in a nationwide medical research study. This
information sheet gives you details about the study. We explain why we are asking you
to consider joining in. Please read this leaflet carefully. Talk about it with your
parents/guardians and also with the doctor or nurse if you want to. Please remember
that you do not have to take part. 
This information sheet is in two parts: 
Part I tells you about why we are doing this study and what will happen if you agree
to join in. 
Part 2 gives you some more information which you will need if you want to take part.
2. Why are we doing this research?
Young people usually go into a Paediatric Intensive Care Unit after a heart operation.
The levels of sugar in their blood can go up. This is called hyperglycaemia. It can
happen because they have had an operation. In Paediatric Intensive Care, we take
small samples of blood regularly. We use these to check sugar levels. Young people as
well as children with high blood sugar are usually treated with a drug called insulin,
but only if the blood sugar reaches quite a high level. We measure the level of sugar
with a scale called millimoles per litre, shortened to mmol/L When the level goes up to
12 (mmol/L), we would say that this is too high and should be treated. 
Research with adults makes us think that controlling the blood sugar levels tightly
may speed recovery time. Tight control means checking the blood more often. If the
sugar level is going up, we give a drug called insulin at around level 7, rather than
waiting until a higher level is reached. This tight control may also be a promising
treatment for young people. However we do not know whether young people will
respond in the same way as adults. 
3. Why have I been asked to take part in this study? 
We have given you this information leaflet because you may have an operation on
your heart. After the operation you may need to spend a few days in the Paediatric
Intensive Care Unit as you recover. You may need the help of a breathing machine
(ventilator) and medicines to support your blood pressure. If you are on the ventilator
you may be the sort of patient who could take part in this study. We are inviting 1500
children and young people to take part. Doctors and nurses from Paediatric Intensive
Care Units in ten hospitals are helping with this study. 
4. What is the study testing? 
We are testing two different ways of controlling blood sugar levels using insulin.
Insulin is a drug that helps to control the level of sugar in the blood. It is also used by
people who have diabetes. Although we might use insulin for you, this does not mean
that we think you have diabetes. 
If blood sugar levels are raised above normal this is called hyperglycaemia
PART 1
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We are doing the study to help us find out whether it is better to tightly control the
sugar levels. This means giving insulin when the blood sugar rises above level 7 or to
treat only when the sugar level reaches level 12. For each way there might be
advantages and disadvantages. The best method of finding out is to carry out a
randomised study such as CHiP. This is a good and a fair test of the two ways of
controlling blood sugar levels. 
5. What will happen to me if I agree to take part?
For CHiP half of the young people will be treated using one way. That is tight control
using insulin to keep the blood sugar between level 4 and 7. The other half will be
treated in the usual way. That is to treat with insulin if the sugar goes up to level 12 on
two tests. A computer is used to put each young person into one of these two groups.
It does this in a random way. This means that it uses chance, a bit like flipping a coin,
to organise the two treatment groups. 
A small blood sample will be taken without any pain from this tube which has already
been put into your vein as part of your care. It will be used to measure the level of
blood sugar. Whichever treatment group you are in, the insulin (if used) is given
through this tube into a vein. Treatment will take place during the time you would be
in the Intensive Care Unit. Young people in the tight control group are likely to
receive more insulin than young people in the usual treatment group. If the blood
sugar levels are not raised then insulin will not be given, whichever group you are in. 
Information about you will be collected while you are in hospital. After you leave
hospital the CHiP Study Manager from the Data Co-ordinating Centre in the 
London School of Hygiene and Tropical Medicine will write to your parents to
follow-up your progress. We are also asking your parents if they will agree for the
study team to give your name to the NHS Information Centre and the NHS Central
Register. This will make it easier for the study team to contact you in the future even 
if you move house. 
If you are admitted to the Paediatric Intensive Care Unit your parents will be asked if
they still agree for you to be in the study. The staff will then make a telephone call to the
study centre. They will give your details and find out which treatment group you are in. 
6. Do I have to take part? 
No it is up to you and your parents. If you are happy to take part, and have had your
questions answered you will asked to sign the form at the end of this leaflet. If you do
not take part it would not affect the quality of care that you receive.
7. What treatment will I be given if I do not take part? 
We will give your child the same treatment that all patients in paediatric intensive care
would receive. This means that we would give insulin if the blood sugar levels go up to
We want to test whether tight control of blood sugar levels will
benefit young people and not do any harm.
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level 12 on two tests. The tests would be taken 30 minutes apart. If the blood sugar
levels do not go up, then we would not need to use any insulin.
8. What are the possible benefits from taking part?
We are doing this study because we do not know whether tight control of blood sugar
produces better results. Some studies carried out in adults have shown that patients
treated with tight control of blood sugar do better but others have not shown any
benefit of tight control. If young people benefit in the same way as adults did in some
of these studies, then tight control may be helpful in speeding recovery time. We
cannot promise the study will help you. However the information we get might help
other young people in the future.
9. What are the possible side effects of the treatment and possible risks of taking part?
For young people in the tight control group, there is a possibility that blood sugar
levels will drop BELOW normal. This is called hypoglycaemia (the opposite of
hyperglycaemia where sugar levels are high). Mild hypoglycaemia can cause confusion
and/or dizziness. Severe hypoglycaemia could cause brain damage but only if left
untreated for a long time. Be reassured that the doctors and nurses in the CHiP study
will be carefully watching you. If you show signs of hypoglycaemia, this will be
picked up very quickly while it still very mild. The staff will stop the insulin treatment
straightaway and will give you extra sugar either by mouth or as a sugar solution
through a drip. 
For young people who are in the usual care group, who will receive insulin if the
blood sugar level goes up to 12, the possible risks are different. For them there is the
possibility that their sugar levels might go too high. This can affect how the organs of
the body work, but as we have said, you will be very carefully checked. There are not
thought to be any other risks to you from taking part.
10. Your contact people for the study in this hospital are: 
Thank you for reading so far. If you are still interested please go to Part 2.
Principal Investigator name
Hospital address 
tel: 
CHiP Research Nurse name
CHiP Research Nurse
Hospital address 
tel: 
Complaints Manager name
Complaints Manager Title
tel: 
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Step by Step Guide to the CHiP Study
Usual treatment
Child is treated
with insulin if
blood sugar
reading reaches
level 12
Patient
selection and
consultation
with parents
Parents
decision
Parents do not wish
to take part
Children likely to have heart surgery
Staff explain study and give written information to parents before surgery.
Parents given the chance to ask questions of doctors and nurses
1
2
OR
Research
in hospital
3
Half children in study receive
tight control
Child treated with insulin if blood
sugar reading reaches level 7
Child treated with insulin if blood
sugar reading reaches level 12
Randomisation
Half children in study receive
usual treatment
Research
follow-up Study manager tells GP
and health visitor that
child is in study
Study manager registers
child with NHS 
Information Centre and
NHS Central Register
On discharge from
hospital study manager
sends letter to parents
+ +
4
Parents agree for child to take part and sign consent form.
Consent confirmed if child admitted to paediatric intensive
care unit and on ventilator.
Data collected in hospital and transferred to Coordinating
Centre in the London School of Hygiene and Tropical Medicine
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Part 2 gives you some more information about the conduct of research studies. 
Please read it before you agree to take part in the study.
What will happen if I don’t want to carry on with the study?
If you decide to take part in the study but then change your mind, just tell the research
nurse or doctor before you have your operation. Your parents may change their mind
after you have had your operation. We will stop collecting information about you. If
you wish, any information we have already collected can be destroyed. If you are in
the usual care group nothing will change. If you are in the tight control group you will
instead be given usual care which is to give insulin at level 12.  
What if there is a problem or something goes wrong?
Information about who to contact if there is a problem is given in the information
sheet for parents. 
Will anyone else know that I am in a research study?
Yes – the study team in this hospital and at the Data Co-ordinating Centre at the
London School of Hygiene and Tropical Medicine will know that you are taking part
in the study. We will also tell your family doctor. If you agree to take part in the
research, any of your medical records may be looked at to check that the study is
being carried out correctly.  
What will happen to the results of the research study? 
The results will not be available until 2012 when everyone taking part has been
followed up and the results analysed. The research will be published in a scientific
journal and the results publicised widely. A research summary will be posted on the
study website www.chip-trial.org.uk. A summary of the results will be sent to you and
your parents if you let the Study Manager know that you would like to have this.
Who is organising and funding the research? 
This study is run by the Royal Brompton and Harefield NHS Trust and the London
School of Hygiene and Tropical Medicine. The study is funded by the Health
Technology Assessment Programme of the NHS. The Royal Brompton Hospital is
responsible for the conduct of the study. The doctor who is co-ordinating the study at
this hospital is not being paid to include you in the study. 
Dr Duncan Macrae, Chief Investigator CHiP Study, Royal Brompton Hospital 
Tel: 020-7351 8546    Email: d.macrae@rbht.nhs.uk 
Laura Van Dyck/Lucy Brooks, Study Manager  
CHiP Data Co-ordinating Centre, London School of Hygiene and Tropical Medicine
Tel: 020-7927 2075    Email: Laura.VanDyck@lshtm.ac.uk/Lucy.Brooks@lshtm.ac.uk
Who has reviewed the study? 
Before any research goes ahead it has to be checked by an Ethics Committee to make
sure that the research is suitable. This study has been checked by the East Brighton
Ethics Committee. 
Thank you for taking the time to read this information. Please ask any questions if you
need to.
PART 2
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Appendix 2 CHiP: summary of protocol
amendments
Amendment 1 (protocol version 2, 20 November 2007)
l Changes to the Patient Information Sheets and Consent Forms for parents to include why their child
had been chosen the this study, that blood taken speciﬁcally for this study would be painless and
taken only from a line that already been inserted, and clarity on where and who was signing the
consent form.
l Changes to the protocol to more clearly deﬁne how the insulin infusions should be prepared
and managed.
Amendment 2 (protocol version 3, 13 February 2008)
l Changes to the protocol to clarify the dosing in the control group.
Amendment 3 (16 October 2008)
l Poster to be displayed in intensive care units.
Amendment 4 (17 March 2009)
l Addition of the following two sites:
¢ Leicester Royal Inﬁrmary and Glenﬁeld Hospital (in Leicester).
¢ University Hospital of North Staffordshire (in Stoke on Trent).
Amendment 5 (5 February 2009)
l Letter to be sent to parents at discharge.
l Diary to be given to parents at discharge.
l Letter to be sent to parents at 12 months.
l Questionnaire to be sent to parents at 12 months.
Amendment 6 (protocol version 4, 15 May 2009)
l Changes to the protocol to make minor alterations to the insulin control guidelines for the tight group.
Amendment 7 (not applicable)
l Not applicable, due to misnumbering by ethics (incorrectly number amendment 6 as amendment 7,
and then unable to correct the numbering in their database).
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Amendment 8 (28 June 2009)
l Follow-up questionnaires to be sent at 1 year to TBI patients (Conners’ Parent Rating Scale - Revised,
Health Utilities Index-2, and Child Behaviour Checklist).
Amendment 9 (18 November 2009)
l Letter to parents of children who have died.
Amendment 10 (protocol version 5, 5 March 2010)
l Changes in the protocol, patient information sheets and GP and parent letters to reﬂect changes
in the TBI follow-up (all questionnaires now to be sent to them, rather than one to be completed over
the telephone).
l Changes in the protocol to add the publication policy.
l Letter for parents of children who are inpatients for over 1 year.
Amendment 11 (protocol version 6, 23 August 2010)
l Changes in the protocol, patient information sheets, consent forms, GP and parent letters due to the
1 year follow-up questionnaires no longer being sent out to parents (due to reasons of cost).
l Changes in patient information sheets and consent forms to reﬂect the change in name of the NHS
information centre.
l Changes in the protocol, patient information sheets and consent forms to make it clearer that their
patient data (including personal details) would be sent to the London School of Hygiene and
Tropical Medicine.
l Changes in the protocol to update the study background section to include more recent studies
and literature.
Amendment 12 (23 August 2010)
l Addition of the following site:
¢ St George’s Healthcare NHS Trust (in London).
Amendment 13 (14 December 2010)
l Change in PI at University Hospitals of North Staffordshire NHS Trust.
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Appendix 3 Protocol version 6 (August 2010)
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SUMMARY 
There is evidence that tight glucose control (TGC) of blood glucose (BG) favorably influences outcomes in 
adults who are critically ill or recovering from major surgery.   Children have been shown to exhibit similar 
hyperglycaemic responses to ‘stresses’ of surgery or critical illness. However it is not known whether TGC will 
benefit children because of factors including maturational differences and the different disease spectrum seen 
in children.   We are therefore seeking in this clinical trial to determine whether a policy of strictly controlling 
BG using insulin in children admitted to paediatric intensive care reduces mortality, morbidity and/or the use of 
healthcare resources.    
 
 
BACKGROUND 
 
Glucose homeostasis is known to be  impaired in patients subjected to the stress of major surgery or critical 
illness resulting in hyperglycaemia[1]. This may in part result from insulin resistance, as insulin-dependent 
glucose uptake has been shown to be reduced in various organs and tissues during critical illness.  Glucose 
uptake is however increased in non-insulin dependent tissues such as brain, red blood cells and wounds. This 
imbalance of glucose metabolism has previously been interpreted as the body’s plea for tolerating moderately 
high levels of glucose during critical illness and injury and treatment of ‘stress-induced’ hyperglycaemia has 
typically only been initiated if BG levels are persistently and substantially elevated.  
 
HYPERGLYCAEMIA IN CRITICALLY ILL ADULTS 
Over recent years several studies have associated hyperglycaemia with adverse outcomes during acute 
illness in adults: 
 
Myocardial infarction 
In a meta-analysis  [2], patients with acute myocardial infarction without diabetes who had glucose 
concentrations more than or equal to range 6.1-8.0 mmol/L had a 3.9-fold (95% CI 2.9-5.4) higher risk of death 
than patients without diabetes who had lower glucose concentrations. Glucose concentrations higher than 
values in the range of 8.0-10.0 mmol/L on admission were associated with increased risk of congestive heart 
failure or cardiogenic shock in patients without diabetes. Stress hyperglycaemia with myocardial infarction is 
associated with an increased risk of in-hospital mortality and increased risk of congestive heart failure or 
cardiogenic shock in patients without diabetes.  
 
Stroke 
Capes et al. conducted a systematic review and meta-analysis of the literature relating acute post stroke 
glucose levels to the subsequent course [3]. A comprehensive literature search was done for cohort studies 
reporting mortality and/or functional recovery after stroke in relation to admission glucose level. Thirty-two 
studies were identified for which pre-defined outcomes could be analysed in 26. After stroke, the unadjusted 
relative risk of in-hospital or 30-day mortality associated with admission glucose level >6 to 8 mmol/L was 3.07 
(95% CI, 2.50 to 3.79) in non-diabetic patients and 1.30 (95% CI, 0.49 to 3.43) in diabetic patients. Non-
diabetic stroke survivors whose admission glucose level was >6.7 to 8 mmol/L also had a greater risk of poor 
functional recovery (relative risk=1.41; 95% CI, 1.16 to 1.73).  
 
Head injury and multi-system trauma 
Hyperglycaemia has been shown to be an independent predictor of poor outcome in adult patients[4]  and 
children with head injury[5-6] and multiple trauma[7]. 
 
 
 
 
APPENDIX 3
102
NIHR Journals Library www.journalslibrary.nihr.ac.uk
 
 
 
EurodrCT number      2006/-005715/-10  
ISRCTN61735247                
  
Pulmonary function 
Hyperglycaemia has been shown to be associated with diminished pulmonary function in adults even in the 
absence of diabetes mellitus[8] and a range of other effects with potential to injure the lung [9]. 
 
Gastrointestinal effects 
Hyperglycaemia has been shown to be associated with delayed gastric emptying[10], decreased small bowel 
motility and to increase sensation and cerebral evoked potentials to a range of gastrointestinal stimuli in adult 
volunteers [11-14].  
 
Infections 
In  vitro  responsiveness of leukocytes stimulated by inflammatory mediators is inversely correlated with 
glycaemic control [15]. This reduction in polymorphonuclear leucocyte  responsiveness may contribute to the 
compromised host defence associated with sustained hyperglycaemia [15], and indeed, hyperglycaemia has 
been shown to be associated with an increased rate of serious infections after adult cardiac[16] and 
vascular[17] surgery. 
 
STUDIES OF CONTROL OF GLYCAEMIA IN ADULTS 
Recent reports from adult populations suggest that control of glycaemia during acute illness can be associated  
with improved outcomes [18-22]. 
 
Furnary et al.[21] studied the hypothesis that since hyperglycaemia was associated with higher sternal wound 
infection rates following adult cardiac surgery, aggressive control of glycaemia might lead to lower infection 
rates. In a prospective study of 2,467 consecutive diabetic patients who underwent open heart surgical 
procedures, patients were classified into two sequential groups. A control group included 968 patients treated 
with sliding-scale-guided intermittent subcutaneous insulin injections. A study group included 1,499 patients 
treated with a continuous intravenous insulin infusion in an attempt to maintain a BG level of less than 11.1 
mmol/l. Compared with subcutaneous insulin injections, continuous intravenous insulin infusion induced a 
significant reduction in perioperative BG levels, which led to a significant reduction in the incidence of deep 
sternal wound infection in the continuous intravenous insulin infusion group (0.8% [12 of 1,499]) versus the 
intermittent subcutaneous insulin injection group (2.0% [19 of 968], p = 0.01 ). The use of perioperative 
continuous intravenous insulin infusion in diabetic patients undergoing open heart surgical procedures appears 
to significantly reduce the incidence of major infections. 
 
Malmberg et al.[19] randomly allocated patients with diabetes mellitus and acute myocardial infarction to 
intensive insulin therapy (n=306) or standard treatment (controls, n= 314). The mean (range) follow up was 3.4 
(1.6-5.6) years. There were 102 (33%) deaths in the treatment group compared with 138 (44%) deaths in the 
control group (relative risk (95% confidence interval) 0.72 (0.55 to 0.92); P = 0.011). The effect was most 
pronounced among the predefined group that included 272 patients without previous insulin treatment and at a 
low cardiovascular risk (0.49 (0.30 to 0.80); P = 0.004). Intensive insulin therapy improved survival in diabetic 
patients with acute myocardial infarction. The effect seen at one year continued for at least 3.5 years, with an 
absolute reduction in mortality of 11%.  
 
In 2001 Van den Berghe and colleagues from Leuven, Belgium, [18] reported the results of a randomised trial 
in adults undergoing intensive care following surgical procedures. This trial showed that the use of insulin to 
tightly control BG led to a reduction in mortality (32%), mean length of intensive care stay (22%), and 
significantly lower occurrence of a range of complications of critical illness such as renal failure, infection, 
inflammation, anaemia and polyneuropathy. Duration of intensive care stay was 3.4 days shorter in the insulin 
group. 
In 2006 the Leuven group  [22] have reported that, in addition to adult surgical intensive care patients,  
intensive insulin therapy reduces morbidity in adults who require  intensive care for treatment of  medical 
conditions. In this prospective randomised controlled trial, patients were randomly assigned to a regime of 
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strict normalisation of BG (4.4-6.1 mmol/l) with use of insulin, or conventional therapy where insulin is 
administered only when BG levels exceeded 12 mmol/l, with the infusion tapered when the level fell below 10 
mmol/l.  In the intention to treat analysis of the 1200 patients included, ICU and in-hospital mortality were not 
significantly altered by intensive insulin therapy, however for those patients requiring more than 3 days 
intensive care, mortality was significantly reduced from 52.5 to 43% (p= 0.009). Morbidity was significantly 
reduced by intensive insulin therapy with a lower incidence of renal injury and shorter length of mechanical 
ventilation and duration of hospital stay noted.  Beyond the fifth day of intensive insulin therapy, all morbidity 
endpoints were beneficially affected, whereas for those patients staying less than 3 days, none of the 
morbidity end-points were significantly different between the two treatment groups.  
 
On the basis of these studies, several groups have recommended that tight glycaemic control with intensive 
insulin therapy become a standard of care for the critically ill adult patients. The Joint Commission on 
Accreditation of Healthcare Organization (JACHO) recently proposed tight glucose control for the critically ill as 
a core quality of care measure for all U.S. hospitals that participate in the Medicare program[23]. The Institute 
for Healthcare Improvement, together with an international initiative by several professional societies including 
the American Thoracic Society, is promoting a care "bundle" for severe sepsis that also includes intensive 
glycaemic control for critically ill adults [24]. Both the Society of Critical Care Medicine and European Society 
of Intensive Care Medicine have incorporated TGC into their recently publicised ‘Surviving Sepsis’ guidelines. 
These initiatives represent important attempts to translate research findings into improved care at the 
bedside[25]. 
 
Since then, the NICE-SUGAR Study [26], a large international multicentre study which compared two glucose 
control strategies (targets of 4.5 – 6.0 mmol/l versus < 10 mmol/l) in 6104 adults undergoing intensive care, 
has reported. This found that intensive glucose control as compared to conventional glucose control led to a 
statistically significant increase in the rate of the primary end-point, death by 90 days, with intensive insulin 
control (27.5% v. 24.9%; odds ratio (OR) 1.14, 95%CI 1.02-1.28, p=0.02 ). There was also more severe 
hypoglycaemia (<40 mg per decilitre) in the intensive control group (6.8% v. 0.5%; OR 14.7, 95%CI 9-25.9, 
p<0.001). 
 
The authors discuss possible explanations for why their results differ from those of the Leuven group [17,22] in 
terms of their specific treatment algorithm, the fact that most of their patients received enteral nutrition, or that 
their greater power and longer follow up allowed more accurate determination of effects.  They speculate that 
the mechanism for the increased mortality may be the reduced blood glucose level, increased insulin 
administration, more hypoglycaemia, or other factors.  They conclude by not recommending the use of a lower 
blood glucose target in critically ill adults. 
 
In the accompanying editorial [27], Inzucchi and Siegel caution against over-reaction to the NICE-SUGAR 
study.  They point out that the trial’s weaknesses include open label design (although they do recognise that 
this is understandable), and an imbalance between the groups in corticosteroid therapy (but this is post-
randomisation and may be a consequence of the intervention, not a weakness of the trial).  The editorial also 
comments on the intention to treat analysis and that 10% of intensive control discontinued this intervention.  
However, both these approaches are appropriate – statistically and clinically.  Like the authors, they draw 
attention to the differences between this trial and those of the Leuven group, in particular that the latter was 
single-centre and their results may therefore be less generalisable, and that they used parenteral rather than 
enteral nuturiton.  Also, the standard management in the Leuven studies (reduction of glucose levels above 
215 mg per decilitre) was contrasted to a milder range 144-180 mg per decilitre in NICE-SUGAR.  Inzucchi 
and Siegel suggest a number of further exploratory analyses in the NICE-SUGAR trial and recommend that, 
while awaiting further evidence, ICUs continue with where intensive glucose control in adult critical care where 
this  practice is already strongly embedded. 
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Griesdale et al. [28] have recently published a meta-analysis which summarises data from a total of 26 trials of 
intensive glucose control involving a total of 13,567 adult patients, including the NICE-SUGAR trial.  The meta-
analysis did not show an overall benefit of tight glucose control on mortality (RR 0.93, 95% CI 0.83-1.04).  
There was some evidence of heterogenity between effects by the type of ICU (p<0.01) such that patients in 
surgical intensive care appeared to benefit from intensive glucose control (RR 0.63, 95% CI 0.44-0.91) 
whereas patients in other ICU settings did not (medical ICU RR 1.0,  95% CI 0.78 – 1.28; mixed ICU RR 0.99,  
95% CI 0.87 – 1.12).  Whereas the results from the trials in surgical and in medical ICU settings were mainly 
similar, there was more heterogenity in the results from the mixed ICUs (P<0.01).  The results of this meta-
analysis from the mixed ICUs were dominated by the largest trial [26]. Griesdale et al conclude that, while their 
results “do not support widespread adoption of intensive insulin therapy in critically ill [adult] patients” further 
resarch is needed to identify which, if any, patients might benefit from tight glucose control. 
 
The possible mechanisms by which different glucose control strategies might influence clinical outcomes are 
yet to be fully elucidated. There is a substantial body of published research which points to an association 
between hyperglycaemia and organ/tissue dysfunction. In models of both focal and global cerebral ischaemia, 
hyperglycaemia has been shown to be associated with exacerbation of intracellular acidosis [29-31], 
accumulation of extracellular glutamate [32], cerebral oedema formation and disruption [33]of the blood-brain 
barrier[34].  In ischaemic brain injury, hyperglycaemia may worsen injury by promoting anaerobic metabolism 
and consequent intracellular acidosis. In the rat myocardium, hyperglycaemia leads to up-regulation of 
inducible nitric oxide synthase, resulting ultimately in an increase in production of superoxide, a condition 
favouring the production of the powerful pro-oxidant peroxynitrite. This highly reactive free radical has the 
power to cause direct oxidant damage to myocardial cells or to induce myocardial cell apoptosis[35-36]. 
Similar adverse mechanisms have been shown to exist in hyperglycaemic patients [37-38].  Improved clinical 
outcomes may arise not necessarily solely as a result of control of BG. Insulin lowers free fatty acids and 
normalises endothelial function [39]; is associated with anabolic effects [40-41]; has been shown to have anti-
inflammatory effects [42-43] and to have cardio-protective effects [44], all of which may contribute 
independently to better outcomes in critical illness. 
 
HYPERGLYCAEMIA IN LOW BIRTHWEIGHT NEONATES 
The population for the NIRTURE trial [45] was 389 very low birthweight neonates, recruited from 8 NICUs in 
the UK and mainland Europe.  The primary outcome was death at the expected date of delivery (EDD).  The 
trial was stopped early by the trial steering committee on the advice of the independent data monitoring 
committee for a combination of futility in terms of the primary mortality outcome, and concerns about potential 
harm in terms of an excess of ventricular haemorrhage and parenchymal lesions on cerebral ultrasound scans.  
More infants in the early insulin group had episodes of hypoglycaemia (<47 mg per decilitre) than in the control 
group (29% v. 17%; OR 2.21, 95%CI 1.34-3.65, p<0.005).  There was no statistically significant difference in 
the primary outcome of mortality at EDD (14% v. 9%; OR 1.64, 95%CI 0.87-3.03, p<0.2), but the secondary 
mortality outcome of death at 28 days was increased in the tight glucose control group (12% v. 6%; OR 2.22, 
95%CI 1.04-4.76, p<0.04).  The authors speculate that the results might be due to a smaller difference in the 
levels of glucose control than seen in their pilot study; or too short a period (7 days) of tight control.  They 
stress the importance of long term follow up for the surviving babies.  An accompanying editorial [46] 
recommends caution in the use of this therapy in very low birth weight infants. 
 
 
 
HYPERGLYCAEMIA IN CRITICALLY ILL CHILDREN 
Over 10,000 children are admitted to intensive care units in England and Wales each year [47].  
Hyperglycaemia, defined as BG > 7 mmol/l, occurs frequently during critical illness or after major surgery in 
children, with a  reported incidence of up to 86% [48].  As in adults, the occurrence of hyperglycaemia has 
been shown to be associated with poorer outcomes  including death, sepsis, and longer length of intensive 
care stay in critically ill children[48-51].on-randomised research in children includes a number of reports from 
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general paediatric intensive care units [48-50, 52] and paediatric cardiac intensive care units [51] showing that 
high BG levels occur frequently in critically ill children and that BG levels are significantly higher in children 
who die than in children who survive. 
 
Srinivasan et al.[48] studied the association of timing, duration, and intensity of hyperglycaemia with paediatric 
intensive care unit (PICU) mortality in critically ill children. The study was a retrospective, cohort design and 
included 152 critically ill children receiving vasoactive infusions or mechanical ventilation. Peak BG of  >7 
mmol/L occurred in 86% of patients. Compared with survivors, non-survivors had higher peak BG (17.3mmol/L 
+/- 6.4 vs. 11.4 +/- 4.4 mmol/L, p <.001).  Non-survivors had more intense hyperglycaemia during the first 48 
hrs in the PICU (7 +/-2.1 mmol/L) vs. survivors (6.4 +/- 1.9 mmol/L, p <.05). Univariate logistic regression 
analysis showed that peak BG and the duration and intensity of hyperglycaemia were each associated with 
PICU mortality (p <.05). Multivariate modelling controlling for age and Paediatric Risk of Mortality scores 
showed independent association of peak BG and duration of hyperglycaemia with PICU mortality (p <.05).  
This study demonstrated that hyperglycaemia is common among critically ill children. Peak BG and duration of 
hyperglycaemia appear to be independently associated with mortality. The study was limited by its 
retrospective design; its single-centre location and the absence of cardiac surgical cases, a group which make 
up approximately 40% of paediatric intensive care admissions in the UK. 
 
Halverson-Steele et al.[51] have recently shown in a retrospective study, that hyperglycaemia was associated 
with poor outcomes in 526 children following cardiac surgery. Nineteen patients (3.6%) died postoperatively 
(median 11 days, range 1-17 days). Peak plasma glucose concentrations in survivors (mean 10.7 mmol/l,SD 
3.7) was significantly lower than the peak value recorded in non-survivors (mean 14.3 mmol/l,SD 
4.2;p=0.0017).  The 147 patients who were discharged from ICU within 24 hours had lower plasma glucose 
concentrations on admission (mean 7.5mmol/l,SD 2.3) and peak plasma glucose concentrations (mean 9.2 
mmol/l,SD 2.3) than the remaining patients staying longer than 24 hours (mean 8.1 mmol/l,SD 4.0;p=003 and 
mean 11.3mmol/l,SD 3.9;p<0.0001, respectively). Peak plasma glucose concentrations were also lower in 387 
patients admitted for up to 5 days (mean 10.1mmol/l,SD 2.9) when compared with those patients with ICU 
stays of > 5 days  (mean 12.7mmol/l/,SD 4.6;p<0.0001). 
 
Hall et al.[50] investigated the incidence of hyperglycaemia in infants with necrotizing enterocolitis (NEC) and 
the relationship between glucose levels and outcome in these infants. Glucose measurements (n = 6508) in 95 
neonates with confirmed NEC admitted to the surgical intensive care unit were reviewed. Glucose levels 
ranged from 0.5 to 35.0 mmol/L. 69% of infants became hyperglycaemic (>8 mmol/L) during their admission. 
Thirty-two infants died. Mortality rate tended to be higher in infants when maximal glucose concentration 
exceeded 11.9 mmol/L compared with those with maximum glucose concentrations of less than 11.9 mmol/L, 
and late (>10 days admission) mortality rate was significantly higher in these infants (29% v, 2%; P =.0009). 
Linear regression analysis indicated that maximum glucose concentration was significantly related to length of 
stay (P <.0001).  
 
Branco et al. [49] have shown that there is an association between hyperglycaemia and increased mortality in 
children with septic shock. They prospectively studied all children admitted to a regional PICU with septic 
shock refractory to fluid therapy over a period of 32 months. The peak glucose level in those with septic shock 
was 11.9 +/- 5.4 mmol/L (mean +/- SD), and the mortality rate was 49.1% (28/57). In non-survivors, the peak 
glucose level was 14.5 +/- 6.1 mmol/L, which was higher (p < .01) than that found in survivors (9.3 +/- 3.0 
mmol/L). The relative risk of death in patients with peak glucose levels of ≥9.9 mmol/L was 2.59 (range, 1.37-
4.88).   
 
Faustino [52] demonstrated that hyperglycaemia occurs frequently among critically ill non-diabetic children and 
is associated with higher mortality and longer lengths of stay. They performed a retrospective cohort study of 
942 non-diabetic patients admitted to a PICU over a 3 year period. The prevalence of hyperglycaemia was 
based on initial PICU glucose measurement, highest value within 24 hours, and highest value measured 
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during PICU stay up to 10 days after the first measurement. Through the use of three cut-off values (6.7 
mmol/L, 8.3 mmol/L, and 11.1 mmol/L), the prevalence of hyperglycaemia was 16.7% to 75.0%. The relative 
risk (RR) for dying increased for maximum glucose within 24 hours >8.3 mmol/L (RR, 2.50; 95% confidence 
interval (CI), 1.26 to 4.93) and highest glucose within 10 days >6.7 mmol/L (RR, 5.68; 95% CI, 1.38 to 23.47).  
 
Pham  et al. [53]  have recently reported their experience of adopting a policy of 'intensive' insulin therapy to 
achieve BG levels 5 mmol/L to 6.7 mmol/L. They reviewed the records of children with ≥ 30% total body 
surface area burn injury admitted over a 3 year period. The first cohort of 31 children received 'conventional 
insulin therapy', whilst the subsequent cohort of 33 children received 'intensive insulin therapy'. The 
demographic characteristics and injury severity were similar between the groups. Intensive insulin therapy was 
positively associated with survival and a reduced incidence of infections. The authors therefore concluded that 
intensive insulin therapy to maintain normoglycaemia in severely burned children could be safely and 
effectively implemented in a paediatric burns unit and that this therapy seemed to lower infection rates and 
improve survival.  
 
The study by Vlasselaers et al. [54] I was a single centre study from the Leuven group of Van den Berghe, 
and involved 700 PICU patients who were randomly assigned to either intensive glucose control (targeted to 
achieve blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children), or to insulin 
infusion only to prevent blood glucose from exceeding 11.9 mmol/L (conventional care).  Three quarters of the 
patients were admitted following cardiac surgery.  There was more hypoglycaemia (defined as a blood glucose 
of <2.2 mmol/L) in the intensive control vs conventional arm (25% v. 1%, p=0.0001).  Patients in the intensive 
control arm had redcued PICU stay (5.51 vs 6.15 days, p=0.017).  The study was not powered for mortality but 
showed a reduction in deaths with intensive control (3% v. 6%, p=0.038).  The authors consider their trial as a 
‘proof of concept’ and call for further multicentre trials with a broader case-mix, powered to address mortality 
and with longer term follow up.   
 
While there is therefore mounting evidence to suggest that a policy of TGC may be beneficial to children 
undergoing paediatric intensive care, none of this evidence is from large multicentre rigorous randomized 
controlled trials with longer term follow up. The aim of the present study is to determine whether a policy of 
strictly controlling BG using insulin in children admitted to paediatric intensive care reduces mortality, morbidity 
and / or the use of healthcare resources. 
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STUDY DESIGN 
 
Main hypothesis  
 
For children aged from birth to <16 years on ventilatory support, Tight glucose control (TGC) will increase the 
numbers of days alive and free of mechanical ventilation at 30 days. 
 
Secondary hypotheses 
 
That TGC will lead to improvement in a range of complications associated with intensive care treatment and be 
cost effective. 
 
Inclusion criteria 
 
• Children from birth to <16 years who are undergoing intensive care treatment with an arterial line in-
situ and receiving both mechanical ventilation and vasoactive support drugs* following injury, major 
surgery or in association with critical illness in whom it is anticipated such treatment will be required to 
continue for at least 12 hours. 
 
Exclusion criteria prior to trial entry 
 
• Children born pre-term and who are < 36 weeks corrected gestation 
• Children with diabetes mellitus 
• Children with an established or suspected diagnosis of an inborn error of metabolism 
• Children for whom treatment withdrawal or limitation of intensive care treatment is being considered 
• Children who have been in a PICU for more than 5 days in succession 
• Children admitted to a PICU who have already participated in the CHIP study during a previous PICU 
admission. 
 
Consent 
 
Parents/guardians of babies and children in intensive care will be asked to give consent in their role of legal 
representatives. We understand that parents will be stressed and anxious.  However they will usually have 
limited time to consider trial entry as it may not be medically appropriate to delay the start of treatment.  
Parents of babies and children listed for cardiac surgery will be given information about the trial pre-operatively 
and consent provisionally obtained to be confirmed later if the child is admitted to intensive care.  In addition, 
where possible, older children will be given information and asked to assent to their participation in the study. 
 
Patients not entered into the trial will receive standard care. 
 
Allocation of patients 
 
After inclusion in the study, children will be randomised to one of two groups: 
 
 
Group 1 - Standard treatment 
 
                                                            
* Vasoactive drugs : Catecholamines or similar (dopamine, dobutamine, adrenaline, noradrenaline), PDEIII inhibitors (milrinone, enoximone), other  vasopressors 
(vasopressin, phenylephrine or similar).  
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Group 2 - Tight glycaemic control 
 
To reduce the risk of selection bias at trial entry, allocation will be administered through a 24 hour, 7 day a 
week central randomisation service.  Minimisation with a probablistic element will be used to ensure a balance 
of key prognostic factors between groups using the following criteria:  
 
• Centre 
 
• age <1 year v. 1year – <16 years 
 
• admitted following cardiac surgery or not 
 
• For cardiac surgical children, RACHS1[55] category 1 to 4 versus 5 to 6 
• For non-cardiac surgical children, PIM2 score at randomization categorised by probabilities of death of 
<5%, 5% - <15% and ≥15%.   
• accidental traumatic brain injury or not 
 
Interventions 
 
Group 1 - Standard treatment  
Children in this group will be treated according to a standard, current, approach to BG management. Insulin 
will be given by intravenous infusion in this group only if BG levels exceed 12mmol/l on two blood samples 
taken at least 30 minutes apart and will be discontinued once BG falls to <10mmol/l.  
 
A protocol for glucose control in this group is attached as Appendix A.   
 
Group 2 - Tight glycaemic control  
Children in this group will receive insulin by intravenous infusion titrated to maintain a BG between the limits of 
4 and 7.0 mmol/l.  
 
A protocol for glucose control in this group is attached as Appendix B.  
 
The protocol for glucose control in group 2 has been carefully designed to achieve a tight glucose control 
whilst minimizing the risk of hypoglycaemia, the principal side effect of insulin therapy.  Standard insulin 
solutions will be used and changes in insulin infusion rates will be guided both by the current glucose levels 
and its rate of change from previous measurements. BG levels will be routinely measured as in all intensive 
care units using commercially available ‘point of care’ analysers which utilise very small blood samples, 
producing results in approximately 1 minute. Analysers are rigorously maintained and subjected to laboratory-
standard quality assurance programmes.  
 
Training in use of the glucose control protocol will be provided before the first patient is enrolled in each 
collaborating centre and for new staff throughout the trial. The Clinical Co-ordinating centre team will liaise 
closely with local clinicians to ensure that glucose control algorithms are followed closely and safely.
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Potentially eligible patients: 
 
• Information given to parents of babies and children (<16) likely to have cardiac 
surgery. 
• Babies and children screened in PICU: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information given to parents 
Inclusion Criteria:  
• Children from birth to <16 years who are undergoing intensive care treatment 
with an arterial line in-situ and receiving both mechanical ventilation and 
vasoactive support drugs following injury, major surgery or in association with 
critical illness in whom it is anticipated such treatment will be required to 
continue for at least 12 hours. 
 
Exclusion criteria prior to trial entry:  
• Children born pre-term and who are < 36 weeks corrected gestation 
• Children with diabetes mellitus 
• Children with an established or suspected diagnosis of an inborn error 
of metabolism 
• Children for whom treatment withdrawal or limitation of intensive care 
treatment is being considered 
• Children who have been in a PICU for more than 5 days in succession 
• Children admitted to a  PICU  who have already participated in the CHIP 
study during a previous PICU admission. 
CONSENT given 
No traumatic brain Injury Traumatic brain Injury 
Standard Treatment Tight Control Standard Treatment Tight Control 
Follow up for 30 days (or discharge if hospital stay > 30 days) 
Follow up: 
• Letter to GP/Health visitor 
• Following discharge: 
◊ Letter to parents about follow-up  
◊ Registration with NHS IC and NHS CR 
At 11 months checks with GP/HV before contact with parents 
(for patients recruited until September 2010) 
No traumatic brain Injury: 
Letter to parents with resource use 
questionnaire between discharge and 
12 months. 
Traumatic brain Injury: 
Letter to parents with resource use questionnaire 
between discharge and 12 months, Conner’s 
rating scale, Health Utilities Index and Child 
Behavioural Check List. 
Allocation to: Allocation to:
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Outcome measures 
 
Primary:  
Following the influential ARDSNET study [56] we will use as the primary outcome the number of days alive 
and free from mechanical ventilation within the 30 days after trial entry. Death is obviously an important 
outcome.   Mechanical ventilation can be seen as a measure of disease severity, defining the need for 
complex intensive care. The concept of ventilator free days (Vedas) brings together these two outcomes.  
Schoenfeld et al [57] define ventilator free days (VFDs) as: VFD=0 if the child dies before 30 days; VDF=(30-x) 
if the child is successfully weaned from ventilator within 30 days (where x is the number of days on ventilator); 
or VFD=0 if the child is ventilated for 30 days or more.  The use of organ failure free days to determine patient-
related morbidity surrogate end-points in paediatric trials has been supported by influential paediatric trialists in 
the current low mortality paediatric critical care environment [58]. 
 
Secondary:   
Death within 30 days after trial entry (or before discharge from hospital if duration is greater than 30 days) 
Death within 12 months of trial entry 
Number of days in ICU 
Duration of mechanical ventilation 
Duration of vasoactive drug usage (adrenaline, noradrenaline, dopamine, dobutamine, or PDEIII inhibitors or 
vasopressors) 
Need for renal replacement therapy 
Blood stream infection (positive cultures associated with two or more features of systemic inflammation or any 
positive blood culture for fungus) 
Use of antibiotics >10 days 
Number of red cell transfusions 
Number of hypoglycaemic episodes moderate (less than 2.5 mmol/L), severe (less than 2.0 mmol/L) 
Occurrence of seizures (clinical seizures requiring anticonvulsant therapy) 
Organ dysfunction score (PELOD)[58-60], 
Hospital length of stay 
Number of children readmitted within 30 days of trial entry 
Cost and cost-effectiveness measures 
 Hospital costs within 30 days of trial entry 
 Cost per life year (based on 30 days costs and survival) 
 Hospital and community health service costs within 12 months of trial entry† 
 Cost per life year (based on 12 month costs and survival for all cases)† 
 Cost per disability-free survivor (based on 12 month cost and outcome data for sub group with traumatic 
 brain injury)† 
 
Follow-up at 12 months: 
If parents give their consent all children surviving to hospital discharge will be followed up to 12 months post-
randomisation to determine mortality using the NHS Information Centre and the NHS Central Register.   
Parents will be informed about the follow-up study at trial entry and asked to give consent.  The Trial Manager 
at the Data Co-ordinating Centre (DCC) will write to parents following discharge home to remind them about 
the follow-up and ask them to keep the DCC informed about any change of address.  At around 11 months†, 
following checks with the GP/Health Visitor to determine that this is appropriate, the Trial Manager will send a 
questionnaire to parents to determine the use of health care resources between discharge and 12 months.   
Non-responders will be followed–up by letter and telephone. 
 
                                                            
† For patients recruited until September 2010 
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Follow-up of traumatic brain Injury sub-group:   
This sub-group is more likely to have longer-term morbidity and parents of children (aged 4 or over) in this sub-
group will be asked to provide additional information at 12 months†, regarding overall health status, global 
neurological outcome, attention and behavioural status .  Further details are given in Appendix D 
 
Adverse events and safety reporting 
 
The Royal Brompton & Harefield NHS Trust, as sponsor of this study, has responsibility to ensure 
arrangements are in place to record, notify, assess, report, analyse and manage adverse events in order to 
comply with the UK regulations of Medicines for Human Use (Clinical Trials) Regulations 2004. 
 
All sites involved in the study are expected to inform the Chief Investigator and Study nurse of any serious 
adverse events/reactions within 24 hours so that appropriate safety reporting procedures can be followed by 
the Sponsor.  
 
It is therefore important that all site investigators involved in the study are aware of the reporting process and 
timelines. Details of the mandatory Adverse Event and Safety Reporting requirements are detailed in Appendix 
C of this protocol. 
 
Expected side effects 
All adverse events judged by either the investigator or the sponsor as having a reasonable suspected causal 
relationship to insulin therapy qualify as adverse reactions.  
 
Whilst any suspected, unexpected, serious adverse reaction (SUSAR) involving insulin therapy will be reported 
according to the timelines for SUSARs, expected sides effect of insulin will be reported in the annual safety 
report unless serious enough to warrant expedited reporting. 
 
The most prominent adverse effect of insulin treatment is hypoglycaemia.  We are aiming to control BG within 
the range 4 – 7 mmol/l which is well above the 2 mmol/l threshold for clinically important hypoglycaemia[61]. 
The principal measure to avoid clinically important hypoglycaemia will be hourly measurement of BG when 
insulin is first administered. The insulin administration protocols aim to achieve glucose control with the lowest 
possible incidence of hypoglycaemia and the avoidance of neuroglycopaenia.   Hypoglycaemic events will be 
reported to the Clinical Co-coordinating Centre and if necessary, the BG control protocols will be revised, 
whilst still aiming to achieve BG levels within the target ranges. 
 
Insulin is reported to occasionally cause a rash which may be associated with itching. 
 
Data collection 
 
To minimise the data collection load for busy units, the trial will collaborate with the Paediatric Intensive Care 
Audit Network (PICANet) to make best use of the established data collection infrastructure which exists in all 
PICUs in the UK. The PICANet dataset includes most of the items being used in the trial and these data will be 
transmitted from the participating centres to the Data Co-ordinating Centre electronically using strong 
encryption.   The remaining short term data items will be collected locally by the research nurses, and those for 
the longer term follow-up will be collected separately by telephone and postal questionnaires.  These data will 
be double entered onto electronic database storage systems at the Data Co-ordinating Centre.   
 
Economic evaluation 
 
                                                            
† For patients recruited until September 2010 
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Cost-consequence and cost-effectiveness analyses will be undertaken as part of the proposed study. These 
economic evaluations will assess whether the costs of achieving tight blood glucose control are justified by 
subsequent reductions in hospitalisation costs and/ or by improvements in patient outcomes. The evaluations 
will be conducted in two phases, in the first phase all hospital costs at 30 days post randomisation will be 
compared across treatment groups alongside 30-day outcomes, in the second phase cost and outcomes at 
12-months† will be compared across the groups. 
 
For the first phase evaluations, detailed resource use data will be collected for each patient enrolled in CHIP 
using the Paediatric Critical Care Minimum Dataset (PCCMDS)[62]  which will be collected by each PICANet  
unit. Where information on resource use is required in CHIP is not available from these sources  datasheets 
similar to those developed as part of the INNOVO study will be used [63].  Information will also be collected on 
the resources required to achieve tight blood glucose control, in particular all medication use and the staff time 
involved in monitoring the patients and managing adverse events (e.g. hypoglycaemia) will be noted.  
 
Unit costs for hospital services will be taken from the NHS reference costs database [64]. Where more detailed 
unit costs are required, for example those associated with staff time and the use of insulin infusion, these will 
be collected on site visits to centres. Hospital costs up to 30 days will be estimated by valuing each resource 
use item by the appropriate unit cost. 
 
In the second phase of the study the time horizon of the economic evaluation will be extended to 12 months†, 
and resource use data on hospital re-admissions will be collected for all cases. For the sub-sample of patients 
diagnosed as having traumatic brain injury at study entry,  information on the patient's disability at one-year will 
be collected by postal questionnaire’s† to the patients' relatives based on previously developed interview 
schedules [63]. 
 
All the economic analyses will be based on the treatment groups as randomly allocated ('intention to treat'). 
The initial analysis will include a cost-consequence analysis and will report mean differences (95% CI) 
between treatment groups in resource use (e.g. length of hospital stay) and total hospital costs per patient, 
alongside the primary clinical endpoint. The initial analysis will also combine costs and outcomes at 30 days 
post-randomisation in a cost-effectiveness analysis, which will report cost per death averted and cost per 
adverse event averted.  The subsequent analysis will use 12-month cost and outcome data† to report the cost 
per death averted for all patients. For the sub-sample of patients diagnosed as having brain injury at study 
entry, the cost-effectiveness analysis will also report the cost per death or disabled case averted.  
 
The sensitivity analysis will test whether the results are robust to key assumptions made, for example to the 
choice of unit costs and the time horizon of the analysis.  The cost and outcome data collected at one-year† 
will be used to project the impact of the intervention on longer-term costs and outcomes. 
 
Sample size 
 
The primary outcome is the number of ventilator-free days within the first 30 days post-randomisation.  A 
difference of 2 days in the number of ventilator-free days (VFD) is considered clinically important for the trial to 
be able to detect.  Information from PICANet from a sample of PICUs for 2003-4 estimates that the mean 
number of VFDs in cardiac patients is 26.7, with a standard deviation (SD) of 4.2.  Corresponding figures for 
non-cardiac patients are a mean of 22.7 days, with a standard deviation (SD) of 6.8 days.  As the SD is 
estimated with error, to be conservative we have assumed the SD is nearer 5.5 days for the cardiac and 8 
days for the non-cardiac patients.  There are likely to be more non-cardiac than cardiac patients eligible for the 
trial.  We have therefore assumed an overall SD across both cardiac and non-cardiac strata of 7 days.  
Assuming this is the same in both trial arms, and taking a type I error of 1% (with a 2-sided test), a total 
sample size of 750 patients would have 90% power to detect this difference.  Whereas we can assume 
                                                            
† For patients recruited until September 2010 
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minimal loss to follow up to 30 days, there may be some non-compliance (some patients allocated to tight 
control not receiving this, and some allocated to usual care being managed with tight control).  The target size 
will therefore be inflated to 1000 to take account of possible dilution of effect.    
 
As information from PICANet indicates that there are differences in outcome between cardiac and non-cardiac 
patients not merely in VFDs but also in 30 day mortality rate (3.4% vs. 20%) and mean duration of time on a 
ventilator (3.7 vs. 8.0 days, survivors and non-survivors combined), we also wish to be able to detect whether 
any effect of tight glucose control differs between the cardiac and non-cardiac strata.  To have 80% power for 
an interaction test to be able to detect a difference of two days in the effect of intervention between the strata 
at the 5% level of statistical significance, we would need to increase the sample size to 1500.  If the interaction 
test was positive this size would allow us to assess the effect of tight glucose control separately in the two 
strata.   
 
Recruitment rate 
 
There are approximately eligible 1300 cardiac and 1550 non-cardiac patients per year in collaborating PICUs    
we estimate about half of those eligible will be recruited into the trial.  The overall total sample size of 1500 
should be accrued by September 2011. 
 
Type of analysis 
 
Analysis will be by intention to treat. The following sub-group analyses will be conducted: age (<1year or 1-
<16years), severity of illness, traumatic brain injury or not, cardiac surgical versus non-cardiac cases,  
RACHS1 (cardiac cases) (Groups 1-4 versus 5 and 6), PIM2 group (non-cardiac cases) (categorised by 
probabilities of death of <5%, 5% - <15% and ≥15%),  run in cases v. non-run in cases.   
 
Frequency of analysis 
 
An independent Data Monitoring and Ethics Committee (DMEC) will review, in strict confidence, data from the 
trial approximately half way through the recruitment period. The Chair of the DMEC may also request 
additional meeting/analyses. In the light of these data and other evidence from relevant studies, the DMEC will 
inform the Steering Committee if in their view: 
 
i. There is proof that the data indicate that any part of the protocol under investigation is either clearly 
indicated or clearly contra-indicated either for all patients or a particular subgroup of patients. using 
the Peto and Haybittle rule [65-66] 
ii. It is evident that no clear outcome will be obtained with the current trial design. 
iii. That they have a major ethical or safety concern 
 
Ancillary studies 
 
In addition to the main study, some collaborators may wish to conduct other more detailed or complementary 
studies. The grant holders welcome this provided that proposals are discussed in advance with the Trial 
Steering Committee and appropriate additional Research Ethics approval is sought. 
 
Publication policy 
 
To safeguard the integrity of the trial, data from this study will not be presented in public or submitted for 
publication without requesting comments and receiving agreement from the Trial Steering Committee. The 
primary results of the trial will be published by the group as a whole with local investigators acknowledged. The 
success of the trial depends on the collaboration of many people.  The results will be presented first to the trial 
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local investigators.  A summary of the results of the trial will be sent to parents of participating children on 
request and also made available on the trial website.   
 
The full Publication Policy is shown in Appendix H 
 
 
ORGANISATION  
 
A Data Monitoring and Ethics Committee (DMEC) and a Trial Steering Committee (TSC) have been 
established.   Day to day management of the trial will be overseen by a Trial Management Group.  
 
Trial Management Group  
 
A Trial Management Group will be established and will be responsible for the day to day management of the 
trial.  The group will comprise the grant holders and project staff from the Clinical Co-coordinating Centre at 
the Royal Brompton Hospital NHS Trust and the Data Co-coordinating Centre at the LSHTM.  The group will 
meet regularly in person and by telephone. 
 
The responsibilities of the TMG are: 
a) To establish and monitor recruitment of participating centres 
b) To distribute and supply of data collection forms and other appropriate documentation for the trial 
c) Data collection and management 
d) Data entry and cleaning 
e) Data analysis 
f) Organising and servicing the Data Monitoring and Ethics Committee 
g) Assure data security and quality and observe data protection laws 
h) Ensure trial is conducted in accordance with ICH GCP 
 
Data Co-coordinating Centre responsibilities 
• To ensure that all members of the study team are able by knowledge, training and experience to 
undertake the roles assigned to them and to comply with requirements as specified by the host 
organisation. 
• To provide overall efficient day to day management of the trial ensuring compliance with Good Clinical 
Practice (GCP). 
• To ensure each centre is put on-line with the randomization service after LREC, R&D approval and the 
signed local collaborator agreement have been received from the sponsor. 
• To provide site folders and relevant documentation to each centre  
• To contribute to the development of the protocol, and all study documentation including data sheets 
• To design, produce and regularly update all trial materials and arrange printing and supply of 
documentation. 
• To monitor recruitment and advise on remedial action if targets are not being met. 
• To set up and maintain the website 
• To service the Project management Committee, Steering Committee and any other relevant advisory 
groups. 
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• To use all reasonable efforts to ensure that the data collected and reported are accurate, complete 
and identifiable at source; and that record keeping and data transfer procedures adhere to the Data 
Protection Act 1998 
• To undertake the interim and final analyses and report regularly to the Data Monitoring and Ethics 
Committee in a timely way at their request.  
• To supply documentation and reports as deemed necessary by the sponsors to fulfill their obligations. 
• To co-ordinate the preparation and publication of data, reports and information, ensuring that these 
meet legislative, contractual and ethical requirements.  
• To co-operate with audits or inspections undertaken by the host institution, the sponsors and 
regulatory authorities including the MHRA as required. 
• To assist investigations into any alleged research misconduct undertaken by or on behalf of the co-
sponsors  
• To ensure safe storage of data, including trial site file, data sheets and other records for a period of 15 
years after the conclusion of the trial. 
 
• To inform the Chief Investigator of any changes in the trial protocol that effect the conduct of the Trial.   
 
Trial Steering Committee 
 
The Trial Steering Committee (TSC) responsibilities are to approve the main study protocol and any 
amendments, monitor and supervise the trial towards its interim and overall objectives, review relevant 
information from other sources, consider the recommendations of the DMEC, and resolve problems brought by 
the trial co-coordinating centres.   
 
Face to face meetings will be held at regular intervals determined by need and not less than once a year.  
Routine business is conducted by telephone, email and post.   The TSC will be chaired by Professor Michael 
Preece. The TSC membership is shown  below and its terms of reference shown in Appendix F. 
 
Membership 
Professor Michael Preece (Chair)  Consultant Paediatrician, Great Ormond Street Children’s Hospital 
Mrs. Pamela Barnes    Lay member 
Ms Sian Edwards   Paediatric Pharmacist, Royal Brompton Hospital, 
Professor David Field    Neonatologist, Leicester Royal Infirmary and the University of  
     Leicester 
Dr. James Hooper   Consultant Clinical Biochemist, Royal Brompton Hospital, 
Mrs. Tara Quick    Lay member, Parent 
Dr Claire Snowdon   Centre for Family Research, University of Cambridge. 
 
Ms Lyvonne Tume   Research Nurse, Royal Liverpool Children’s Hospital 
Dr. Dirk Vlasselaers    Consultant Paediatric Intensivist, Leuven, Belgium 
Professor Paula Williamson  Professor of Medical Statistics, University of Liverpool 
 
In attendance 
Mr. Michael Loveridge (till Mar. 2008)  Royal Brompton Hospital (Trial sponsor) 
HTA representative  
Trial Management Group:- (see below) 
Dr. Duncan Macrae (Chief Investigator)  Director of Paediatric Intensive Care, Royal Brompton Hospital 
Dr Elizabeth Allen   Lecturer, Medical Statistics Unit, LSHTM 
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Miss Helen Betts   Lead Study Nurse, Royal Brompton Hospital 
Professor Diana Elbourne  Professor of Healthcare Evaluation, Medical Statistics Unit, London 
     School of Hygiene and Tropical Medicine (LSHTM) 
Dr Richard Grieve  Senior Lecturer in Health Economics, Health Services Research Unit, 
 LSHTM 
Dr. Kevin Morris Consultant in Paediatric Intensive Care, Birmingham Children’s 
Hospital 
Dr.  Roger Parslow   Senior research fellow, University of Leeds 
Dr. Robert Tasker   Clinical Senior Lecturer, Department of Paediatrics, University of  
     Cambridge 
Mrs Ann Truesdale (till 2008)  Trials Advisor, Medical Statistics Unit, LSHTM 
Miss Laura Van Dyck (from Aug. 2009) Study Manager, Medical Statistics Unit, LSHTM 
 
Data Monitoring and Ethics Committee (DMEC) 
A DMEC has been established, chaired by Professor David Dunger (membership listed below).  The terms of 
reference of the DMEC are set out in Appendix G 
 
Membership 
Professor David Dunger (CHAIR) Department of Paediatrics, University of Cambridge 
Dr David Harrison   Statistician, Intensive Care Audit and Research Network (ICNARC), 
Professor David Hatch   Emeritus Professor of Paediatric Anaesthesia and Intensive Care, 
     Great Ormond Street Hospital 
Dr Jon Smith (from Sept. 2009)  Consultant Cardiothoracic Anaethetist, Newcastle General Hospital 
Mr. Giles Peek (till Sept. 2009)  Consultant Cardiac Surgeon, Glenfield Hospital, Leicester  
 
Principal Investigator’s Responsibilities 
Each participating centre will identify a paediatric intensivist as a principal investigator (PI).  Each participating 
centre will be allocated funding for research nursing time and will be expected to employ or second a 
Research Nurse to support all aspects of the trial at the local centre. 
 
The responsibility of the principal investigator will be to: 
a) Ensure local research ethics and R& D approval is obtained 
Discuss the trial with medical, and nursing staff who see eligible patients and ensure that they are updated 
on the current state of knowledge, the trial and its procedures. 
b) Provide clinical support for the trial research nurse ensuring that relevant staff are trained in the trial 
procedures. 
c) Ensure that potentially eligible patients are considered for the trial. 
d) Report promptly to the Clinical Co-coordinating Centre any problems in meeting recruitment targets so that 
support can be provided. 
e) Maintain good contact with the paediatric cardiac unit to ensure that potentially eligible patients are given 
information about the trial.  
f) Ensure that mechanisms for consent and recruitment are in place. 
g) Ensure that data collection forms are completed and returned to the Data Co-coordinating Centre promptly 
and to deal with any queries. 
h) Inform and advise the relevant Co-coordinating Centre promptly. 
i) Facilitate other aspects of co-ordination as relevant. 
j) Make data available for verification, audit and inspection purposes as necessary. 
k) Respond to requests for data from the Economics team.  
l) Ensure that the confidentiality of all information about trial participants is respected by all persons and that 
records are kept in areas to which access is restricted. 
m) Ensure the trial is conducted in accordance with ICH GCP. 
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n) Allow access to source data for audit and verification. 
o) Ensure that adverse events are reported in line with statutory guidelines. 
 
Confidentiality 
 
Patients will be identified by their trial number to ensure confidentiality.  However, as the patients in the trial will 
be contacted about the study results (and patients recruited until September 2010 will be followed up to 12 
months following randomisation), it is essential that the team at the Data Co-coordinating Centre has the 
names and addresses of the trial participants recorded on the data collection forms in addition to the allocated 
trial number.  Stringent precautions will be taken to ensure confidentiality of names and addresses at the Data 
Co-coordinating Centre. 
 
The Chief Investigator and local investigators will ensure conservation of records in areas to which access is 
restricted. 
 
Audit 
 
To ensure that the trial is conducted according to ICH GCP guidelines, site audits will be carried out on a 
random basis.  The local investigator will be required to demonstrate knowledge of the trial protocol and 
procedures and Good Clinical Practice.  The accessibility of the site file to trial staff and its contents will be 
checked to ensure all trial records are being properly maintained.  Adherence to local requirements for consent 
will be examined. 
 
If the site has full compliance the Site Visit Form will be signed by the Trial Manager.  In the event of non-
compliance the Data Coordinating Centre will address the specific issues to ensure that relevant training and 
instruction is given.   
 
Termination of the study 
 
At the termination of planned recruitment the Data Co-coordinating Centre will contact all sites by telephone, 
email or fax in order to terminate all patient recruitment as quickly as possible.   If the study is terminated 
prematurely by the Steering Committee all sites will be informed immediately.  When all recruited patients have 
been followed until 30 days post randomisation (or hospital discharge if stay longer than 30 days) a declaration 
of the end of trial form will be sent to EurdraCT and the MREC.  The following documents: original consent 
forms, data forms, trial related documents and correspondence will be archived in each Site File and kept for 
at least five years.   At the end of the analysis and reporting phase, the Trial Master Files at the Clinical and 
Data Co-coordinating Centres will be archived for 15 years.  
 
Funding 
 
The costs for the study itself are covered by a grant from the Health Technology Assessment Programme 
(HTA).  Clinical costs will be met by the NHS under existing contracts.   
 
Indemnity 
 
If there is negligent harm during the clinical trial when the NHS body owes a duty of care to the person 
harmed, NHS Indemnity covers NHS staff, medical academic staff with honorary contracts, and those 
conducting the trial. NHS Indemnity does not offer no-fault compensation. 
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Appendix A  
Insulin management of control group 
 
Introduction 
 
• The guidelines are only indicative and are to be used with common sense.  
 
 
Preparation of insulin infusion 
 
ACTRAPID:  Actrapid® is a short-acting human insulin solution for injection. 
Actrapid contains: glycerol hydrochloric acid and/or sodium hydroxide if pH adjusted, insulin soluble human, metacresol,  
water for injections, zinc chloride. 
 
Draw up 5 units per Kg of Actrapid and further dilute up to a total volume of 50mls with  
0.9% sodium chloride - (1ml/hr is equal to 0.1Units /kg/ hour) 
 
OR 
 
Make up an infusion of Actrapid diluted in 0.9% sodium chloride according to own local drug policy. 
 
• Insulin sticks to the syringe and tubing, so flush with several times the volume of the tubing before starting the infusion. 
 
• Insulin infusions should be changed every 12 hours or according to local unit policy. 
 
• Make sure the insulin infusion line is connected as close as possible to the patient to avoid flushes and to assure that small 
adjustments of the infusion speed are delivered in time to the patient. 
 
• Glucose and insulin makes potassium go into the cells (hence its value in hyperkalaemia) Monitor the potassium closely. 
 
• Blood glucose levels should be monitored using blood taken from arterial sampling. However if for any reason this is not 
possible the blood glucose level should be monitored for safety reasons according to the usual local practice.  
 
• The frequency of blood glucose measurements should be adapted to the speed and magnitude of changes in glycaemia. It 
is recommended that following any change of the insulin infusion rate the following blood glucose level should be 
monitored within 45 minutes.  
 
• The half life of intravenously injected insulin is short (7-9 minutes) and blood glucose may rise rapidly if the infusion is  
stopped. Similarly If feed or parenteral glucose-containing fluids are restricted or suspended blood glucose levels may fall 
rapidly therefore monitor the blood glucose levels closely and reduce or discontinue insulin in anticipation of a fall in blood 
glucose. 
 
 
 
CONTROL GROUP (permissive) BG management 
 
a. Start up and initial stabilising 
 
Eligible for insulin if BG > 12 mmol/l on 2 BG measurements at least 30 minutes apart 
 
 
• If BG is >12.0 – 15.0 mmols start the insulin infusion at 0.05 Units / Kg / bodyweight / hour. 
Check BG within 30 minutes. 
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• If BG is >15.0 mmols start the insulin infusion at 0.1 Units /Kg / bodyweight / hour 
Check BG within 30 minutes. 
 
• If control BG is 10-12 mmol/l maintain insulin at same dose  (unless BG fall since last reading has been > 50 % in which 
case reduce the infusion by 50%, if fall has been 25-49% reduce infusion by 25%)   
 
• When BG < 10 mmols discontinue insulin 
 
• If BG > 15mmol/l: increase insulin infusion by 0.1 Units/kg/h (unless BG fall since last reading has been > 50 % in which 
case reduce the infusion by 50%, if fall has been 25-49% reduce infusion by 25%) 
 
• If BG is > 12 and ≤ 15 mmol/l mg/dl: increase insulin infusion by 0.05 Units/kg/h (unless BG fall since last reading has 
been > 50 % in which case reduce the infusion by 50%, if fall has been 25-50% reduce infusion by 25%)  
 
• Check BG at least every 45 minutes until BG controlled within required range and stable glucose and insulin infusion rates 
have been achieved.  
 
If the insulin infusion is stopped and restarted at a later time, always go back and use the start up 
and initial stabilising regime. 
 
 
 
b. Adjustments after stabilisation  
 
• Hourly BG checks should be maintained. 
 
• If BG drops  > 50%: decrease insulin infusion rate by 50% and recheck BG within  45 minutes 
 
• If BG < 10 mmol/l: stop insulin infusion and check BG within 1 hour 
 
• If BG < limit for hypoglycaemia: Stop insulin infusion and IV bolus 5mls / kg of 10% glucose.  Alternatively for a 
smaller fluid bolus 2.5mls / kg of 20% glucose can be used. Check BG after 15 minutes and repeat bolus until 
normalisation of BG.  
 
• Restart insulin infusion only if BG > 12 mmol/l 
 
When a child no longer requires an infusion of insulin to maintain their blood glucose within the range 
specified by their study arm, Blood glucose measurements should be recorded 12 hourly until 
discharge from PICU or day 30, whichever is sooner.  
 
 
 
Control group BG ranges  
 
Starting insulin:   
Insulin will be started when BG levels exceed 12mmol/l on two blood samples taken at least 30 minutes apart 
 
Stopping insulin:  
Insulin must be discontinued if BG falls below 10 mmol/l 
Hypoglycaemia BG < 2.5 mmol/l 
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Appendix B 
 
Insulin management of tight glycaemic control 
 
Introduction 
 
• The guidelines are only indicative and are to be used with common sense.  
 
Preparation of insulin infusion 
 
 ACTRAPID:  Actrapid® is a short-acting human insulin solution for injection. 
 
 Actrapid contains: glycerol hydrochloric acid and/or sodium hydroxide if pH adjusted, insulin soluble human, metacresol,  
water for injections, zinc chloride. 
 
Draw up 5 units per Kg of Actrapid and further dilute up to a total volume of 50mls with  
0.9% sodium chloride - (1ml/hr is equal to 0.1Units /kg/ hour)  
  
OR 
 
Make up an infusion of Actrapid diluted in 0.9% sodium chloride according to own local drug policy. 
 
• Insulin sticks to the syringe and tubing, so flush with several times the volume of the tubing before starting the infusion. 
 
• Insulin infusions should be changed every 12 hours or according to local unit policy. 
 
• Make sure the insulin infusion line is connected as close as possible to the patient to avoid flushes and to assure that small 
adjustments of the infusion speed are delivered in time to the patient. 
 
• Glucose and insulin makes potassium go into the cells (hence its value in hyperkalaemia) Monitor the potassium closely. 
 
• Blood glucose levels should be monitored using blood taken from arterial sampling. However if for any reason this is not 
possible the blood glucose level should be monitored for safety reasons according to the usual local practice. 
  
• The frequency of blood glucose measurements should be adapted to the speed and magnitude of changes in glycaemia. It 
is recommended that following any change of the insulin infusion rate the blood glucose level should be monitored within 
45 minutes. 
 
• The half life of intravenously injected insulin is short (7-9 minutes) and blood glucose may rise rapidly if the infusion is 
stopped. Similarly If feed or parenteral glucose-containing fluids are restricted or suspended blood glucose levels may fall   
rapidly therefore monitor the blood glucose levels closely and reduce or discontinue insulin in anticipation of a fall in blood 
glucose. 
 
TIGHT GLYCAEMIC CONTROL (TGC) management 
 
a. Start up and initial stabilising 
 
If BG is > than the upper limit (> 7.0 mmols) start the insulin infusion at 0.05 Units/ Kg/ bodyweight /hour.  
Check BG within 30 minutes.  
 
If BG is > twice upper limit (>14.0 mmols) start the insulin infusion at 0.1 Units/Kg/ bodyweight /hour. 
Check BG within 30 minutes. 
 
If BG > 2mmol/l above upper limit: increase insulin infusion by 0.1 IU/kg/h (unless BG fall since last reading has been > 50 % in 
which case stop the infusion. if fall has been 25-49% reduce infusion by 50%) 
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If BG ≤ 2 mmol/l mg/dl above upper limit: increase insulin infusion by 0.05 IU/kg/h (unless BG fall since last reading has been > 50 % 
in which case stop the insulin infusion. if fall has been 25-50% reduce infusion by 50%. if fall has been <25% continue checking at 30 
min intervals and if after 2 hours still in this range only then increase insulin infusion by 0.05 IU/kg/h) 
 
If the blood glucose level has dropped by <25% but is within the tight glycaemic range we recommend reducing the infusion by 25%.  
 
If there has been no drop in blood glucose level and the blood glucose is within the tight glycaemic range we recommend continuing 
the infusion at the same infusion rate. 
 
Check BG every 45 minutes until BG controlled within required range and stable glucose and insulin infusion rates have been 
achieved.  
 
If the insulin infusion is stopped and restarted at a later time, always go back and use the start up and 
initial stabilising regime. 
 
b. Adjustments after stabilisation  
 
• Hourly BG checks should be maintained. 
 
• If BG < lower TGC limit: stop insulin infusion and check BG within 1 hour 
 
• If BG < limit for hypoglycaemia: Stop insulin infusion and IV bolus 5mls / kg of 10% glucose. Alternatively for a 
smaller fluid bolus, 2.5mls / kg of 20% glucose can be used. Check BG after 15 minutes and repeat bolus until 
normalisation of BG. 
 
• Restart insulin infusion only if BG > upper TGC limit (>7mmols) 
 
When a child no longer requires an infusion of insulin to maintain their blood glucose within the range 
specified by their study arm, Blood glucose measurements should be recorded 12 hourly until 
discharge from PICU or day 30, whichever is sooner.  
 
TGC ranges and target BG 
 
Target range for TGC   4-7 mmol/l 
 
Target range A  5-7 mmol/l 
   Used by all centres when randomising first cohort of children 
 
Target range B  4-6 mmol/l 
   Used by centres comfortable with experience of 5-7 mmol/l 
 
Hypoglycaemia Treatment required if BG < 2.5 mmol/l 
 
All trial centres will initially use Target range A. Subsequently, when centres are fully conversant with achieving 
TGC to Target A, they may with the agreement of the Clinical Coordinating centre move to Target range B. 
Both ranges are consistent with the treatment aims of the TGC arm of the protocol. Range B will however 
ensure a greater difference in effect compared to the control group but will not be imposed on investigators to 
ensure that the risk of hypoglycaemia is minimised, ensuring that centres are safely applying the higher Target 
A before moving to Target B. 
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Appendix C 
 
Adverse Events and Safety Reporting 
 
This document must remain in the Trial Master File at all times 
 
Royal Brompton & Harefield NHS Trust, as sponsor of this study, has responsibility to ensure arrangements are in place 
to record, notify, assess, report, analyse and manage adverse events in this study in order to comply with the UK 
regulations of Medicines for Human Use (Clinical Trials) Regulations 2004. 
 
It is therefore important that all site investigators involved in the study are aware of the regulatory reporting 
process and timelines.   In addition, the following people at the Royal Brompton & Harefield NHS Trust should be 
notified immediately or within 24 hours of being made aware of a serious adverse event.  
 
Helen Betts (Lead Study Nurse)  
Royal Brompton Hospital 
020 7351 8546 
h.betts@rbht.nhs.uk 
 
Dr Duncan Macrae 
Chief Investigator CHIP Trial 
Royal Brompton Hospital 
020 7351 8546 
d.macrae@rbht.nhs.uk  
 
Definitions 
 
Adverse Event (AE) 
 
Any untoward medical occurrence in a subject to whom insulin has been administered. This includes occurrences which 
are not necessarily caused by or related to insulin 
 
Adverse Reaction (AR) 
 
Any untoward and unintended response in a subject to insulin which is related to any dose administered to that subject. 
 
Unexpected Adverse Reaction 
 
An adverse reaction is ‘unexpected’ if its nature and severity are not consistent with the information about insulin in the 
summary of product characteristics. 
 
Serious Adverse Reaction/Event  
 
An adverse reaction is ‘serious’ if it: 
• results in death; 
• is life-threatening; 
• requires hospitalization or prolongation of existing hospitalization; 
• results in persistent or significant disability or incapacity; 
• consists of a congenital anomaly or birth defect. 
 
 
Suspected Serious Adverse Reaction (SSAR)  
 
Any adverse reaction that is classed as serious and which is consistent with the information about insulin listed in the 
Summary of Product Characteristics (SPC) Information on known adverse reactions can be found at 
http://emc.medicines.org.uk  
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Any adverse reaction that is classed as serious and is suspected to be caused by insulin that is not consistent with the 
information about the product in the Summary of Product Characteristics, i.e. it is suspected and unexpected.  
 
The trial protocol includes a list of known side effects for insulin. This should be checked with each serious adverse 
event that occurs in terms of expectedness. If the event is not listed as expected, or has occurred in a more serious form 
than anticipated, this should be considered a SUSAR.  
 
Causality 
 Adverse reactions should be assessed for causality using the definitions below.  
 
Not Related - There is no evidence of any causal relationship  
Unlikely - There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a 
reasonable time after administration of insulin). There is another reasonable explanation for the event (e.g. the patient’s 
clinical condition, other concomitant treatment).  
Possibly Related* - There is some evidence to suggest a causal relationship (e.g. because the event occurs within a 
reasonable time after administration of insulin). However, the influence of other factors may have contributed to the 
event (e.g. the patient’s clinical condition, other concomitant treatments).  
Probably Related* - There is evidence to suggest a causal relationship and the influence of other factors is unlikely.  
Definitely Related* - There is clear evidence to suggest a causal relationship and other possible contributing factors can 
be ruled out.  
Not Assessable - There is insufficient or incomplete evidence to make a clinical judgement of the causal relationship.  
 
* If the AE is serious and unexpected, the possible, probable and definitely related should be notified to the 
MHRA, the relevant REC and the Sponsor as SUSAR 
 
Reporting Timeline 
 
Adverse Events that are not considered serious should be reported in accordance with each Trust’s policy for such 
events.  
 
A SUSAR which is fatal or life-threatening must be reported to the Pharmacovigilance Unit at the MHRA and the main 
REC as soon as possible and in any event within 7 days after the sponsor became aware of the event.  Any additional 
relevant information must be reported within 8 days of sending the first report. 
 
A SUSAR which is not fatal or life-threatening must be reported to the MHRA and the MREC as soon as possible and in 
any event within 15 days after the sponsor first became aware of the event. 
 
In the case of double-blinded trials, the European Commission guidance recommends that reports of SUSARs should 
normally be unblinded.  So far as the UK is concerned, both the MHRA and the main REC will expect all such reports to 
be unblinded. 
 
Other expedited safety reports 
 
The European Commission guidance recommends that expedited reports on the following occurrences should also be 
sent to the MHRA and the MREC according to the same timelines as SUSARs: 
 
• single case reports of an expected serious adverse reaction with an unexpected outcome (e.g. death) 
• an increase in the rate of occurrence of an expected serious adverse reaction, which is judged to be clinically 
important 
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• post-study SUSARs that occur after the patient has completed a trial 
 
• a new event, related to the conduct of the trial or the development of insulin that is likely to affect the safety of 
subjects, such as: 
 
• a serious adverse event which could be associated with the trial procedures and which could 
modify the conduct of the trial 
• a significant hazard to the subject population such as lack of efficacy of the insulin used for the 
treatment of a life threatening disease 
Contacts 
 
Following a serious adverse event, site investigators must inform the Study Nurse and Chief Investigator at the Royal 
Brompton Hospital immediately or within 24 hours of being made aware of the event.  
 
Helen Betts (Lead Study Nurse)  
Royal Brompton Hospital 
020 7351 8546 
h.betts@rbht.nhs.uk 
 
Dr Duncan Macrae 
Chief Investigator CHIP Trial 
Royal Brompton Hospital 
020 7351 8546 
d.macrae@rbht.nhs.uk  
 
It will then be the responsibility of the Chief Investigator to inform the Research and Development Department at the 
Royal Brompton & Harefield NHS Trust Hospital.  
 
 
MHRA, Pharmacovigilance Unit:   0207 084 2000  Weekdays (9am-5pm) 
     0207 210 3000 all other times 
 
MREC     Brighton East Research Ethics 
Brighton & Hove City Teaching PCT 
1st Floor, Prestamex House 
171-173 Preston Road 
Brighton 
BN1 6AG 
Forms 
 
SUSAR should be reported on the following standard forms and sent to the appropriate address. 
 
MHRA – CIOMS 1 form (available at http://www.cioms.ch/cioms.pdf) 
MHRA 
P.O Box 20, Mitcheldean, GL17 0WQ 
Ethics Committee – CTIMP Safety Report to main ethics committee (available at  
http://www.corec.org.uk/applicants/apply/docs/Safety_Report_Form_(CTIMPs)v2.0.doc )  
 
Brighton East Research Ethics 
Brighton & Hove City Teaching PCT 
1st Floor, Prestamex House 
171-173 Preston Road 
Brighton 
BN1 6AG 
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Other Reports 
 
Annual Progress Reports and End of Study Reports 
 
Ethics Committee 
 
NHS Research Ethics Committees are required to monitor research with a favourable opinion. A progress report should 
be submitted to the MREC 12 months after the date on which the favourable opinion was given using the form available 
at.  
http://www.corec.org.uk/applicants/apply/docs/Progress_Report_Form_(CTIMPs)v3.1.doc  
 
All SAEs should also be reported. 
 
Annual progress reports should be submitted thereafter until the end of the study, when the following form should be 
used.  
 
http://eudract.emea.eu.int/docs/Declarationoftheendoftrialform170805withfields.doc  
This form should be sent to the MREC no later than 12 months after the end of the study. 
 
MHRA 
 
An Annual report is required to be sent to the MHRA 12 months after the CTA is granted and then annually until the end 
of the study. All SAE s should also be reported 
 
At the end of the study the sponsor is responsible for notifying the MHRA that the trial has ended. This notification should 
be sent by the sponsor within 90 days of its conclusion. An end of trial notification form is available from the EudraCT 
website. Reports should be sent to 
 
Clinical Trials Unit, MHRA, Market Towers, 1 Nine Elms Lane, London SW8 5NQ 
 
The end of the trial is defined as when the last patient recruited has completed their scheduled involvement in the trial  
e.g. last follow-up visit. 
 
Early Termination 
 
If a trial is terminated before the specified date for its conclusion then the investigators should notify the R&D Office 
immediately so that the Royal Brompton & Harefield NHS Trust, as sponsor, can notify the MHRA and the MREC within 
15 days of the date of termination. 
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Adverse Events 
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Appendix D 
Follow-up – Traumatic brain Injury sub-group 
The sub group of children with traumatic brain injury (TBI) is more likely to have longer-term morbidity and parents of 
children in this sub-group will be asked to provide additional information at 12 months†.  We will specifically include 
assessments of attention and behaviour as patients with TBI are commonly left with deficits in these areas.  
 
Definition of TBI 
Accidental trauma to the head resulting in need for intubation and mechanical ventilation  
 
Population 
750 ICU admissions per year in UK.  Estimate of 150 recruited to the trial 
 
Outcomes assessment 
This will comprise four components: 
Overall health status: measured by the Health Utilities Index (HUI) 
Global neurological outcome: measured by the Kings Outcome Scale for Childhood Head Injury (KOSCHI) 
Attention and behavioural assessment: measured by the Child Behavioural Check List (CBCL) and the Conner’s Rating 
Scales revised – short version (CRS-R:S) 
 
The HUI, CBCL and CRS are written questionnaires that will be posted out to the families. They take approximately 30 
minutes to complete. 
 
 
Health Utilities Index is a multi-attribute health status classification system.  Seven attributes (sensation, mobility, 
emotion, cognition, self-care, pain, fertility) are categorised according to one of 4 or 5 levels.  In this population fertility 
will be excluded.  The algorithm (from death to perfect health scale) provides a single numerical value. 
 
KOSCHI is a 5 point categorical scale, ranging from death to normal neurological function, and is similar in structure to 
the Glasgow Outcome Scale, which is widely used in adult studies. In addition the KOSCHI is further subdivided into two 
subcategories at points 4 and 5 on the scale (moderate outcome and good outcome). Patient outcomes will be 
dichotomized between patients in categories 1, 2, 3, 4A and those in 4B, 5A, 5B. 
 
Child behaviour checklist (CBCL/4-18), problem scales 
The CBCL is based on parent’s report and assesses problematic child behaviour that is summarised in internalising 
behaviour (anxious/depressed, withdrawn/depressed, somatic complaints), externalising behaviour (rule-braking, 
aggressive) and other (social problems, thought problems, attention problems). 
 
In reference to 1991 normative data: 
 
T-score 
(whole) 
Guideline T-score 
(individual scale) 
Guideline 
<60 Normal <65 Normal 
60-63 Borderline 65-69 Borderline 
>63 Clinical >69 Clinical 
 
Patient outcome can be summarised according to placement within one of the three groups, or according to the T-score. 
 
                                                            
† For patients recruited until September 2010 
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Appendix D 
Conners’ rating scales revised – short version (CRS-R:S) 
 
 
The CRS assesses symptoms of attention-deficit/hyperactivity disorder and related problem behaviour in children and 
adolescents based on parent’s report [67]. 
 
In reference to 1993 normative data: 
 
T-score Guideline 
≥70 Markedly atypical (significant problem) 
66-69 Moderately atypical (significant problem) 
61-65 Mildly atypical (possible significant problem) 
56-60 Slightly atypical (borderline) 
45-55 Average (no concern) 
≤44 Good 
 
Patient outcome can be summarised according to placement within one of the three groups (marked + moderate, mild + 
slight, average + good), or according to the T-score. 
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Trial Steering Committee (TSC): Terms of reference.              Appendix F 
 
The role of the TSC is to provide overall supervision for CHIP on behalf of the HTA and the Royal Brompton and 
Harefield NHS Trust (sponsor) and to ensure that the trial is conducted to the rigorous standards set out in the MRC 
Guidelines for Good Clinical Practice.  It should be noted that the day-to-day management of the trial is the responsibility 
of the Investigators and the Chief Investigator will set up a separate Trial Management Group (TMG) to assist with this 
function.  
 
• The TSC should approve the protocol and trial documentation in a timely manner.  
• In particular the TSC should concentrate on progress of the trial, adherence to the protocol, patient safety and 
consideration of new information of relevance to the research question. 
• The safety and well being of the trial participants are the most important consideration and should prevail over the 
interests of science and society. 
• The TSC should provide advice, through its chair, to the Chief Investigator, the Trial Sponsor, the Trial Funder, on 
all appropriate aspects of the trial.  Specifically the TSC will:- 
• Monitor recruitment rates and encourage the TMG to develop strategies to deal with any recruitment problems.  
• Monitor completion of data sheets and comment on strategies from TMG to encourage satisfactory completion 
in the future.   
• Monitor follow-up rates and review strategies from TMG to deal with problems including sites that deviate from 
the protocol. 
• Approve any amendments to the protocol, where appropriate  
• Approve any proposals by the TMG concerning any change to the design of the trial, including additional sub-
studies 
• Oversee the timely reporting of trial results 
• Approve and comment on the statistical analysis plan 
• Approve and comment on the publication policy 
• Approve and comment on the main trial manuscript 
• Approve  and comment on any abstracts and presentations of any results during the running of the trial  
• Approve external or early internal requests for release of data or subsets of data or samples including clinical 
data and stored biological samples.  
• Receive reports from the Data Monitoring and Ethics Committee. 
• The TSC will make decisions as to the future continuation (or otherwise) of the trial. 
• Membership of the TSC should be limited and include an independent Chair, at least two other independent 
members, two collaborators and two members of the public.  The Investigators and the trial project staff are ex– 
officio. 
• Representatives of the trial sponsor and the HTA should be invited to all TSC meetings. 
• Responsibility for calling and organising the TSC meetings lies with the Chief Investigator.  The TSC should meet at 
least annually, although there may be periods when more frequent meetings are necessary.  
• There may be occasions when the Trial sponsor or the HTA will wish to organise and administer these meetings in 
exceptional circumstances. 
• The TSC will provide evidence to support any requests for extensions, including that all practicable steps have been 
taken to achieve targets. 
• The TSC will maintain confidentiality of all trial information that is not already in the public domain. 
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Appendix G 
Data Monitoring and Ethics Committee (DMEC): Terms of reference 
 
To safeguard the interests of trial participants, monitor the main outcome measures including safety and efficacy, and 
monitor the overall conduct of the CHIP study. 
 
The DMEC should receive and review information on the progress and accruing data of CHIP and provide advice on the 
conduct of the trial to the Trial Steering Committee (TSC). 
 
The DMEC should inform the Chair of the TSC if, in their view the results are likely to convince a broad range of 
clinicians, including those supporting the trial and the general clinical community, that, on balance, one trial arm is clearly 
indicated or contraindicated for all participants or a particular category of participants, and there was a reasonable 
expectation that this new evidence would materially influence patient management. 
 
Interim review of the trial’s progress including updated figures on recruitment, data quality, adherence to protocol, follow-
up, and main outcomes and safety data.  Specifically, these roles include to: 
• monitor evidence for treatment differences in the main efficacy outcome measures 
• monitor evidence for treatment harm (e.g. toxicity, SAEs and SARs, treatment related deaths) 
• assess the impact and relevance of external evidence 
• decide whether to recommend that the trial continues to recruit participants or whether recruitment should be 
terminated either for everyone or for some treatment groups and/or some participant subgroups 
• decide whether trial follow-up should be stopped earlier 
• assess data quality, including completeness (and by so doing encourage collection of high quality data) 
• maintain confidentiality of all trial information that is not in the public domain 
• monitor recruitment figures and losses to follow-up 
• monitor compliance with the protocol by participants and investigators 
• consider the ethical implications of any recommendations made by the DMEC 
• monitor planned sample size assumptions, preferably with regards to  
(i) a priori assumptions about the control arm outcome and/or  
(ii) emerging differences in clinically relevant subgroups, rather than on emerging, unblinded differences between 
treatment groups, overall 
• suggest additional data analyses if necessary 
• advise on protocol modifications proposed by investigators or HTA (e.g. to inclusion criteria, trial endpoints, or 
sample size) 
• monitor continuing appropriateness of patient information 
• monitor compliance with previous DMEC recommendations 
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Appendix H 
Publication Policy 
 
To safeguard the integrity of the trial, data from this study will not be presented in public or submitted for publication 
without requesting comments and receiving agreement from the Trial Steering Committee.  The primary results of the 
trial will be published by the group as a whole with local investigators acknowledged.  The success of the trial depends 
on the collaboration of many people.  The results will be presented first to the trial local investigators.  A summary of the 
results of the trial will be sent to parents of participating children on request and also made available on the trial website. 
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Appendix 4 Published protocol
STUDY PROTOCOL Open Access
Control of hyperglycaemia in paediatric intensive
care (CHiP): study protocol
Duncan Macrae1*, John Pappachan2, Richard Grieve3, Roger Parslow4, Simon Nadel5, Margrid Schindler6,
Paul Baines7, Peter-Marc Fortune8, Zdenek Slavik9, Allan Goldman10, Ann Truesdale11, Helen Betts12,
Elizabeth Allen13, Claire Snowdon14, Deborah Percy15, Michael Broadhead16, Tara Quick17, Mark Peters18,
Kevin Morris19, Robert Tasker20, Diana Elbourne21
Abstract
Background: There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill
adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known
whether tight control will benefit children given maturational differences and different disease spectrum.
Methods/Design: The study is an randomised open trial with two parallel groups to assess whether, for children
undergoing intensive care in the UK aged ≤ 16 years who are ventilated, have an arterial line in-situ and are receiving
vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such
treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and
free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with
intensive care treatment and be cost effective.
Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and
7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management.
Children will be followed up to determine vital status and healthcare resources usage between discharge and 12
months post-randomisation. Information regarding overall health status, global neurological outcome, attention
and behavioural status will be sought from a subgroup with traumatic brain injury (TBI).
A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is consid-
ered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I
error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90%
power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target
sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control
are justified by subsequent reductions in hospitalisation costs.
Discussion: The relevance of tight glycaemic control in this population needs to be assessed formally before
being accepted into standard practice.
Trial Registration: Current Controlled Trials ISRCTN61735247
Background
The ability to control blood sugar is known to be
impaired in patients subjected to the stress of major sur-
gery or critical illness resulting in high blood sugar
levels (hyperglycaemia)[1]. This may in part result from
insulin resistance, as insulin-dependent glucose uptake
has been shown to be reduced in various organs and tis-
sues during critical illness. Glucose uptake is however
increased in non-insulin dependent tissues such as
brain, red blood cells and wounds. This imbalance of
glucose metabolism has previously been interpreted as
the body’s plea for tolerating moderately high levels of
glucose during critical illness and injury and treatment
of ‘stress-induced’ hyperglycaemia has typically only* Correspondence: D.macrae@rbht.nhs.uk
1Paediatric Intensive Care Unit, Royal Brompton Hospital, Sydney Street,
London SW3 6NP, UK
Macrae et al. BMC Pediatrics 2010, 10:5
http://www.biomedcentral.com/1471-2431/10/5
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been initiated if BG levels are persistently and substan-
tially elevated.
Hyperglycaemia in Critically Ill Adults
Over recent years several studies have associated hyper-
glycaemia with adverse outcomes during acute illness in
adults:
Myocardial infarction
In a meta-analysis [2], patients with acute myocardial
infarction without diabetes who had glucose concentra-
tions more than or equal to range 6.1-8.0 mmol/L had a
3.9-fold (95% CI 2.9-5.4) higher risk of death than
patients without diabetes who had lower glucose con-
centrations. Glucose concentrations higher than values
in the range of 8.0-10.0 mmol/L on admission were
associated with increased risk of congestive heart failure
or cardiogenic shock in patients without diabetes. Stress
hyperglycaemia with myocardial infarction is associated
with an increased risk of in-hospital mortality and
increased risk of congestive heart failure or cardiogenic
shock in patients without diabetes.
Stroke
Capes et al. conducted a systematic review and meta-
analysis of the literature relating acute post stroke glu-
cose levels to the subsequent course [3]. A comprehen-
sive literature search was done for cohort studies
reporting mortality and/or functional recovery after
stroke in relation to admission glucose level. Thirty-
two studies were identified for which pre-defined out-
comes could be analysed in 26. After stroke, the unad-
justed relative risk of in-hospital or 30-day mortality
associated with admission glucose level >6 to 8 mmol/
L was 3.07 (95% CI, 2.50 to 3.79) in non-diabetic
patients and 1.30 (95% CI, 0.49 to 3.43) in diabetic
patients. Non-diabetic stroke survivors whose admis-
sion glucose level was >6.7 to 8 mmol/L also had a
greater risk of poor functional recovery (relative risk =
1.41; 95% CI, 1.16 to 1.73).
Head injury and multi-system trauma
Hyperglycaemia has been shown to be an independent
predictor of poor outcome in adult patients[4] and chil-
dren with head injury[5,6] and multiple trauma[7].
Pulmonary function
Hyperglycaemia has been shown to be associated with
diminished pulmonary function in adults even in the
absence of diabetes mellitus[8] and a range of other
effects with potential to injure the lung[9].
Gastrointestinal effects
Hyperglycaemia has been shown to be associated with
delayed gastric emptying[10], decreased small bowel
motility and to increase sensation and cerebral evoked
potentials to a range of gastrointestinal stimuli in adult
volunteers [11-14].
Infections
In vitro responsiveness of leukocytes stimulated by
inflammatory mediators is inversely correlated with gly-
caemic control[15]. This reduction in polymorphonuc-
lear leucocyte responsiveness may contribute to the
compromised host defence associated with sustained
hyperglycaemia[15], and indeed, hyperglycaemia has
been shown to be associated with an increased rate of
serious infections after adult cardiac[16] and vascular
[17] surgery.
Studies of Control of Glycaemia in Adults
Recent reports from adult populations suggest that con-
trol of glycaemia during acute illness can be associated
with improved outcomes[18-22].
Furnary[21] studied the hypothesis that since hyper-
glycaemia was associated with higher sternal wound
infection rates following adult cardiac surgery, aggressive
control of glycaemia might lead to lower infection rates.
In a prospective study of 2,467 consecutive diabetic
patients who underwent open heart surgical procedures,
patients were classified into two sequential groups. A
control group included 968 patients treated with sliding-
scale-guided intermittent subcutaneous insulin injec-
tions. A study group included 1,499 patients treated
with a continuous intravenous insulin infusion in an
attempt to maintain a BG level of less than 11.1 mmol/l.
Compared with subcutaneous insulin injections, contin-
uous intravenous insulin infusion induced a significant
reduction in perioperative BG levels, which led to a sig-
nificant reduction in the incidence of deep sternal
wound infection in the continuous intravenous insulin
infusion group (0.8% [12 of 1,499]) versus the intermit-
tent subcutaneous insulin injection group (2.0% [19 of
968], p = 0.01). The use of perioperative continuous
intravenous insulin infusion in diabetic patients under-
going open heart surgical procedures appears to signifi-
cantly reduce the incidence of major infections.
Malmberg[19] randomly allocated patients with dia-
betes mellitus and acute myocardial infarction to inten-
sive insulin therapy (n = 306) or standard treatment
(controls, n = 314). The mean (range) follow up was 3.4
(1.6-5.6) years. There were 102 (33%) deaths in the
treatment group compared with 138 (44%) deaths in the
control group (relative risk (95% confidence interval)
0.72 (0.55 to 0.92); p = 0.011). The effect was most pro-
nounced among the predefined group that included 272
patients without previous insulin treatment and at a low
cardiovascular risk (0.49 (0.30 to 0.80); p = 0.004).
Intensive insulin therapy improved survival in diabetic
patients with acute myocardial infarction. The effect
seen at one year continued for at least 3.5 years, with an
absolute reduction in mortality of 11%.
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In 2001 Van den Berghe and colleagues from Leuven,
Belgium[18] reported the results of a randomised trial in
adults undergoing intensive care following surgical pro-
cedures. This trial showed that the use of insulin to
tightly control BG led to a reduction in mortality (32%),
mean length of intensive care stay (22%), and signifi-
cantly lower occurrence of a range of complications of
critical illness such as renal failure, infection, inflamma-
tion, anaemia and polyneuropathy. Duration of intensive
care stay was 3.4 days shorter in the insulin group.
Recently the Leuven group[22] have reported that, in
addition to adult surgical intensive care patients, inten-
sive insulin therapy reduces morbidity in adults who
require intensive care for treatment of medical condi-
tions. In this prospective randomised controlled trial,
patients were randomly assigned to a regime of strict
normalisation of BG (4.4-6.1 mmol/l) with use of insu-
lin, or conventional therapy where insulin is adminis-
tered only when BG levels exceeded 12 mmol/l, with
the infusion tapered when the level fell below 10 mmol/
l. In the intention to treat analysis of the 1200 patients
included, ICU and in-hospital mortality were not signifi-
cantly altered by intensive insulin therapy, however for
those patients requiring more than 3 days intensive
care, mortality was significantly reduced from 52.5 to
43% (p = 0.009). Morbidity was significantly reduced by
intensive insulin therapy with a lower incidence of renal
injury and shorter length of mechanical ventilation and
duration of hospital stay noted. Beyond the fifth day of
intensive insulin therapy, all morbidity endpoints were
beneficially affected, whereas for those patients staying
less than 3 days, none of the morbidity end-points were
significantly different between the two treatment groups.
On the basis of these studies, several groups have
recommended that tight glycaemic control with inten-
sive insulin therapy become a standard of care for the
critically ill adult patients. The Joint Commission on
Accreditation of Healthcare Organization (JACHO)
recently proposed tight glucose control for the critically
ill as a core quality of care measure for all U.S. hospitals
that participate in the Medicare program[23]. The Insti-
tute for Healthcare Improvement, together with an
international initiative by several professional societies
including the American Thoracic Society, is promoting
a care “bundle” for severe sepsis that also includes
intensive glycaemic control for critically ill adults[24].
Both the Society of Critical Care Medicine and Eur-
opean Society of Intensive Care Medicine have incorpo-
rated TGC into their recently publicised ‘Surviving
Sepsis’ guidelines. These initiatives represent important
attempts to translate research findings into improved
care at the bedside[25].
The possible mechanisms by which different glucose
control strategies might influence clinical outcomes are
yet to be fully elucidated. There is a substantial body of
published research which points to an association
between hyperglycaemia and organ/tissue dysfunction.
In models of both focal and global cerebral ischaemia,
hyperglycaemia has been shown to be associated with
exacerbation of intracellular acidosis[26-28], accumula-
tion of extracellular glutamate[29], cerebral oedema for-
mation and disruption[30]of the blood-brain barrier[31].
In ischaemic brain injury, hyperglycaemia may worsen
injury by promoting anaerobic metabolism and conse-
quent intracellular acidosis. In the rat myocardium,
hyperglycaemia leads to up-regulation of inducible nitric
oxide synthase, resulting ultimately in an increase in
production of superoxide, a condition favouring the pro-
duction of the powerful pro-oxidant peroxynitrite. This
highly reactive free radical has the power to cause direct
oxidant damage to myocardial cells or to induce myo-
cardial cell apoptosis[32,33]. Similar adverse mechan-
isms have been shown to exist in hyperglycaemic
patients [34,35]. Improved clinical outcomes may arise
not necessarily solely as a result of control of BG. Insu-
lin lowers free fatty acids and normalises endothelial
function[36], is associated with anabolic effects[37,38],
has been shown to have anti-inflammatory effects[39,40]
and to have cardio-protective effects[41], all of which
may contribute independently to better outcomes in cri-
tical illness.
Hyperglycaemia in Critically Ill Children
Over 10,000 children are admitted to intensive care
units in England and Wales each year[42]. Hyperglycae-
mia, defined as BG > 7 mmol/l, occurs frequently during
critical illness or after major surgery in children, with a
reported incidence of up to 86%[43]. As in adults, the
occurrence of hyperglycaemia has been shown to be
associated with poorer outcomes including death, sepsis,
and longer length of intensive care stay in critically ill
children[43-46]. Non-randomised research in children
includes a number of reports from general[43-45,47]
and cardiac PICUs[46] showing that high BG levels
occur frequently in critically ill children and that BG
levels are significantly higher in children who die than
in children who survive.
Srinivasan[43] studied the association of timing, dura-
tion, and intensity of hyperglycaemia with PICU mortal-
ity in critically ill children. The study was a
retrospective, cohort design and included 152 critically
ill children receiving vasoactive infusions or mechanical
ventilation. Peak BG of > 7 mmol/L occurred in 86% of
patients. Compared with survivors, non-survivors had
higher peak BG (17.3 mmol/L +/- 6.4 vs. 11.4 +/- 4.4
mmol/L, p <.001). Non-survivors had more intense
hyperglycaemia during the first 48 hrs in the PICU (7
+/-2.1 mmol/L) vs. survivors (6.4 +/- 1.9 mmol/L, p
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<.05). Univariate logistic regression analysis showed that
peak BG and the duration and intensity of hyperglycae-
mia were each associated with PICU mortality (p <.05).
Multivariate modelling controlling for age and Paediatric
Risk of Mortality scores showed independent association
of peak BG and duration of hyperglycaemia with PICU
mortality (p <.05). This study demonstrated that hyper-
glycaemia is common among critically ill children. Peak
BG and duration of hyperglycaemia appear to be inde-
pendently associated with mortality. The study was lim-
ited by its retrospective design, its single-centre location
and the absence of cardiac surgical cases, a group which
make up approximately 40% of paediatric intensive care
(PICU) admissions in the UK.
Halverson-Steele[46] has recently shown in a retro-
spective study, that hyperglycaemia was associated with
poor outcomes in 526 children following cardiac sur-
gery. Nineteen patients (3.6%) died postoperatively
(median 11 days, range 1-17 days). Peak plasma glucose
concentrations in survivors (mean 10.7 mmol/l, SD 3.7)
was significantly lower than the peak value recorded in
non-survivors (mean 14.3 mmol/l, SD 4.2; p = 0.0017).
The 147 patients who were discharged from ICU within
24 hours had lower plasma glucose concentrations on
admission (mean 7.5 mmol/l, SD 2.3) and peak plasma
glucose concentrations (mean 9.2 mmol/l, SD 2.3) than
the remaining patients staying longer than 24 hours
(mean 8.1 mmol/l, SD 4.0; p = 003 and mean 11.3
mmol/l, SD 3.9; p < 0.0001, respectively). Peak plasma
glucose concentrations were also lower in 387 patients
admitted for up to 5 days (mean 10.1 mmol/l, SD 2.9)
when compared with those patients with ICU stays of >
5 days (mean 12.7 mmol/l/, SD 4.6; p < 0.0001).
Hall[45] investigated the incidence of hyperglycaemia
in infants with necrotizing enterocolitis (NEC) and the
relationship between glucose levels and outcome in
these infants. Glucose measurements (n = 6508) in 95
neonates with confirmed NEC admitted to the surgical
intensive care unit were reviewed. Glucose levels ranged
from 0.5 to 35.0 mmol/L. 69% of infants became hyper-
glycaemic (>8 mmol/L) during their admission. Thirty-
two infants died. Mortality rate tended to be higher in
infants when maximal glucose concentration exceeded
11.9 mmol/L compared with those with maximum glu-
cose concentrations of less than 11.9 mmol/L, and late
(>10 days admission) mortality rate was significantly
higher in these infants (29% v, 2%; p = .0009). Linear
regression analysis indicated that maximum glucose
concentration was significantly related to length of stay
(p <.0001).
Branco[44] showed that there is an association
between hyperglycaemia and increased mortality in chil-
dren with septic shock. They prospectively studied all
children admitted to a regional PICU with septic shock
refractory to fluid therapy over a period of 32 months.
The peak glucose level in those with septic shock was
11.9 +/- 5.4 mmol/L (mean +/- SD), and the mortality
rate was 49.1% (28/57). In non-survivors, the peak glu-
cose level was 14.5 +/- 6.1 mmol/L, which was higher (p
<.01) than that found in survivors (9.3 +/- 3.0 mmol/L).
The relative risk of death in patients with peak glucose
levels of ≥ 9.9 mmol/L was 2.59 (range, 1.37-4.88).
Faustino[47] demonstrated that hyperglycaemia occurs
frequently among critically ill non-diabetic children and
is associated with higher mortality and longer lengths of
stay. They performed a retrospective cohort study of
942 non-diabetic patients admitted to a PICU over a 3
year period. The prevalence of hyperglycaemia was
based on initial PICU glucose measurement, highest
value within 24 hours, and highest value measured dur-
ing PICU stay up to 10 days after the first measurement.
Through the use of three cut-off values (6.7 mmol/L, 8.3
mmol/L, and 11.1 mmol/L), the prevalence of hypergly-
caemia was 16.7% to 75.0%. The relative risk (RR) for
dying increased for maximum glucose within 24 hours
>8.3 mmol/L (RR, 2.50; 95% confidence interval (CI),
1.26 to 4.93) and highest glucose within 10 days >6.7
mmol/L (RR, 5.68; 95% CI, 1.38 to 23.47).
Pham[48] have recently reported their experience of
adopting a policy of ‘intensive’ insulin therapy to achieve
BG levels 5 mmol/L to 6.7 mmol/L. They reviewed the
records of children with ≥ 30% total body surface area
burn injury admitted over a 3 year period. The first
cohort of 31 children received ‘conventional insulin
therapy’, whilst the subsequent cohort of 33 children
received ‘intensive insulin therapy’. The demographic
characteristics and injury severity were similar between
the groups. Intensive insulin therapy was positively asso-
ciated with survival and a reduced incidence of infec-
tions. The authors therefore concluded that intensive
insulin therapy to maintain normoglycaemia in severely
burned children could be safely and effectively imple-
mented in a paediatric burns unit and that this therapy
seemed to lower infection rates and improve survival.
There is therefore mounting evidence to suggest that a
policy of TGC may be beneficial to neonates and chil-
dren undergoing neonatal and paediatric intensive care,
but none of this evidence is from large rigorous rando-
mized controlled trials. The aim of the present study is
to determine whether a policy of strictly controlling BG
using insulin in children admitted to paediatric intensive
care reduces mortality, morbidity and is cost-effective.
Methods/Design
Study Design
The study is an individually randomised controlled open
trial with two parallel groups. The protocol is sum-
marised in Figure 1.
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Figure 1 Flow diagram of the CHiP Trial Protocol.
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Main hypothesis
For children aged from birth to ≤ 16 years on ventila-
tory support and vasoactive support drugs, tight glucose
control (TGC) will increase the numbers of days alive
and free of mechanical ventilation at 30 days.
Secondary hypotheses
That TGC will lead to improvement in a range of com-
plications associated with intensive care treatment and
be cost effective.
Setting
The following PICUs in the United Kingdom (UK) will
be recruiting patients into the CHiP trial: Birmingham
Children’s Hospital; Bristol Royal Hospital for Children;
Great Ormond Street Hospital; Leeds General Infirmary;
University Hospitals of Leicester - Glenfield Hospital;
Royal Brompton & Harefield NHS Trust (Royal Bromp-
ton Hospital); Royal Liverpool Children’s NHS Trust;
Royal Manchester Children’s Hospital; St Mary’s Hospi-
tal; Sheffield Children’s NHS Foundation Trust; South-
ampton General Hospital; University Hospital of North
Staffordshire.
Ethical Approval
MREC approval obtained from the Brighton East
Research Ethics Committee (re 07/Q1907/24) in 2007
and SSIs have been successfully completed for all 10
participating centres. Over 500 children have thus far
been recruited.
Type of participants
Inclusion criteria
Children from birth (≥ 36 weeks corrected gestation) to
≤ 16 years who are undergoing treatment on a PICU
with an arterial line in-situ and who are receiving both
mechanical ventilation and vasoactive drugs (Table 1)
following injury, major surgery or in association with
critical illness in whom it is anticipated that such treat-
ment will be required to continue for at least 12 hours.
Exclusion criteria prior to trial entry
• Children born pre-term and who are < 36 weeks
corrected gestation
• Children with diabetes mellitus
• Children with an established or suspected diagno-
sis of an inborn error of metabolism
• Children for whom treatment withdrawal or limita-
tion of intensive care treatment is being considered
• Children who have been in a PICU for more than
5 days
• Children admitted to a PICU who have already
participated in the CHIP study during a previous
PICU admission.
Consent
Parents/guardians of babies and children in intensive
care are likely to be stressed and anxious. However they
will be asked to give consent in their role of legal repre-
sentatives and will usually have limited time to consider
trial entry as it may not be medically appropriate to
delay the start of treatment. Parents of babies and chil-
dren listed for cardiac surgery will be given information
about the trial pre-operatively and consent provisionally
obtained to be confirmed later if the child is admitted
to intensive care. In addition, where possible, older chil-
dren will be given information and asked to assent to
their participation in the study.
Patients not entered into the trial will receive standard
care
Allocation
To reduce the risk of selection bias at trial entry, alloca-
tion will be administered through a 24 hour, 7 day a
week central randomisation service. Minimisation with a
probabilistic element will be used to ensure a balance of
key prognostic factors between groups using the follow-
ing criteria:
• Centre
• Age ≤ 1 year versus between 1 year and ≤ 16 years
• Admitted following cardiac surgery or not
• For cardiac surgical children, Risk adjusted classifi-
cation for Congenital Heart Surgery 1 (RACHS1)[49]
category 1 to 4 versus 5 to 6
• For non-cardiac surgical children, Paediatric index
of mortality version 2 (PIM2) score at randomization
categorised by probabilities of death of <5%, 5% -
<15% and ≥ 15%
• Accidental TBI or not
Interventions
After inclusion in the study, children will be randomised
to one of two groups: Group 1 (Standard treatment) or
Group 2 (Tight glycaemic control).
Group 1 - Standard treatment
Children in this group will be treated according to a
standard, current, approach to BG management. Insulin
will be given by intravenous infusion in this group only
if BG levels exceed 12 mmol/l on two blood samples
Table 1 Definition of vaso-active drugs
Vaso-active drug name Dose
Dobutamine > 5 mcg/kg/min
Dopamine > 5 mcg/kg/min
Epinephrine Any dose
Norepinephrine Any dose
Milrinone Any dose
Vasopressin Any dose
Macrae et al. BMC Pediatrics 2010, 10:5
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taken at least 30 minutes apart and will be discontinued
once BG falls to <10 mmol/l. A protocol for glucose
control in this group is in Figure 2.
Group 2 - Tight glycaemic control
Children in this group will receive insulin by intrave-
nous infusion titrated to maintain a BG between the
limits of 4 and 7.0 mmol/l. A protocol for glucose con-
trol in this group is in Figure 3.
The protocol for glucose control in group 2 has been
carefully designed to achieve tight glucose control
whilst minimizing the risk of hypoglycaemia, the prin-
cipal side effect of insulin therapy. Standard insulin
solutions will be used and changes in insulin infusion
rates will be guided both by the BG and its rate of
change from previous measurements. BG levels will be
routinely measured as in all PICUs using commercially
available ‘point of care’ analysers which utilise very
small blood samples, producing results in approxi-
mately 1 minute. Analysers are rigorously maintained
and subjected to laboratory-standard quality assurance
programmes.
Training in use of the BG control protocol will be
provided before the first patient is enrolled in each col-
laborating centre and for new staff throughout the trial.
The Clinical Co-ordinating centre team will liaise closely
with local clinicians to ensure that BG control algo-
rithms are followed closely and safely.
Outcome measures
Primary outcome
Following the influential ARDSNET study[50] the pri-
mary outcome for CHiP trial is the number of days alive
and free from mechanical ventilation within the 30 days
after trial entry. Death is obviously an important out-
come. Mechanical ventilation can be seen as a measure
of disease severity, defining the need for complex inten-
sive care. The concept of ventilator free days (VFDs)
brings together these two outcomes. Schoenfeld[51]
define VFDs as: VFD = 0 if the child dies before 30
days; VDF = (30-x) if the child is successfully weaned
from ventilator within 30 days (where × is the number
of days on ventilator); or VFD = 0 if the child is
Figure 2 Algorithm for the titration of insulin in the normal control group.
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ventilated for 30 days or more. The use of organ failure
free days to determine patient-related morbidity surro-
gate end-points in paediatric trials has been supported
by influential paediatric trialists in the current low mor-
tality paediatric critical care environment[52].
Secondary outcomes
Death within 30 days after trial entry (or before dis-
charge from hospital if duration is greater than 30 days)
Death within 12 months of trial entry
Number of days in PICU
Duration of mechanical ventilation
Duration of vasoactive drug usage (adrenaline, nora-
drenaline, dopamine, dobutamine, or Phoshopdiesterase
type III [PDEIII] inhibitors or vasopressors)
Need for renal replacement therapy
Blood stream infection (positive cultures associated
with two or more features of systemic inflammation or
any positive blood culture for bacteria or fungi)
Use of antibiotics >10 days
Number of red cell transfusions
Number of hypoglycaemic episodes moderate (≤ 2.5
mmol/L), severe (≤ 2.0 mmol/L)
Occurrence of seizures (clinical seizures requiring
anticonvulsant therapy)
Paediatric logistic organ dysfunction (PELOD) score
[52-54],
Hospital length of stay
Number of children readmitted to PICU within 30
days of trial entry
Cost and cost-effectiveness measures
Hospital costs within 30 days of trial entry
Cost per life year (based on 30 days costs and survival)
Hospital and community health service costs within 12
months of trial entry
Cost per life year (based on 12 month costs and survi-
val for all cases)
Cost per disability-free survivor (based on 12 month
cost and outcome data for sub group with traumatic
brain injury)
Follow-up at 12 months
If parents give their consent, all children surviving to
hospital discharge will be followed up to 12 months
post-randomisation to determine mortality using the
NHS Central Register of the Office of National Statistics
Figure 3 Algorithm for the titration of insulin in the tight control group.
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(ONS). Parents will be informed about the follow-up
study at trial entry and asked to give consent. The Trial
Manager at the Data Co-ordinating Centre (DCC) will
write to parents following discharge home to remind
them about the follow-up and ask them to keep the
DCC informed about any change of address. At hospital
discharge parents will be given a diary to help them
record their child’s service use post discharge. At around
11 months, following checks with the GP/Health Visitor
to determine that this is appropriate, the Trial Manager
will send a questionnaire to parents to determine the
use of health care resources between discharge and 12
months. Non-responders will be followed-up by letter
and telephone.
Follow-up of traumatic brain Injury sub-group
TBI is defined for this study as accidental trauma to the
head resulting in need for intubation and mechanical
ventilation. There are approximately 750 ICU admis-
sions per year in the UK, and an estimated 150 will be
recruited into CHiP.
This sub-group is more likely to have longer-term
morbidity and parents of children (aged 4 or over) in
this sub-group will be asked to provide additional infor-
mation at 12 months, regarding overall health status,
global neurological outcome, attention and behavioural
status.
Outcome assessment will comprise four components:
Overall health status: measured by the Health Utilities
Index (HUI)
Global neurological outcome: measured by the Kings
Outcome Scale for Childhood Head Injury (KOSCHI)
Attention and behavioural assessment: measured by
the Child Behavioural Check List (CBCL) and the Con-
nor’s Rating Scales revised - short version (CRS-R:S)
The HUI and KOSCHI will be completed using a
structured telephone interview (around 10 minutes).
The CBCL and CRS are both written questionnaires
that will be posted out to the families. They take
approximately 30 minutes to complete.
The Health Utilities Index is a multi-attribute health
status classification system. Seven attributes (sensation,
mobility, emotion, cognition, self-care, pain, fertility) are
categorised according to one of 4 or 5 levels. In this
population fertility will be excluded. The algorithm
(from death to perfect health scale) provides a single
numerical value.
KOSCHI is a 5 point categorical scale, ranging from
death to normal neurological function, and is similar in
structure to the Glasgow Outcome Scale, which is widely
used in adult studies. In addition the KOSCHI is further
subdivided into two subcategories at points 4 and 5 on the
scale (moderate outcome and good outcome). Patient out-
comes will be dichotomized between patients in categories
1, 2, 3, 4A and those in 4B, 5A, 5B.
Child behaviour checklist (CBCL/4-18) (problem
scales) is based on parental report and assesses proble-
matic child behaviour that is summarised in internalis-
ing behaviour (anxious/depressed, withdrawn/depressed,
somatic complaints), externalising behaviour (rule-
breaking, aggressive) and other (social problems,
thought problems, attention problems).
In reference to 1991 normative data (Table 2) Patient
outcome can be summarised according to placement
within one of the three groups, or according to the T-
score.
The Conners’ rating scales (revised - short version
CRS-R:S) assesses symptoms of attention-deficit/hyper-
activity disorder and related problem behaviour in chil-
dren and adolescents based on parent’s report.
In reference to 1993 normative data (Table 3) Patient
outcome can be summarised according to placement
within one of the three groups (marked + moderate,
mild + slight, average + good), or according to the T-
score.
Adverse events and safety reporting
The Royal Brompton & Harefield NHS Trust, as spon-
sor of this study, has responsibility to ensure arrange-
ments are in place to record, notify, assess, report,
analyse and manage adverse events in order to comply
with the UK regulations of Medicines for Human Use
(Clinical Trials) Regulations 2004.
All sites involved in the study are expected to inform
the Chief Investigator and Study nurse of any serious
adverse events/reactions within 24 hours so that appro-
priate safety reporting procedures can be followed by
the Sponsor.
Expected side effects
All adverse events judged by either the investigator or
the sponsor as having a reasonable suspected causal
relationship to insulin therapy qualify as adverse
reactions.
Whilst any suspected, unexpected, serious adverse
reaction (SUSAR) involving insulin therapy will be
reported according to the timelines for SUSARs,
expected side effects of insulin will be reported in the
annual safety report unless serious enough to warrant
expedited reporting.
The most prominent adverse effect of insulin treat-
ment is hypoglycaemia. This is particularly important in
Table 2 Child behavior checklist (CBCL/4-18) assessment
of outcome according to T-score
T-score (Whole) Guideline T-score (Individual scale) Guideline
<60 Normal <65 Normal
60-63 Borderline 65-69 Borderline
>63 Clinical >69 Clinical
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the TCG arm of the study which is aiming to control
BG within the range 4 - 7 mmol/l which is well above
the 2 mmol/l threshold for clinically important hypogly-
caemia [55]. The principal measure to avoid clinically
important hypoglycaemia will be hourly measurement of
BG when insulin is first administered. The insulin
administration protocols aim to achieve glucose control
with the lowest possible incidence of hypoglycaemia and
the avoidance of neuroglycopaenia. Hypoglycaemic
events will be reported to the Clinical Co-coordinating
Centre and if necessary, the BG control protocols will
be revised, whilst still aiming to achieve BG levels within
the target ranges.
Insulin is reported to occasionally cause a rash which
may be associated with itching.
Data collection
To minimise the data collection load for busy units, the
trial will collaborate with the Paediatric Intensive Care
Audit Network (PICANet http://www.picanet.org.uk) to
make best use of the established data collection infra-
structure which exists in all PICUs in the UK. The
PICANet dataset includes most of the items being used
in the trial and these data will be transmitted from the
participating centres to the Data Co-ordinating Centre
electronically using strong encryption. The remaining
short term data items will be collected locally by the
research nurses, and those for the longer term follow-up
will be collected separately by telephone and postal
questionnaires. These data will be double entered onto
electronic database storage systems at the Data Co-ordi-
nating Centre.
Economic evaluation
Cost-consequence and cost-effectiveness analyses will be
undertaken as part of the proposed study. These eco-
nomic evaluations will assess whether the costs of
achieving tight BG control are justified by subsequent
reductions in hospitalisation costs and/or by improve-
ments in patient outcomes. The evaluations will be con-
ducted in two phases, in the first phase all hospital costs
at 30 days post randomisation will be compared across
treatment groups alongside 30-day outcomes, in the sec-
ond phase cost and outcomes at 12-months will be
compared across the groups.
For the first phase evaluations, detailed resource use
data will be collected for each patient enrolled in CHIP
using the Paediatric Critical Care Minimum Dataset
(PCCMDS)[56] which will be collected by each PICANet
unit. Where information on resource use required in
CHIP is not available from these sources datasheets
similar to those developed as part of the INNOVO
study will be used [57]. Information will also be col-
lected on the resources required to achieve tight BG
control, in particular all medication use and the staff
time involved in monitoring the patients and managing
adverse events (e.g. hypoglycaemia) will be noted.
Unit costs for hospital services will be taken from the
NHS ‘payment by results’ database[58]. Where more
detailed unit costs are required, for example those asso-
ciated with staff time and the use of insulin infusion,
these will be collected on site visits to centres. Hospital
costs up to 30 days will be estimated by valuing each
resource use item by the appropriate unit cost.
In the second phase of the study the time horizon of
the economic evaluation will be extended to 12 months,
and resource use data for hospital re-admissions, outpa-
tient visits and the use of community health services
will be collected for all cases. For the sub-sample of
patients diagnosed as having traumatic brain injury at
study entry, information on the patient’s disability at
one-year will be collected during telephone interviews
with the patients’ relatives based on previously devel-
oped interview schedules [57]. All community service
use will be valued using national unit costs[59]. Total
costs for each patient will be calculated by summing the
costs of all hospital and community health services used.
All the economic analyses will be based on the treat-
ment groups as randomly allocated (’intention to treat’).
The initial analysis will include a cost-consequence ana-
lysis and will report mean differences (95% CI) between
treatment groups in resource use (e.g. length of hospital
stay) and total hospital costs per patient, alongside the
primary clinical endpoint. The initial analysis will also
combine costs and outcomes at 30 days post-randomisa-
tion in a cost-effectiveness analysis, which will report
cost per death averted and cost per adverse event
averted. The subsequent analysis will use 12-month cost
and outcome data to report the cost per death averted
for all patients. For the sub-sample of patients diagnosed
as having brain injury at study entry, the cost-effective-
ness analysis will also report the cost per death or dis-
abled case averted.
The sensitivity analysis will test whether the results
are robust to key assumptions made, for example to the
choice of unit costs and the time horizon of the analysis.
Table 3 The Conner’s’ rating scales (revised - short
version CRS-R:S) assessment of outcome according to T-
score
T-score Guideline
≥ 70 Markedly atypical (significant problem)
66-69 Moderately atypical (significant problem)
61-65 Mildly atypical (possible significant problem)
56-60 Slightly atypical (borderline)
45-55 Average (no concern)
≤ 44 Good
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The cost and outcome data collected at one-year will be
used to project the impact of the intervention on
longer-term costs and outcomes.
Sample size
A difference of 2 days in the number of ventilator-free
days (VFD) within the first 30 days post-randomisation
between the two groups has been chosen as the primary
outcome measure for the trial. Information from PICA-
Net using data from UK PICUs for 2003-4 estimates
that the mean number of VFDs in cardiac patients is
26.7, with a standard deviation (SD) of 4.2. Correspond-
ing figures for non-cardiac patients are a mean of 22.7
days, with a standard deviation (SD) of 6.8 days. As the
SD is estimated with error, to be conservative we have
assumed the SD is nearer 5.5 days for the cardiac and 8
days for the non-cardiac patients. There are likely to be
more non-cardiac than cardiac patients eligible for the
trial. We have therefore assumed an overall SD across
both cardiac and non-cardiac strata of 7 days. Assuming
this is the same in both trial arms, and taking a type I
error of 1% (with a 2-sided test), a total sample size of
750 patients would have 90% power to detect this differ-
ence. Whereas we can assume minimal loss to follow up
to 30 days, there may be some non-compliance (some
patients allocated to tight control not receiving this, and
some allocated to usual care being managed with tight
control). The target size will therefore be inflated to
1000 to take account of possible dilution of effect.
As information from PICANet indicates that there are
differences in outcome between cardiac and non-cardiac
patients not merely in VFDs but also in 30 day mortality
rate (3.4% vs. 20%) and mean duration of time on a venti-
lator (3.7 vs. 8.0 days, survivors and non-survivors com-
bined), we also wish to be able to detect whether any
effect of tight glucose control differs between the cardiac
and non-cardiac strata. To have 80% power for an interac-
tion test to be able to detect a difference of two days in
the effect of intervention between the strata at the 5%
level of statistical significance, we would need to increase
the sample size to 1500. If the interaction test was positive
this size would allow us to assess the effect of tight glucose
control separately in the two strata.
Recruitment rate
There are approximately 1300 cardiac and 1550 non-car-
diac eligible patients per year in the collaborating PICUs.
If half of those eligible are recruited into the trial, it
should be feasible to recruit the overall total sample size
of 1500 within the 24 months recruitment period.
Type of analysis
Analysis will be by intention to treat. The following sub-
group analyses will be conducted; age (Age ≤ 1 year ver-
sus between 1 year and ≤ 16 years), severity of illness,
traumatic brain injury or not, cardiac surgical versus
non-cardiac cases, RACHS1 (cardiac cases) (Groups 1-4
versus 5 and 6), PIM2 group (non-cardiac cases) (cate-
gorised by probabilities of death of <5%, 5% - <15% and
≥ 15%), run in cases v. non-run in cases.
Frequency of analysis
An independent Data Monitoring and Ethics Committee
(DMEC) will review, in strict confidence, data from the
trial approximately half way through the recruitment
period. The Chair of the DMEC may also request addi-
tional meeting/analyses. In the light of these data and
other evidence from relevant studies, the DMEC will
inform the Steering Committee if in their view:
i. There is proof that the data indicate that any part
of the protocol under investigation is either clearly
indicated or clearly contra-indicated either for all
patients or a particular subgroup of patients. using
the Peto and Haybittle rule [60,61]
ii. It is evident that no clear outcome will be
obtained with the current trial design.
iii. That they have a major ethical or safety concern
Ancillary studies
In addition to the main study, some collaborators may
wish to conduct other more detailed or complementary
studies. The grant holders welcome this provided that
proposals are discussed in advance with the Trial Steer-
ing Committee and appropriate additional Research
Ethics approval is sought.
Organisation
The Trial Steering Committee (TSC) responsibilities are
to approve the main study protocol and any amend-
ments, monitor and supervise the trial towards its
interim and overall objectives, review relevant informa-
tion from other sources, consider the recommendations
of the DMEC, and resolve problems brought by the trial
co-coordinating centres. Day to day management of the
trial will be overseen by a Trial Management Group
(TMG) comprising the grant holders and project staff
from the Clinical Co-coordinating Centre at the Royal
Brompton Hospital NHS Trust and the Data Co-coordi-
nating Centre (DCC) at the LSHTM.
Publication policy
To safeguard the integrity of the trial, data from this
study will not be presented in public or submitted for
publication without requesting comments and receiving
agreement from the Trial Steering Committee. The pri-
mary results of the trial will be published by the group
as a whole with local investigators acknowledged. The
success of the trial depends on the collaboration of
many people. The results will be presented first to the
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trial local investigators. A summary of the results of the
trial will be sent to parents of participating children on
request and also made available on the trial website.
Confidentiality
Patients will be identified by their trial number to
ensure confidentiality. However, as the patients in the
trial will be followed up to 12 months following rando-
misation, it is essential that the team at the Data Co-
coordinating Centre has the names and addresses of the
trial participants recorded on the data collection forms
in addition to the allocated trial number. Stringent pre-
cautions will be taken to ensure confidentiality of names
and addresses at the Data Co-coordinating Centre.
The Chief Investigator and local investigators will
ensure conservation of records in areas to which access
is restricted.
Audit
To ensure that the trial is conducted according to ICH
GCP guidelines, site audits will be carried out on a ran-
dom basis. The local investigator will be required to
demonstrate knowledge of the trial protocol and proce-
dures and Good Clinical Practice. The accessibility of
the site file to trial staff and its contents will be checked
to ensure all trial records are being properly maintained.
Adherence to local requirements for consent will be
examined.
If the site has full compliance the Site Visit Form will
be signed by the Trial Manager. In the event of non-
compliance the Data Coordinating Centre will address
the specific issues to ensure that relevant training and
instruction is given.
Termination of the study
At the termination of planned recruitment the Data Co-
coordinating Centre will contact all sites by telephone,
email or fax in order to terminate all patient recruitment
as quickly as possible. If the study is terminated prema-
turely by the Steering Committee all sites will be informed
immediately. When all recruited patients have been fol-
lowed until 30 days post randomisation (or hospital dis-
charge if stay longer than 30 days) a declaration of the end
of trial form will be sent to EurdraCT and the MREC. The
following documents: original consent forms, original data
forms, trial related documents and correspondence will be
archived in each Site File and kept for at least five years.
At the end of the analysis and reporting phase, the Trial
Master Files at the Clinical and Data Co-coordinating
Centres will be archived for 15 years.
Indemnity
If there is negligent harm during the clinical trial when
the NHS body owes a duty of care to the person
harmed, NHS Indemnity covers NHS staff, medical aca-
demic staff with honorary contracts, and those conduct-
ing the trial. NHS Indemnity does not offer no-fault
compensation.
Discussion
Data from level 2 trials have driven the adult intensive
care clinicians to adopt treatment regimes that favour
tight glycaemic control. Equipoise presently exists in the
paediatric intensive care community and this allows us a
very important opportunity to conduct an adequately
powered randomised controlled trial in this setting.
Data monitoring committee
Professor David Dunger (CHAIR), Department of Pae-
diatrics, University of Cambridge; Dr David Harrison,
Statistician, Intensive Care Audit and Research Network
(ICNARC); Professor David Hatch, Emeritus Professor
of Paediatric Anaesthesia and Intensive Care, Great
Ormond Street Hospital; Mr. Giles Peek, Consultant
Cardiac Surgeon, Glenfield Hospital, Leicester (until
2009);
Dr Jon Smith, Consultant Paediatric Cardiothoracic
Anaesthetist, Freeman Hospital, Newcastle (from 2009).
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Appendix 5 Diary on use of health services
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Appendix 6 Follow-up: traumatic brain injury
subgroup
The subgroup of children with TBI is more likely to have longer-term morbidity and parents of children(aged ≥ 4 years) in this subgroup will be asked to provide additional information at 12 months
(for patients recruited until September 2010). We will speciﬁcally include assessments of attention and
behaviour as patients with TBI are commonly left with deﬁcits in these areas.
Deﬁnition of traumatic brain injury
Accidental trauma to the head resulting in need for intubation and mechanical ventilation.
Population
Seven hundred and ﬁfty ICU admissions per year in UK. Estimate of 150 recruited to the trial.
Outcomes assessment
This will comprise four components:
Overall health status: measured by the Health Utilities Index (HUI-3) [HUI-3. Copyright 2002 Health Utilities
Inc. (HUInc), 88 Sydenham Street, Dundas ON, Canada L9H 2V3. www.healthutilities.com].
Global neurological outcome: measured by the Kings Outcome Scale for Childhood Head Injury
(KOSCHI).46
Attention and behavioural assessment: measured by the CBCL (CBCL. Copyright 2000 Achenbach T
and Rescorla L. ASEBA, University of Vermont, 1 South Prospect Street, Burlington, VT 05401-3456.
www.ASEBA.org).
The CRS-R:S.47
The HUI, CBCL and CRS-R:S are written questionnaires that will be posted out to the families. They take
approximately 30 minutes to complete.
Health Utilities Index is a multi-attribute health status classiﬁcation system. Seven attributes (sensation,
mobility, emotion, cognition, self-care, pain, fertility) are categorised according to one of 4 or 5 levels.
In this population fertility will be excluded. The algorithm (from death to perfect health scale) provides
a single numerical value.
KOSCHI is a 5-point categorical scale, ranging from death to normal neurological function, and is similar
in structure to the Glasgow Outcome Scale, which is widely used in adult studies. In addition the KOSCHI
is further subdivided into two subcategories at points 4 and 5 on the scale (moderate outcome and good
outcome). Patient outcomes will be dichotomised between patients in categories 1, 2, 3 and 4A, and
those in 4B, 5A and 5B.
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Child behaviour checklist (CBCL/4–18), problem scales
The CBCL is based on parent’s report and assesses problematic child behaviour that is summarised in
internalising behaviour (anxious/depressed, withdrawn/depressed, somatic complaints), externalising
behaviour (rule-breaking, aggressive) and other (social problems, thought problems, attention problems).
In reference to 1991 normative data:
T-score (whole) Guideline T-score (individual scale) Guideline
< 60 Normal < 65 Normal
60–63 Borderline 65–69 Borderline
> 63 Clinical > 69 Clinical
Patient outcome can be summarised according to placement within one of the three groups, or according
to the T-score.
Conners’ rating scales revised – short version
The CRS-R:S assesses symptoms of attention-deﬁcit/hyperactivity disorder and related problem behaviour in
children and adolescents based on parent’s report.
In reference to 1993 normative data:
T-score Guideline
≥ 70 Markedly atypical (signiﬁcant problem)
66–69 Moderately atypical (signiﬁcant problem)
61–65 Mildly atypical (possible signiﬁcant problem)
56–60 Slightly atypical (borderline)
45–55 Average (no concern)
≤ 44 Good
Patient outcome can be summarised according to placement within one of the three groups
(marked +moderate, mild + slight, average + good), or according to the T-score.
APPENDIX 6
158
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Appendix 7 Post-discharge letters to patients and
general practitioners, follow-up forms and case
report form
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Appendix 7a
 
 
<Date>  
«Parent_title» «Parent_Forename» «Parent_Surname» 
«Address_Line1» 
«Address_Line2» 
«Address_Line3», «Address_Line4» 
«Postcode» 
 
Dear «Parent_title» «Parent_Surname», 
 
We are pleased that «Patients_Forename» has now been discharged from hospital.  We are writing to thank you 
for taking part in the CHiP Study so far.  In case you didn’t keep the information leaflet you read when 
«Patients_Forename» was in intensive care, we enclose another copy as a reminder. 
 
This letter is to summarise what happens next.   
 
• We will be writing to «GP_Name», your child’s GP, to inform them that «Patients_Forename» is in the 
study.   
 
• About 11 months after «Patients_Forename» joined the study, we will contact you again and send a 
questionnaire about use of health services for you to fill in at home and send back to us.   
 
You may wonder why we need to contact you again with extra questions now that «Patients_Forename» is home.  
These questions are because families and researchers feel strongly that it is very important not just to look at the 
short-term, but also to compare the longer-term health of children who had tight glucose control with those who 
had the more usual care.  It is very important that we follow up as many children as possible as it is only by doing 
this that we will be able to tell which approach is better. 
  
We will keep you informed about the progress of the study unless you say that you do not want this 
information.  When the study finishes we will ask if you would like to have a summary of the study results.   
 
We attach the contact details we have for you.  Please can you confirm these details by completing and 
returning the enclosed reply slip. Also, if you are going to change your address between now and the time we 
will be contacting you next, please send us the enclosed change of address card in the freepost envelope. You 
don’t need a stamp. 
 
If you have any questions about «Patients_Forename»’s health, you should go to your own doctor.  But if 
there is anything further you would like to know about the study, please do not hesitate to contact us at the 
study office at the address above. 
 
Thank you again for your participation.  The results of the CHiP study will help other parents in the future. 
 
Yours sincerely 
 
Laura Van Dyck / Korotimi Diallo 
Study Manager 
 
Enc:  
Original information sheet  Contact details 
Change of address card   Freepost envelopes 
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                Study Number: «Study_Number» 
 
Reply Slip 
 
Please can you check whether the below details are correct and amend any incorrect 
information. 
 
 
Your Contact Details 
 
Home address:  
  
 «Parent_title» «Parent_Forename» «Parent_Surname» 
 «Address_Line1» 
 «Address_Line2» 
 «Address_Line3» «Address_Line4» 
 «Postcode» 
   
 
Telephone number: «Telephone_Number» 
 
Mobile number: «Mobile_Number» 
 
Email address: «Email» 
 
GP Contact Details  
  
 «GP_Name» 
 «GP_Address1» 
 «GP_Address2» 
 «GP_Address3» «GP_Address4» 
 «GP_Postcode»  
 
I would like to receive updates about the CHiP Trial (please tick)                
Yes  No  
 
 
I would like to receive a copy of the CHiP Trial results when available (please tick) 
Yes  No  
 
 
Thank you.  Please now return this reply slip in the FREEPOST envelope provided to: 
 
The CHIP Trial Data Co-ordinating Centre, Medical Statistics Unit 
London School of Hygiene and Tropical Medicine 
 FREEPOST, Keppel Street, LONDON 
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Appendix 7b
Letter at discharge, version 2, Aug 2010 
 
 
<Date>  
«Parent_title» «Parent_Forename» «Parent_Surname» 
«Address_Line1» 
«Address_Line2» 
«Address_Line3», «Address_Line4» 
«Postcode» 
 
Dear «Parent_title» «Parent_Surname», 
 
We are pleased that «Patients_Forename» has now been discharged from hospital.  We are writing to thank you 
for taking part in the CHiP Study so far.  In case you didn’t keep the information leaflet you read when 
«Patients_Forename» was in intensive care, we enclose another copy as a reminder. 
 
This letter is to summarise what happens next.   
 
• We will be writing to «GP_Name», your child’s GP, to inform them that «Patients_Forename» is in the 
study.   
 
  
We will keep you informed about the progress of the study unless you say that you do not want this 
information.  When the study finishes we will ask if you would like to have a summary of the study results.   
 
We attach the contact details we have for you.  Please can you confirm these details by completing and 
returning the enclosed reply slip. Also, if you are going to change your address between now and the time we 
will be contacting you next, please send us the enclosed change of address card in the freepost envelope. You 
don’t need a stamp. 
 
If you have any questions about «Patients_Forename»’s health, you should go to your own doctor.  But if 
there is anything further you would like to know about the study, please do not hesitate to contact us at the 
study office at the address above. 
 
Thank you again for your participation.  The results of the CHiP study will help other parents in the future. 
 
Yours sincerely 
 
Laura Van Dyck / Korotimi Diallo 
Study Manager 
 
Enc:  
Original information sheet  Contact details 
Change of address card   Freepost envelopes 
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Letter at discharge, version 2, Aug 2010 
                Study Number: «Study_Number» 
 
Reply Slip 
 
Please can you check whether the below details are correct and amend any incorrect 
information. 
 
 
Your Contact Details 
 
Home address:  
  
 «Parent_title» «Parent_Forename» «Parent_Surname» 
 «Address_Line1» 
 «Address_Line2» 
 «Address_Line3» «Address_Line4» 
 «Postcode» 
   
 
Telephone number: «Telephone_Number» 
 
Mobile number: «Mobile_Number» 
 
Email address: «Email» 
 
GP Contact Details  
  
 «GP_Name» 
 «GP_Address1» 
 «GP_Address2» 
 «GP_Address3» «GP_Address4» 
 «GP_Postcode»  
 
I would like to receive updates about the CHiP Trial (please tick)                
Yes  No  
 
I would like to receive a copy of the CHiP Trial results when available (please tick) 
Yes  No  
 
Thank you.  Please now return this reply slip in the FREEPOST envelope provided to: 
 
The CHIP Trial Data Co-ordinating Centre, Medical Statistics Unit 
London School of Hygiene and Tropical Medicine 
 FREEPOST, Keppel Street, LONDON 
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Appendix 7c
Letter at discharge, >1yr I/P, version 1 18Mar2010 
 
 
 
<Date> 
«Parent_title» «Parent_Forename» «Parent_Surname» 
«Address_Line1» 
«Address_Line2» 
«Address_Line3», «Address_Line4» 
«Postcode» 
 
Dear «Parent_title» «Parent_Surname», 
 
We are pleased that «Patients_Forename» has now been discharged from hospital.  We are writing to thank you 
for taking part in the CHiP Study so far.  In case you didn’t keep the information leaflet you read when 
«Patients_Forename» was in intensive care, we enclose another copy as a reminder. 
 
This letter is to summarise what happens next.   
 
• We will be writing to «GP_Name», your child’s GP, to inform them that «Patients_Forename» is in the 
study.   
 
 
We will keep you informed about the progress of the study unless you say that you do not want this 
information.  When the study finishes we will ask if you would like to have a summary of the study results.   
 
We attach the contact details we have for you.  Please can you confirm these details by completing and 
returning the enclosed reply slip. Also, if you are going to change your address between now and the time we 
will be contacting you next, please send us the enclosed change of address card in the freepost envelope. You 
don’t need a stamp. 
 
If you have any questions about «Patients_Forename»’s health, you should go to your own doctor.  But if 
there is anything further you would like to know about the study, please do not hesitate to contact us at the 
study office at the address above. 
 
Thank you again for your participation.  The results of the CHiP study will help other parents in the future. 
 
Yours sincerely 
 
 
Laura Van Dyck / Korotimi Diallo 
Study Manager 
 
Enc:  
Original information sheet  Contact details 
Change of address card   Freepost envelopes 
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                Study Number: «Study_Number» 
 
Reply Slip 
 
Please can you check whether the below details are correct and amend any incorrect 
information. 
 
 
Your Contact Details 
 
Home address:  
  
 «Parent_title» «Parent_Forename» «Parent_Surname» 
 «Address_Line1» 
 «Address_Line2» 
 «Address_Line3» «Address_Line4» 
 «Postcode» 
   
 
Telephone number: «Telephone_Number» 
 
Mobile number: «Mobile_Number» 
 
Email address: «Email» 
 
GP Contact Details  
  
 «GP_Name» 
 «GP_Address1» 
 «GP_Address2» 
 «GP_Address3» «GP_Address4» 
 «GP_Postcode»  
 
I would like to receive updates about the CHiP Trial (please tick)                
Yes  No  
 
 
I would like to receive a copy of the CHiP Trial results when available (please tick) 
Yes  No  
 
 
Thank you.  Please now return this reply slip in the FREEPOST envelope provided to: 
 
The CHIP Trial Data Co-ordinating Centre, Medical Statistics Unit 
London School of Hygiene and Tropical Medicine 
 FREEPOST, Keppel Street, LONDON 
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Appendix 7d
   
 
Date 
Parent Name 
Address 
 
 
 
Dear Parent Name, 
 
On behalf of everyone involved with the CHiP study, I am writing to say how sorry we were to hear of 
the death of your son/daughter [Child’s first name]. 
 
Your son/daughter has played a really valuable part in this study and we would like to thank you for your 
help.  It is through the contributions of children and parents like yourselves that we will eventually be 
able to find the best way to control blood sugar levels in very ill children in the future. 
 
I am the study manager for CHiP, and I am writing to you to ask whether or not you would like to have 
any further contact with CHiP.  Some bereaved parents wish to be kept informed about the progress of 
the study; other bereaved parents might prefer not to be sent any further details.   We want to make 
sure that we give everyone the chance to stay in touch, but we fully understand if you would prefer us 
not to send anything more to you. 
 
There is a reply slip with this letter to let us know if you would like to receive the newsletters that other 
CHiP parents are sent, and/or the final results of the study.  The results should be available sometime 
in 2012. 
 
The reply slip can be sent to me in the FREEPOST envelope provided.  If we do not hear from you we 
will not contact you again; but even if you do not reply now, but later change your mind and would like 
to see the newsletters or results, do not hesitate to contact me. 
 
We in the CHiP team are very grateful for your help so far and do hope that this letter has not caused 
you any distress.  If it has done, I do apologise. 
 
Thank you again. 
 
With kind regards,  
 
 
 
Laura Van Dyck 
CHiP Study Manager 
 
Enc: 
Reply slip 
Freepost envelope 
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

 
 
Study no.: Study number 
 
I/We would like to receive the CHiP Newsletters which are sent periodically to families participating 
in CHiP (please tick): 
Yes  No  
 
I/We wish to be informed of the final results of the CHiP Study when they are available around 
2012 (please tick): 
Yes  No  
 
 
Name: Parent Name 
 
Address: Address 
 
 
 
Telephone: Telephone number 
 
Mobile:  Mobile number 
 
Email: Email address 
(If you would prefer us to contact you this way) 
 
Please correct any of the above details if they are incorrect. 
 
 
If you have any further comments, please let us know: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please return this form in the postage paid, pre-addressed envelope provided. 
 
Thank you. 
Further Contact Reply Slip 
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Appendix 7e
 
From:  Laura Van Dyck/Lucy Brooks 
Phone: 020 7927 2075 
Fax: 020 7927 2189 
Company Name: CHiP Data Coordinating centre, LSHTM 
  
To:  «GP_Name» 
Fax:  «GP_Fax» 
GP Surgery:       «GP_Address1» 
 
 
Dear «GP_Name» 
 
RE:  Patient Name: «Patients_Forename» «Patients_Middlename» «Patients_Surname»     
DOB:  «DOB»     Study Number:   «Study_Number» 
 
We wrote to you recently regarding the above patient who is taking part in the CHiP 
trial and we thank you for your reply.  We are now ready to send the parents the one 
year follow up questionnaire to which they gave consent for when the child entered 
the study.  We would just like to confirm with you that the child is still registered with your 
practice and that there is no reason why we should not contact the family. 
 The child is still registered with the practice and it is ok to contact the family. 
 
 The child is no longer registered with this practice. 
 
 I think it is unsuitable to make contact with this family at this time. 
 
Please indicate above and fax back to 020 7927 2189. 
Thank you for your time. 
Yours Sincerely, 
Laura Van Dyck/Lucy Brooks 
  


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Appendix 7f
GPslettertbi, version2, 19 Feb 10  
 
<Date> 
 
«GP_Name» 
«GP_Address1» 
«GP_Address2» 
«GP_Address3», «GP_Address4» 
«GP_Postcode» 
 
Dear «GP_Name», 
 
Re:  «Patients_Forename» «Patients_Middlename» «Patients_Surname»,     DOB:  
«DOB»,   CHIP study number: «Study_Number»    
 
«Patients_Forename» was recruited into The CHIP Study on «Date_of_Randomisation».  A copy of the 
information sheet which was given to «Patients_Forename»’s parents prior to trial entry is enclosed.  The 
parent’s consent included agreement to random allocation and to being contacted by researchers at around 12 
months from trial entry.  I am also enclosing a copy of the letter which has been sent to 
«Patients_Forename»’s parents following «hisher» discharge home on «Discharge_date».  
 
If the parent(s) are still willing to take part I will fax you two months before making contact with the parents 
to confirm that «Patients_Forename» is alive, is still registered with you and that there is no reason that you 
know of why we should not contact «Patients_Forename»’s parents about follow-up.   
 
Non-TBI patients 
Nearer the time I will follow-up the fax with a phone call to check that there have been no changes before I 
contact the parents to make arrangements to send them a questionnaire about resource use.  
 
TBI patients 
Nearer the time I will follow-up the fax with a phone call to check that there have been no changes before I 
contact the parents to make arrangements to send them questionnaires about resource use, the child’s overall 
health status, behaviour and attention.  
 
As many families with young children move addresses several times, to keep track of «Patients_Forename»’s 
family and to facilitate this we will be asking «Patients_Forename»’s parent(s) for «hisher» NHS number.  
However we would be very grateful if you would provide this on the reply slip in case they cannot easily find 
it.  Please would you also check that we have the correct contact details.  
 
We will also be registering «Patients_Forename» on the NHS central register for possible later follow-up.  
«Patients_Forename»’s parents have already given their permission for this. 
 
Please return the reply slip using the enclosed freepost envelope.  Alternatively you can fax it on 020 7637 
2853, or send an email message to Laura.VanDyck@lshtm.ac.uk.    
 
If you wish, we will send you the results of the study when it is completed – please indicate on the reply slip if 
this would be of interest to you.  If you have any questions about the enclosed, or would like any further 
information, please do not hesitate to get in touch with me. 
 
With many thanks for your time and assistance. 
 
Yours sincerely 
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GPslettertbi, version2, 19 Feb 10  
Laura Van Dyck / Korotimi Diallo 
Trial Manager 
 
Enc:  Reply slip, Copy of letter to parents, Information sheet for parents 
 Freepost envelope 
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GPslettertbi, version2, 19 Feb 10  
 
Reply slip 
 
«GP_Name» 
«GP_Address1» 
«GP_Address2» 
«GP_Address3», «GP_Address4» 
«GP_Postcode» 
 
Re: «Patients_Forename» «Patients_Middlename» «Patients_Surname», DOB: 
«DOB»,   CHIP study number: «Study_Number» 
 
1. I am the GP for above named child 
  Yes (go to question 3) 
  No (go to question 2) 
 
2. The GP responsible for this child/baby is: 
 
 Name:  
 
 Address: 
 
 Postcode:                                            Telephone: 
 
 
3.  The following parent’s home address for «Patients_Forename» is correct/incorrect (please 
delete as applicable and amend if required.  
  
 «Parent_Forename» «Parent_Surname» 
 «Address_Line1» 
 «Address_Line2» 
 «Address_Line3», «Address_Line4» 
 «Postcode» 
 
4. «Patients_Forename»’s NHS number is: «NHS_number» 
 
5. I would like to receive a copy of the CHIP newsletter         Yes   No  
 
6. I would like to receive a copy of the CHIP Trial results when available 
                 Yes   No  
 
 
Thank you.  Please now return this reply slip in the FREEPOST envelope provided to: 
 
The CHIP Trial Data Co-ordinating Centre, Medical Statistics Unit 
London School of Hygiene and Tropical Medicine 
 FREEPOST , Keppel Street, LONDON  
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Appendix 7g
TBI letter at discharge version 2, 19 Feb 10 
 
 
 
<Date> 
 
«Parent_title» «Parent_Forename» «Parent_Surname» 
«Address_Line1» 
«Address_Line2» 
«Address_Line3», «Address_Line4» 
«Postcode» 
 
Dear «Parent_title» «Parent_Surname», 
 
We are pleased that «Patients_Forename» has now been discharged from hospital.  We are writing to 
thank you for taking part in the CHiP Study so far.  In case you didn’t keep the information leaflet 
you read when «Patients_Forename» was in intensive care, we enclose another copy as a reminder. 
 
This letter is to summarise what happens next.   
 
• We will be writing to «GP_Name», your child’s GP, to inform them that 
«Patients_Forename» is in the study.   
 
• About 11 months after «Patients_Forename» joined the study, we will contact you again to 
find out how «heshe» is doing.   
 
• We will send some questionnaires for you to fill in at home and send back to us.     
 
You may wonder why we need to contact you again with extra questions now that 
«Patients_Forename» is home.  These questions are because families and researchers feel strongly 
that it is very important not just to look at the short-term, but also to compare the longer-term health 
of children who had tight glucose control with those who had the more usual care.  It is very 
important that we follow up as many children as possible as it is only by doing this that we will be 
able to tell which approach is better. 
  
We will keep you informed about the progress of the study unless you say that you do not want 
this information.  When the study finishes we will ask if you would like to have a summary of the 
study results.   
 
We attach the contact details we have for you.  If any of these are incorrect, please would you 
amend them and send them back to us.  Also, if you are going to change your address between 
now and the time we will be contacting you next, please send us the enclosed change of address 
card in the freepost envelope.   You don’t need a stamp. 
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If you have any questions about «Patients_Forename»’s health, you should go to your own 
doctor.  But if there is anything further you would like to know about the study, please do not 
hesitate to contact us at the study office at the address above. 
 
Thank you again for your participation.  The results of the CHiP study will help other parents in 
the future. 
 
Yours sincerely 
 
 
 
Laura Van Dyck / Korotimi Diallo 
Study Manager 
 
Enc:  
Original information sheet 
Contact details 
Change of address card 
Freepost envelopes 
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       Study Number: «Study_Number» 
 
Reply Slip 
 
Please can you check whether the below details are correct and amend any 
incorrect information. 
 
 
Your Contact Details 
 
Home address:  
  
 «Parent_title» «Parent_Forename» «Parent_Surname» 
 «Address_Line1» 
 «Address_Line2» 
 «Address_Line3» «Address_Line4» 
 «Postcode» 
   
 
Telephone number: «Telephone_Number» 
 
Mobile number: «Mobile_Number» 
 
Email address: «Email» 
 
GP Contact Details  
  
 «GP_Name» 
 «GP_Address1» 
 «GP_Address2» 
 «GP_Address3» «GP_Address4» 
 «GP_Postcode»  
 
I would like to receive updates about the CHiP Trial (please tick)                
Yes  No  
 
 
I would like to receive a copy of the CHiP Trial results when available (please tick) 
Yes  No  
 
 
Thank you.  Please now return this reply slip in the FREEPOST envelope provided to: 
 
The CHIP Trial Data Co-ordinating Centre, Medical Statistics Unit 
London School of Hygiene and Tropical Medicine 
 FREEPOST, Keppel Street, LONDON 
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Appendix 7h
C
H
Case Report Form (CRF) 
 
CHiP Site Number: 
 
PatientÊs Initials: 
 
CHiP Study Number: 
(as assigned at randomisation) 
 
Patient Hospital Number: 
First Last Middle 
 
PICU Admission Date: 
 
 Date of Birth: 
2 0 
D M D M Y M Y Y Y 
D M D M Y M Y Y Y 
Once this CRF is completed (i.e. 30 days after randomisation or upon 
patient death) please  photocopy all data sheets and store in 
completed CRF file. 
 
The original CRF (including instructions) should be stored in a secure 
location until the Data Co-ordinating Centre at the LSHTM can 
arrange collection by courier. 
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Please place a COPY of the patient’s  consent form 
here. 
Consent Form 
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Appendix 8 Questionnaire on use of health services
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Appendix 9 Trial Steering Committee: terms of
reference and membership
The responsibilities of the TSC were to approve the main study protocol and any amendments, monitorand supervise the trial towards its interim and overall objectives, review relevant information from
other sources, consider the recommendations of the DMEC, and resolve problems brought by the trial
co-ordinating centres. The TSC therefore provided overall supervision for CHiP on behalf of the HTA and
the Royal Brompton and Hareﬁeld NHS Trust (sponsor) to ensure that the trial was conducted to the
rigorous standards set out in the MRC Guidelines for GCP. Face-to-face meetings were held at regular
intervals determined by need and not less than once a year. Routine business was conducted by
telephone, email and post.
Terms of reference
l The TSC should approve the protocol and trial documentation in a timely manner.
l In particular the TSC should concentrate on progress of the trial, adherence to the protocol, patient
safety and consideration of new information of relevance to the research question.
l The safety and well-being of the trial participants are the most important consideration and should
prevail over the interests of science and society.
l The TSC should provide advice, through its chair, to the chief investigator, the trial sponsor, the trial
funder, on all appropriate aspects of the trial. Speciﬁcally, the TSC will:
¢ Monitor recruitment rates and encourage the TMG to develop strategies to deal with any
recruitment problems.
¢ Monitor completion of data sheets and comment on strategies from TMG to encourage satisfactory
completion in the future.
¢ Monitor follow-up rates and review strategies from TMG to deal with problems including sites that
deviate from the protocol.
¢ Approve any amendments to the protocol, where appropriate.
¢ Approve any proposals by the TMG concerning any change to the design of the trial, including
additional sub-studies.
¢ Oversee the timely reporting of trial results.
¢ Approve and comment on the statistical analysis plan.
¢ Approve and comment on the publication policy.
¢ Approve and comment on the main trial manuscript.
¢ Approve and comment on any abstracts and presentations of any results during the running of
the trial.
¢ Approve external or early internal requests for release of data or subsets of data or samples
including clinical data and stored biological samples.
¢ Receive reports from the DMEC.
¢ The TSC will make decisions as to the future continuation (or otherwise) of the trial.
l Membership of the TSC should be limited and include an independent chair, at least two other
independent members, two collaborators and two members of the public. The investigators and the
trial project staff are ex ofﬁcio.
l Representatives of the trial sponsor and the HTA should be invited to all TSC meetings.
l Responsibility for calling and organising the TSC meetings lies with the chief investigator. The TSC should
meet at least annually, although there may be periods when more frequent meetings are necessary.
l There may be occasions when the trial sponsor or the HTA will wish to organise and administer these
meetings in exceptional circumstances.
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l The TSC will provide evidence to support any requests for extensions, including that all practicable
steps have been taken to achieve targets.
l The TSC will maintain conﬁdentiality of all trial information that is not already in the public domain.
Membership
Professor Michael Preece (chairperson) Consultant Paediatrician, Great Ormond Street Children’s Hospital
Mrs Pamela Barnes Lay member
Ms Sian Edwards Paediatric Pharmacist, Royal Brompton Hospital
Professor David Field Neonatologist, Leicester Royal Inﬁrmary and the University of Leicester
Dr James Hooper Consultant Clinical Biochemist, Royal Brompton Hospital
Mrs Tara Quick Lay member, parent
Dr Claire Snowdon Lecturer, Medical Statistics Department, LSHTM, and Centre for Family Research,
University of Cambridge (until 2011)
Ms Lyvonne Tume Research Nurse, Royal Liverpool Children’s Hospital
Dr Dirk Vlasselaers Consultant Paediatric Intensivist, Leuven, Belgium
Professor Paula Williamson Professor of Medical Statistics, University of Liverpool
In attendance
Mr Michael Loveridge (till March 2008) Royal Brompton Hospital (Trial sponsor)
HTA representative
Trial Management Group (see below)
Dr Duncan Macrae (Chief Investigator) Director of Paediatric Intensive Care, Royal Brompton Hospital
Dr Elizabeth Allen Senior Lecturer, Medical Statistics Department, LSHTM
Miss Helen Betts Lead Study Nurse, Royal Brompton Hospital
Professor Diana Elbourne Professor of Healthcare Evaluation, Medical Statistics Department, LSHTM
Dr Richard Grieve Senior Lecturer in Health Economics, Health Services Research Department, LSHTM
Dr Kevin Morris Consultant in Paediatric Intensive Care, Birmingham Children’s Hospital
Dr Roger Parslow Senior research fellow, University of Leeds
Dr Robert Tasker Professor of Neurology and Anesthesia (Pediatric), Harvard Medical School and
Children’s Hospital Boston, Boston, MA, USA
Mrs Ann Truesdale (till 2008) Trials Advisor, Medical Statistics Department, LSHTM
Miss Laura Van Dyck (from August 2009) Study Manager, Medical Statistics Department, LSHTM
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Appendix 10 Data Monitoring and Ethics
Committee
Terms of reference
To safeguard the interests of trial participants, monitor the main outcome measures including safety and
efﬁcacy, and monitor the overall conduct of the CHiP study.
The DMEC should receive and review information on the progress and accruing data of CHiP and provide
advice on the conduct of the trial to the Trial Steering Committee (TSC).
The DMEC should inform the Chair of the TSC if, in their view the results are likely to convince a broad
range of clinicians, including those supporting the trial and the general clinical community, that, on
balance, one trial arm is clearly indicated or contraindicated for all participants or a particular category of
participants, and there was a reasonable expectation that this new evidence would materially inﬂuence
patient management.
Interim review of the trial’s progress including updated ﬁgures on recruitment, data quality, adherence to
protocol, follow-up, and main outcomes and safety data. Speciﬁcally, these roles include to:
l monitor evidence for treatment differences in the main efﬁcacy outcome measures
l monitor evidence for treatment harm (e.g. toxicity, SAEs and SARs, treatment related deaths)
l assess the impact and relevance of external evidence
l decide whether to recommend that the trial continues to recruit participants or if recruitment
should be terminated either for everyone or for some treatment groups and/or some
participant subgroups
l decide whether or not trial follow-up should be stopped earlier
l assess data quality, including completeness (and by so doing encourage collection of high quality data)
l maintain conﬁdentiality of all trial information that is not in the public domain
l monitor recruitment ﬁgures and losses to follow-up
l monitor compliance with the protocol by participants and investigators
l consider the ethical implications of any recommendations made by the DMEC
¢ monitor planned sample size assumptions, preferably with regards to
(i) a priori assumptions about the control arm outcome and/or
(ii) emerging differences in clinically relevant subgroups, rather than on emerging, unblinded
differences between treatment groups, overall
l suggest additional data analyses if necessary
l advise on protocol modiﬁcations proposed by investigators or HTA (e.g. to inclusion criteria, trial
endpoints, or sample size)
l monitor continuing appropriateness of patient information
l monitor compliance with previous DMEC recommendations.
Membership
Professor David Dunger (chairperson) Department of Paediatrics, University of Cambridge
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Dr David Harrison Statistician, Intensive Care Audit and Research Network (ICNARC),
Professor David Hatch Emeritus Professor of Paediatric Anaesthesia and Intensive Care, Great Ormond
Street Hospital
Mr Giles Peek (till Sept. 2009) Consultant Cardiac Surgeon, Glenﬁeld Hospital, Leicester
Dr Jon Smith (from Sept. 2009) Consultant Cardiothoracic Anaesthetist, Newcastle General Hospital
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Appendix 11 Trial Management Group
A Trial Management Group was established and was responsible for the day-to-day management of thetrial. The group comprised the grant holders and project staff from the clinical co-ordinating centre at
the Royal Brompton Hospital NHS Trust and the data co-ordinating centre at the LSHTM. The group met
regularly in person and by telephone.
The responsibilities of the TMG were:
(a) to establish and monitor recruitment of participating centres
(b) to distribute and supply of data collection forms and other appropriate documentation for the trial
(c) data collection and management
(d) data entry and cleaning
(e) data analysis
(f) organising and servicing the DMEC
(g) assure data security and quality and observe data protection laws
(h) ensure trial is conducted in accordance with ICH GCP.
Data co-ordinating centre responsibilities
l To ensure that all members of the study team are able by knowledge, training and experience to
undertake the roles assigned to them and to comply with requirements as speciﬁed by the
host organisation.
l To provide overall efﬁcient day-to-day management of the trial ensuring compliance with GCP.
l To ensure each centre is put on-line with the randomisation service after Local Research Ethics
Committee (LREC), research and development (R&D) approval and the signed local collaborator
agreement have been received from the sponsor.
l To provide site folders and relevant documentation to each centre.
l To contribute to the development of the protocol, and all study documentation including data sheets.
l To design, produce and regularly update all trial materials and arrange printing and supply
of documentation.
l To monitor recruitment and advise on remedial action if targets are not being met.
l To set up and maintain the website.
l To service the Project management Committee, Steering Committee and any other relevant
advisory groups.
l To use all reasonable efforts to ensure that the data collected and reported are accurate, complete and
identiﬁable at source; and that record keeping and data transfer procedures adhere to the Data
Protection Act 1998.
l To undertake the interim and ﬁnal analyses and report regularly to the DMEC in a timely way at
their request.
l To supply documentation and reports as deemed necessary by the sponsors to fulﬁl their obligations.
l To co-ordinate the preparation and publication of data, reports and information, ensuring that these
meet legislative, contractual and ethical requirements.
l To co-operate with audits or inspections undertaken by the host institution, the sponsors and
regulatory authorities including the MHRA as required.
l To assist investigations into any alleged research misconduct undertaken by or on behalf of
the co-sponsors.
l To ensure safe storage of data, including trial site ﬁle, data sheets and other records for a period of
15 years after the conclusion of the trial.
l To inform the chief investigator of any changes in the trial protocol that affect the conduct of the trial.
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Appendix 12 Principal investigator’s
responsibilities
Each participating centre identiﬁed a paediatric intensivist as a PI. Each participating centre was allocatedfunding for research nursing time and expected to employ or second a Research Nurse to support all
aspects of the trial at the local centre.
The responsibility of the PI will be to:
(a) ensure local research ethics and R&D approval is obtained
(b) discuss the trial with medical, and nursing staff who see eligible patients and ensure that they are
updated on the current state of knowledge, the trial and its procedures
(c) provide clinical support for the trial research nurse ensuring that relevant staff are trained in the
trial procedures
(d) ensure that potentially eligible patients are considered for the trial
(e) report promptly to the clinical co-ordinating centre any problems in meeting recruitment targets so
that support can be provided
(f) maintain good contact with the paediatric cardiac unit to ensure that potentially eligible patients are
given information about the trial
(g) ensure that mechanisms for consent and recruitment are in place
(h) ensure that data collection forms are completed and returned to the data co-ordinating centre
promptly and to deal with any queries
(i) inform and advise the relevant co-ordinating centre promptly
(j) facilitate other aspects of co-ordination as relevant
(k) make data available for veriﬁcation, audit and inspection purposes as necessary
(l) respond to requests for data from the Economics team
(m) ensure that the conﬁdentiality of all information about trial participants is respected by all persons and
that records are kept in areas to which access is restricted
(n) ensure the trial is conducted in accordance with ICH GCP
(o) allow access to source data for audit and veriﬁcation
(p) ensure that adverse events are reported in line with statutory guidelines.
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